Inhibitors of PTPN2

Novel compounds targeting PTPN1 and PTPN2 enhance cancer immunotherapy and treat metabolic disorders by inhibiting these enzymes, addressing the limitations of current therapies.

WO2026235860A1PCT designated stage Publication Date: 2026-11-12MONDEGO BIO LDA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/022737
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-10-02
Filing Date
2026-04-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapeutic agents are inadequate in effectively inhibiting both PTPN1 and PTPN2, limiting the applicability and effectiveness of cancer immunotherapy and treatments for metabolic disorders like type 2 diabetes and obesity.

Method used

Development of novel compounds of Formula (A) that inhibit PTPN1 and PTPN2, which can be administered to patients to enhance IFNγ sensing and signaling, thereby improving cancer immunotherapy and treating metabolic disorders.

Benefits of technology

The compounds provide improved efficacy and safety in inhibiting PTPN1 and PTPN2, enhancing cancer immunotherapy and offering therapeutic benefits for metabolic diseases such as diabetes and obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026022737_12112026_PF_FP_ABST
    Figure US2026022737_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to novel inhibitors of PTPN1 and PTPN2, and to pharmaceutical compositions comprising the same. The invention further provides compounds of Formula (A) and their use in the treatment and / or prevention of diseases and disorders modulated by protein tyrosine phosphatase activity, including, but not limited to, autoimmune, inflammatory, metabolic, and oncological conditions. Methods of treatment employing such compounds are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Mondego.26.0001Inhibitors of PTPN2CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and benefit of U. S. Provisional Patent Application Serial No. 63 / 803,485 filed May 9, 2025, entitled “Inhibitors of PTPN2” and U. S. Provisional Patent Application Serial No. 63 / 892,587 filed October 2, 2025, entitled “Inhibitors of PTPN2” the disclosure of which are incorporated by reference in its entirety for all purposes.FIELD OF INVENTION

[0002] The present invention relates to inhibitors of Protein Tyrosine Phosphatase NonReceptor Type 2 (PTPN2). These inhibitors may be beneficial in the treatment of various diseases or disorders associated with PTPN2, including endocrine, genetic, immune, metabolic, bone, eye, respiratory, gastrointestinal, infectious, hematologic, and oncologic conditions. Specifically, the invention concerns compounds and pharmaceutical compositions that inhibit PTPN2, methods for treating diseases or disorders linked to PTPN2 activity, and methods for synthesizing such compounds.BACKGROUND

[0003] A primary function of the immune system is to protect the human body from malignancies by identifying and eliminating damaged, altered, or aged cells. Many mutated cancer cells produce abnormal proteins, known as tumor antigens, which signal that these cells are altered or damaged. Under normal conditions, the immune system is capable of monitoring, detecting, and destroying such cancer cells regularly. However, cancer cells can acquire the ability to evade immune detection and escape the immune response that typically prevents the development of malignant tumors. Tumor cells employ several mechanisms to bypass immune surveillance, including the selection of tumor variants that are resistant to immune effectors — a process known as immune editing — and the progressive establishment of an immunosuppressive environment within the tumor.

[0004] Tyrosine-protein phosphatases non-receptor type 1 and 2 (PTPN1 and PTPN2, also known as PTP1B and TC-PTP, respectively) are closely related members of the class I non-receptor protein tyrosine phosphatase family. Both PTPN1 and PTPN2 are ubiquitously expressed, with particularly high levels found in immune cells. These1.ASBMondego.26.0001phosphatases play key roles in regulating signaling pathways initiated by various growth factor and cytokine receptors, including the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and insulin receptor (IR). Although they share structural and functional similarities, studies in knockout mouse models indicate that PTPN1 and PTPN2 have non-redundant functions. Mice lacking PTPN1 (Ptpnl7") exhibit increased sensitivity to insulin and leptin and are resistant to diet-induced obesity. In contrast, mice lacking PTPN2 (Ptpn27“) die within 3 to 5 weeks after birth due to hematopoietic defects and the onset of progressive systemic inflammatory diseases. Moreover, simultaneous deficiency of both PTPN1 and PTPN2 is lethal during embryonic development.

[0005] Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is an intracellular enzyme belonging to the Class I subfamily of phospho-tyrosine-specific phosphatases. It regulates numerous cellular processes by dephosphorylating tyrosine residues on target proteins. PTPN2 is ubiquitously expressed, with the highest levels found in hematopoietic and placental cells. In humans, PTPN2 expression is regulated post-transcriptionally through the generation of two splice variants: a 45 kDa isoform that contains a nuclear localization signal at the C-terminus upstream of the splice junction, and a 48 kDa canonical isoform that includes a C-terminal endoplasmic reticulum (ER) retention motif. Under certain cellular stress conditions, the 45 kDa isoform can passively diffuse into the cytosol. Both isoforms share an N-terminal catalytic domain responsible for phospho-tyrosine phosphatase activity.

[0006] PTPN2 acts as a negative regulator of various signaling pathways, targeting nonreceptor tyrosine kinases (e.g., JAK1, JAK3), receptor tyrosine kinases (e.g., INSR, EGFR, CSF1R, PDGFR), transcription factors (e.g., STAT1, STAT3, STAT5a / b), and Src family kinases (e.g., Fyn, Lek). As a key negative regulator of the JAK-STAT signaling pathway, PTPN2 plays a crucial role in modulating cytokine receptor signaling, including responses to interferon-gamma (IFNy).

[0007] These findings suggest that enhancing IFNy sensing and signaling by inhibiting PTPN2 may represent a promising therapeutic strategy to improve the effectiveness of cancer immunotherapy. Unlike conventional cancer treatments such as chemotherapy and radiation, which affect both cancerous and healthy cells, immunotherapy offers the0ASBMondego.26.0001advantage of selectively targeting cancer cells, thereby potentially reducing adverse effects. However, the clinical success of immunotherapy remains limited — it is currently effective for only a subset of cancers and does not benefit all patients. Nonetheless, several promising immunotherapeutic approaches are being developed to broaden its applicability and improve patient outcomes.

[0008] The catalytic domain of PTPN2 shares approximately 74% sequence homology and exhibits similar enzymatic kinetics with that of another family member, protein tyrosine phosphatase non-receptor type 1 (PTPN1). Research has identified PTPN1 as a key negative regulator of both insulin and leptin receptor signaling pathways. Animal studies have shown that PTPN1 deficiency leads to improved glucose homeostasis and lipid profiles. Moreover, PTPN1 -deficient animals exhibit resistance to weight gain, even when subjected to a high-fat diet. These findings suggest that PTPN1 inhibitors may hold therapeutic potential for the treatment of type 2 diabetes, obesity, and metabolic syndrome.

[0009] There is a significant need for therapeutic agents capable of inhibiting both PTPN 1 and PTPN2. This invention aims to address this unmet need in current protein tyrosine phosphatase-targeted therapies by providing novel and effective inhibitors.SUMMARY

[0010] A first aspect of the invention relates to compounds of Formula (A):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R1is -OH;R2is selected from H, Ci-Ce alkyl, and R5; orR1and R2together with the atom to which they are attached and any intervening atoms, form 5-6 membered heteroaryl, wherein heteroaryl is optionally substituted with3.ASBMondego.26.0001one or more substituents independently selected from halogen, -OH, Ci-Ce alkyl, -NH2, - CN;R3is selected from H, -OH, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl and R5, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -OH, -CN, halogen, =0, -NR31R32, -C(O)NR31R32, and 3-10 membered heterocyclyl, or two substituents together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl;R4is selected from H, -OH, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl,3-10 membered heterocyclyl, 5-10 membered heteroaryl, R5, aryl,wherein the alkyl, cycloalkyl, heterocyclyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, Ci-Ce alkyl, Ci-Ce alkoxy; orR3and R4together with the atoms to which they are attached and any intervening atoms, form a 6 membered cycloalkyl, a 6 membered aryl, a 6 membered heterocyclyl, optionally substituted with one or more R6;4.ASBMondego.26.0001each R5is independently selected fromeach R6is independently selected from Ci-Ce alkyl, -OH, -NHCH2R24,two geminal or vicinal R6form C3-C10 cycloalkyl, 3-10 membered heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0; or two geminal R6form =0;each E is independently selected from CR52and N;Q is selected from O, S(O)k, C(R21)2, NR22;Q* is selected from O, S(O)k, CH2, NR28;each V is independently selected from CR26and N;W is 5-6 membered cycloalkyl, heterocyclyl or heteroaryl, wherein cycloalkyl, heterocyclyl or heteroaryl optionally substituted with one or more R23;Z is selected from O and NH;5.ASBMondego.26.0001each R* is H, or two R* form a bond;each R** is H, or two R** form a bond;Rais selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;Rbis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rcis H, or Raand Rcform a double bond;Rdis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Reis H, or Reand R8form a double bond;R1is selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rgis H;Rhis selected from Ci-Ce alkyl, 3-8 membered cycloalkyl;R7is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl;each R22is independently selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl;R23is selected from Ci-Ce alkyl, Ci-Ce alkoxy;R24is selected from Ci-Ce alkyl and C2-C6 alkenyl, wherein alkyl or alkenyl is optionally substituted with one or more substituents independently selected from halogen, OH, CN;R25is selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy;each R26is independently selected from H, Ci-Ce alkyl, C3-C7 cycloalkyl, C4-C7 cycloalkenyl, -NHCi-Ce alkyl, and Ci-Ce alkoxy;R27is selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy;R28is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy;R31is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; or6.ASBMondego.26.0001R31and R32together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;R33is selected from H, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl;each R41is independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, C3-Cs cycloalkyl, 3-7 membered heterocyclyl, aryl, 5-6 membered heteroaryl;R43is H; orR31and R43together with the atoms to which they are attached and any intervening atoms, form 5-6 membered heteroaryl, or 5-7 membered heterocycloalkenyl, wherein heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;R51is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl, wherein alkyl or cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, =0, Ci-Ce alkyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, aryl;each R52is independently selected from H, Ci-Ce alkyl;or two R52together with the atoms to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl;R61is selected from H, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, -C(O)N(R28)2, -C(O)OR28, wherein alkyl, cycloalkyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2;R62is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;or R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl, 5-10 membered heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, Ci-Ce alkyl-C(O)-, -C(O)N(R28)2;b is an integer selected from 0, 1, 2 and 3;k is an integer selected from 0, 1, and 2;p is an integer selected from 1, 2 and 3;q is an integer selected from 0, 1 and 2;7.ASBMondego.26.0001t is an integer selected from 0 and 1;r is an integer selected from 0 and 1.

[0011] Another aspect of the invention is directed to pharmaceutical compositions comprising a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof and a pharmaceutically acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.

[0012] Another aspect of the invention relates to a method of treating a disease or disorder associated with PTPN1 and / or PTPN2. The method comprises administering to a patient in need of a treatment for diseases or disorders associated with PTPN1 and / or PTPN2 an effective amount of a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0013] Another aspect of the invention is directed to a method of inhibiting of PTPN2. The method involves administering to a patient in need thereof an effective amount of a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0014] Another aspect of the present invention relates to compounds of Formula (A), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers, or pharmaceutical compositions thereof, for use in the manufacture of a medicament for inhibiting ofPTPNl and / or PTPN2.

[0015] Another aspect of the present invention relates to the use of compounds of Formula (A), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers, or pharmaceutical compositions thereof, in the treatment of a disease or disorder associated with PTPN 1 and / or PTPN2.

[0016] Another aspect of the present invention relates to compounds of Formula (A), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers, or pharmaceutical compositions thereof, for use in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.

[0017] Another aspect of the invention is directed to a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof. The method involves administering to a patient in need of the treatment an effective amount of a compound of8.ASBMondego.26.0001Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0018] Another aspect of the present invention relates to the use of compounds of Formula (A), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, tautomers, or pharmaceutical compositions thereof, in the treatment of a disease or disorder disclosed herein.

[0019] The present invention further provides methods of treating a disease or disorder associated with PTPN1 and / or PTPN2, comprising administering to a patient suffering from at least one of said diseases or disorders a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0020] The present invention provides inhibitors of PTPN1 and / or PTPN2 that are therapeutic agents in the treatment of diseases and disorders.

[0021] The present invention further provides compounds and compositions with an improved efficacy and safety profile relative to known inhibitors of PTPN1 and / or PTPN2.

[0022] The present invention further provides methods of treating a disease or disorder associated with PTPN1 and / or PTPN2, comprising administering to a patient suffering from at least one of said diseases or disorders a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0023] The present invention provides inhibitors of protein tyrosine phosphatase enzymes that are therapeutic agents in the treatment of diseases such as cancer and metabolic diseases.

[0024] The present invention provides inhibitors of PTPN1 and / or PTPN2 that are therapeutic agents in the treatment of diseases and disorders.

[0025] The present invention further provides compounds and compositions with an improved efficacy and safety profile relative to known protein tyrosine phosphatase enzyme inhibitors. The present disclosure also provides agents with novel mechanisms of action toward protein tyrosine phosphatase enzymes in the treatment of various types of diseases, including cancer and metabolic diseases.9.ASBMondego.26.0001

[0026] The present invention further provides methods of preventing, treating, or ameliorating a disease, disorder, or condition selected from cancer, rheumatic disease, inflammatory disease, immune disease, metabolic disease or disorder, infectious disease, neurodegenerative disease, genetic disorder, cardiological disease.

[0027] The present invention further provides methods of treating a disease, disorder, or condition selected from Cancer; Oligoarticular Juvenile Idiopathic Arthritis; Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis; Inflammatory Bowel Disease 20 (IBD20); Crohn's Disease; Immunodeficiency 31c (IMD31C); T-Cell Acute Lymphoblastic Leukemia; Inflammatory Bowel Disease; Inflammatory Bowel Disease 1 (IBD1); Celiac Disease 1 (CELIAC 1); Body Mass Index Quantitative Trait Locus 11 (BMIQ11); Diabetes Mellitus; Type 2 Diabetes Mellitus (T2D); Rasopathy; Ovarian Cancer (OC); Bubonic Plague; Primary Mediastinal B-Cell Lymphoma; Leptin Deficiency or Dysfunction; Alzheimer Disease; Ovemutrition; Noonan Syndrome; Noonan Syndrome With Multiple Lentigines; Rasopathy; Hypertension, Essential; Pancreatic Adenocarcinoma comprising administering to a patient suffering from at least one of said diseases or disorders a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0028] In some aspects, the present disclosure provides a compound obtainable by, or obtained by, a method for preparing compounds described herein (e.g., a method comprising one or more steps described in General Procedures).

[0029] In some aspects, the present disclosure provides an intermediate as described herein, being suitable for use in a method for preparing a compound as described herein (e.g., the intermediate is selected from the intermediates described in Preparative part -P1-P114)

[0030] In some aspects, the present disclosure provides a method of preparing compounds of the present disclosure.

[0031] In some aspects, the present disclosure provides a method of preparing compounds of the present disclosure, comprising one or more steps described herein.

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the specification, the singular forms also include the plural unless10.ASBMondego.26.0001the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods and examples are illustrative only and are not intended to be limiting. In the case of conflict between the chemical structures and names of the compounds disclosed herein, the chemical structures will control.

[0033] Other features and advantages of the disclosure will be apparent from the following detailed description and claims.DETAILED DESCRIPTION

[0034] The present disclosure provides methods for treating, preventing, or ameliorating diseases or disorders associated with PTPN2 by administering a therapeutically effective amount of a compound, as described herein, to a subject in need thereof.

[0035] The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.Definitions

[0036] The articles "a" and "an" are used in this disclosure to refer to one or more than one ( / .<?., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.11.ASBMondego.26.0001

[0037] The term "and / or" is used in this disclosure to mean either "and" or "or" unless indicated otherwise.

[0038] The term “optionally substituted” is understood to mean that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded other substituents (e.g., heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (z.e., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have one or more substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term “optionally substituted” means that a given chemical moiety has the potential to contain other functional groups but does not necessarily have any further functional groups. Suitable substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -O-(Ci-C6) alkyl, (Ci-C6) alkyl, (Ci-C6) alkoxy, (Ci-C6) haloalkyl, (Ci-Ce) haloalkoxy, -O-(C2-Ce) alkenyl, -O-(C2-Ce) alkynyl, (C2-C6) alkenyl, (C2-C6) alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C6) alkyl, -C(O)(Ci-C6) alkyl, -OC(O)O(C1-C6) alkyl, -NH2, -NH((CI-C6) alkyl), -N((CI-C6) alkyl)2, -NHC(O)(CI-C6) alkyl, -C(O)NH(CI-C6) alkyl, -S(O)2(Ci-C6) alkyl, -S(O)NH(Ci-C6)alkyl, and -S(O)N((Ci-C6)alkyl)2. The substituents can themselves be optionally substituted. “Optionally substituted” as used herein also refers to substituted or unsubstituted whose meaning is described below.

[0039] As used herein, the term “substituted” means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.

[0040] As used herein, the term “unsubstituted” means that the specified group bears no substituents.

[0041] Unless otherwise specifically defined, the term "aryl" refers to cyclic, aromatic hydrocarbon groups that have 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g.,12.ASBMondego.26.0001biphenyl), or fused (e.g., naphthyl). The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H, -halogen, -O-(Ci-C6)alkyl, (Ci-C6)alkyl, -O-(C2-C6)alkenyl, -O-(C2-C6) alkynyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C6)alkyl, -C(O)(Ci-C6) alkyl, -OC(O)O(Ci-C6)alkyl, -NH2, -NH((Ci-C6)alkyl), -N((Ci-C6)alkyl)2, -S(O)2-(Ci-C6) alkyl, -S(O)NH(Ci-C6)alkyl, and -S(O)N((Ci-Ce)alkyl)2. The substituents can themselves be optionally substituted. Furthermore, when containing two fused rings the aryl groups herein defined may have one or more saturated or partially unsaturated ring fused with a fully unsaturated aromatic ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.

[0042] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic or a polycyclic aromatic radical of 5 to 24 ring atoms, containing one or more ring heteroatoms selected from N, O, S, P, or B, the remaining ring atoms being C. A polycyclic aromatic radical includes two or more fused rings and may further include two or more spiro-fused rings, e.g., bicyclic, tricyclic, tetracyclic, and the like. Unless otherwise specifically defined, “fused” means two rings sharing two ring atoms. Unless otherwise specifically defined, “spiro-fused” means two rings sharing one ring atom. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, O, S, P, or B. Heteroaryl as herein defined also means a tricyclic heteroaromatic group containing one or more ring heteroatoms selected from N, O, S, P, or B. Heteroaryl as herein defined also means a tetracyclic heteroaromatic group containing one or more ring heteroatoms selected from N, O, S, P, or B. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[l,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-13.ASBMondego.26.0001b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][l,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[l,5-a]pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[l,2-a]pyrimidinyl, tetrahydro pyrrolo[l,2-a]pyrimidinyl, 3,4-dihydro-2H-l-pyrrolo[2,l-b]pyrimidine, dib enzo[b,d] thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, lH-pyrido[3,4-b][l,4]thiazinyl, benzooxazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [l,2,4]triazolo[l,5-a]pyridinyl, benzofl, 2, 3]triazolyl, imidazo[l,2-a]pyrimidinyl, [l,2,4]triazolo[4,3-b]pyridazinyl, benzofc] [1, 2, 5]thiadiazolyl, benzofc] [1, 2, 5]oxadiazole, l,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[l,5-b][l,2]oxazinyl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyridinyl, thiazolo[5,4-d]thiazolyl, imidazo[2,l-b][l,3,4]thiadiazolyl, thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two or more fused rings, the heteroaryl groups defined herein may have one or more saturated or partially unsaturated ring fused with one or more fully unsaturated aromatic ring. In heteroaryl ring systems containing more than two fused rings, a saturated or partially unsaturated ring may further be fused with a saturated or partially unsaturated ring described herein. Furthermore, when containing three or more fused rings, the heteroaryl groups defined herein may have one or more saturated or partially unsaturated ring spiro-fused. Any saturated or partially unsaturated ring described herein is optionally substituted with one or more oxo. Exemplary ring systems of these heteroaryl groups include, for example, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-lH-isoquinolinyl, 2,3-dihydrobenzofuranyl, benzofuranonyl, indolinyl, oxindolyl, indolyl, l,6-dihydro-7H-pyrazolo[3,4-c]pyridin-7-onyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizinyl, 8H-pyrido[3,2-b]pyrrolizinyl, l,5,6,7-tetrahydrocyclopenta[b]pyrazolo[4,3-e]pyridinyl, 7,8-dihydro-6H-pyrido[3,2-b]pyrrolizine, pyrazolo[l,5-a]pyrimidin-7(4H)-only, 3,4-dihydropyrazino[l,2-a]indol-l(2H)-onyl, benzofc] [l,2]oxaborol-l(3 / / )-olyl, 6,6a,7,8-tetrahydro-977-14.ASBMondego.26.0001pyrido[2,3-Z>]puyrrolo[l,2-<7][l,4]oxazin-9-onyl, or 6a’,7’-dihydro-6’H,9’H-spiro[cyclopropane-l,8’-pyrido[2,3-Z>]pyrrolo[l,2-t / ][l,4]oxazin]-9’-onyl.

[0043] Halogen or “halo” refers to fluorine, chlorine, bromine, or iodine.

[0044] Alkyl refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms. Examples of a (Ci-Ce) alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl (Ao-propyl), isobutyl (Ao-butyl),.sec-butyl, tert-butyl, isopentyl (Ao-pentyl), neopentyl (neo-pentyl), and isohexyl (Ao-hexyl).

[0045] “Alkoxy” refers to a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal “O” in the chain, i.e., -O(alkyl). Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, / e / 7-butoxy, or pentoxy groups.

[0046] “Alkenyl” refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The “alkenyl” group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted. Alkenyl, as herein defined, may be straight or branched.

[0047] “Alkynyl” refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The “alkynyl” group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propargyl, / v-butynyl, Ao-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.

[0048] The term “alkylene”, “alkylenyl” or “alkanediyl” refers to a divalent alkyl radical. Any of the above-mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a Ci-Ce alkylene. An alkylene may further be a C1-C4 alkylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and the like.

[0049] “Cycloalkyl” means mono or polycyclic saturated carbon rings containing 3-18 carbon atoms. Polycyclic cycloalkyl may be fused bicyclic cycloalkyl, bridged bicyclic cycloalkyl, or spiro-fused bicyclic cycloalkyl. A polycyclic cycloalkyl comprises at least one non-aromatic ring. Examples of cycloalkyl groups include, without limitations,15.ASBMondego.26.0001cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norbomyl, norborenyl, 1,2,3,4-tetrahydronaphthyl, 2,3-dihydro-lH-indenyl, spiro[3.5]nonyl, spiro [5.5]undecyl, bicyclofl.1.1 ]pentanyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl.

[0050] “Heterocyclyl”, “heterocycle” or “heterocycloalkyl” mono or polycyclic rings containing 3-24 atoms which include carbon and one or more heteroatoms selected from N, O, S, P, or B and wherein the rings are not aromatic, but can comprise one or more double bonds. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.

[0051] The term “aromatic” means a planar ring having 4zz + 2 electrons in a conjugated system. As used herein, “conjugated system” means a system of connected p-orbitals with delocalized electrons, and the system may include lone electron pairs.

[0052] The term “haloalkyl” as used herein refers to an alkyl group, as defined herein, which is substituted one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.

[0053] The term “haloalkoxy” as used herein refers to an alkoxy group, as defined herein, which is substituted with one or more halogen. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.

[0054] The term “cyano” as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, / .<., C=N.

[0055] “Spirocycloalkyl” or “spirocyclyl” means carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring. One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., O,16.ASBMondego.26.0001N, S, or P). A (C3-C12) spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom.

[0056] The term “spiroheterocycloalkyl”, “spiroheterocycle”, or “spiroheterocyclyl” is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperidinyl).

[0057] The term "solvate" refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, DMSO, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.

[0058] The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and / or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (1) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.

[0059] The present disclosure also contemplates isotopically-labelled compounds of Formula A (e.g., those labeled with2H and14C). Deuterated (i.e.,2H or D) and carbon-14 (i.e.,14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of Formula (A) can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or in the Examples herein below, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.

[0060] The disclosure also includes pharmaceutical compositions comprising a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier. Representative "pharmaceutically acceptable salts" include, e.g., water-17.ASBMondego.26.0001soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate, pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.

[0061] A "patient" or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon, or rhesus.

[0062] An "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.

[0063] The term "carrier", as used in this disclosure, encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.

[0064] The term "treating" with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.

[0065] The term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.

[0066] The term "administer", "administering", or "administration" as used in this disclosure refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the18.ASBMondego.26.0001compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.

[0067] The term "prodrug", as used in this disclosure, means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.

[0068] The term “salt” refers to pharmaceutically acceptable salts.

[0069] The term “pharmaceutically acceptable salt” also refers to a salt of the compositions of the present disclosure having an acidic functional group, such as a carboxylic acid functional group, and a base.

[0070] ‘ ‘PTPN 2 inhibitor” as used herein refer to compounds of Formula A and / or compositions comprising a compound of Formula A which inhibits PTPN2.

[0071] The amount of compound of composition described herein needed for achieving a therapeutic effect may be determined empirically in accordance with conventional procedures for the particular purpose. Generally, for administering therapeutic agents (e.g. compounds or compositions comprising compounds of Formula A (and / or additional agents) described herein) for therapeutic purposes, the therapeutic agents are given at a pharmacologically effective dose. A “pharmacologically effective amount”, “pharmacologically effective dose”, “therapeutically effective amount”, or “effective amount” refers to an amount sufficient to produce the desired physiological effect or amount capable of achieving the desired result, particularly for treating the disorder or disease. An effective amount as used herein would include an amount sufficient to, for example, delay the development of a symptom of the disorder or disease, alter the course of a symptom of the disorder or disease (e.g., slow the progression of a symptom of the disease), reduce or eliminate one or more symptoms or manifestations of the disorder or disease, and reverse a symptom of a disorder or disease. For example, administration of therapeutic agents to a subj ect suffering from cancer provides a therapeutic benefit not only when the underlying condition is eradicated or ameliorated, but also when the subject reports a decrease in the severity or duration of the symptoms associated with the disease, e.g., a decrease in tumor burden, a decrease in circulating tumor cells, an increase in progression free survival. Therapeutic benefit also includes halting or slowing the progression of the underlying disease or disorder, regardless of whether improvement is realized.19.ASBMondego.26.0001Compounds of the Present Disclosure

[0072] The compounds of the present invention are represented by general Formula (A):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein R1, R2, R3and R4are as described herein.

[0073] It is understood that, for a compound of Formula (A), R1, R2, R3, and R4can each be, where applicable, selected from the groups described herein, and any group described herein for any R1, R2, R3, and R4can be combined, where applicable, with any group described herein for one or more of the remainders of R1, R2, R3, and R4.

[0074] In some embodiments the compound of Formula (A) is a compound of Formula (I).

[0075] In some embodiments, the present disclosure provides compounds of Formula (I) and salts, stereoisomers, solvates, prodrugs, isotopic derivatives, and tautomers thereof:wherein:Q is selected from O, S(O)k, C(R21)2, NR22;R4is selected from H, -OH, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl;each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl; or20.ASBMondego.26.0001two R21together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl optionally substituted with one or more R22; ortwo R21attached to two vicinal atoms form a double bond; ortwo R21attached to geminal atom form =0;each R22is independently selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl;R31is selected from H, Ci-Ce alkyl, Cs-Cs cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;k is an integer selected from 0, 1, and 2;m is an integer selected from 0, 1, 2, and 3;n is an integer selected from 1, 2, and 3.

[0076] In some embodiments, the compound is of Formula (1-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0077] In some embodiments, the compound is of Formula (I-A-1):21.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0078] In some embodiments, the compound is of Formula (I-A-l-a):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:R4is selected from H, -OH, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl;R31is selected from Ci-Ce alkyl, C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl.

[0079] In some embodiments, the compound is of Formula (I-A-2):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0080] In some embodiments, the compound is of Formula (I-A-2-a):22.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0081] In some embodiments, the compound is of Formula (I-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0082] In some embodiments, the compound is of Formula (I-B-l):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0083] In some embodiments, the compound is of Formula (I-B-l-a):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.ASBMondego.26.0001

[0084] In some embodiments, the compound is of Formula (I-B-l-b):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0085] In some embodiments, the compound is of Formula (I-B-l-c):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0086] In some embodiments, the compound is of Formula (I-B-l-d):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0087] In some embodiments, the compound is of Formula (I-C):(1-C),24.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0088] In some embodiments, the compound is of Formula (I-C-l ):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0089] In some embodiments, the compound is of Formula (I-C-l-a):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0090] In some embodiments, the compound is of Formula (I-D):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0091] In some embodiments, the compound is of Formula (I-D-l ):25.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0092] In some embodiments, the compound is of Formula (I-D-l-a):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0093] In some embodiments, the compound is of Formula (I-D-l-a-I):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0094] In some embodiments, the compound is of Formula (I-D-l-b):26.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0095] In some embodiments, the compound is of Formula (I-D-l-b-I):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0096] In some embodiments, the compound is of Formula (I-D-l-c):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0097] In some embodiments, the compound is of Formula (I-E):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0098] In some embodiments, the compound is of Formula (I-E-l):27.ASBMondego.26.0001.21 R21or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0099] In some embodiments the compound of Formula (A) is a compound of Formula (II).

[0100] In some embodiments, the present disclosure provides compounds of Formula (II) and salts, stereoisomers, solvates, prodrugs, isotopic derivatives, and tautomers thereof:wherein:Q is selected from O, S, S(O)k, C(R21)2, NR22;R3is selected from H, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -N h, -OH, -CN, halogen, =0;each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl; ortwo R21together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl; ortwo R21attached to two vicinal atoms form a double bond; ortwo R21attached to geminal atom form =0;28.ASBMondego.26.0001R22is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl;R31is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;k is an integer selected from 0, 1, and 2;m is an integer selected from 0, 1, 2, and 3;n is an integer selected from 1, 2, and 3.

[0101] In some embodiments the compound of Formula (A) is a compound of Formula (III).

[0102] In some embodiments, the compound is of Formula (III):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:R3is selected from H, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, O;Z is selected from O and NH;W is 5-6 membered cycloalkyl, heterocyclyl or heteroaryl, wherein cycloalkyl, heterocyclyl or heteroaryl optionally substituted with one or more R23;R23is selected from Ci-Ce alkyl, Ci-Ce alkoxy,29.ASBMondego.26.0001t is an integer selected from 0 and 1;r is an integer selected from 0 and 1.

[0103] In some embodiments, the compound is of Formula (III-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein s is an integer selected from 0, 1, 2 and 3.

[0104] In some embodiments, the compound is of Formula (III-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein s is an integer selected from 0, 1, 2 and 3.

[0105] In some embodiments, the compound is of Formula (III-C):30.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein s is an integer selected from 0, 1, 2 and 3.

[0106] In some embodiments the compound of Formula (A) is a compound of Formula (IV).

[0107] In some embodiments, the compound is of Formula (IV):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:R7is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;Rais selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;Rbis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rcis H; orRaand Rcform a double bond;Rdis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Reis H;R1is selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rgis H; orReand Rgform a double bond.

[0108] In some embodiments, the compound is of Formula (IV-A):31.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0109] In some embodiments, the compound is of Formula (FV-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof

[0110] In some embodiments the compound of Formula (A) is a compound of Formula (V).

[0111] In some embodiments, the compound is of Formula (V):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:Rhis selected from Ci-Ce alkyl, 3-8 membered cycloalkyl;p is an integer selected from 1, 2 and 3.32.ASBMondego.26.0001

[0112] In some embodiments the compound of Formula (A) is a compound of Formula (VI).

[0113] In some embodiments, the compound is of Formula (VI):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:Rhis selected from Ci-Ce alkyl, 3-8 membered cycloalkyl;R24is selected from Ci-Ce alkyl and C2-C6 alkenyl, wherein alkyl or alkenyl is optionally substituted with one or more substituents independently selected from halogen, OH, CN.

[0114] In some embodiments the compound of Formula (A) is a compound of Formula (VII).

[0115] In some embodiments, the compound is of Formula (VII):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:R10isH;R11is H; orR10and R11together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl 33.ASBMondego.26.0001is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0;R12is H;R13is H; orR12and R13together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0;provided that when R10and R11each is H, then R12and R13together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl and when R12and R13each is H, then R10and R11together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl.

[0116] In some embodiments, the compound is of Formula (VII-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:Q is selected from O, S(O)k, CH2, NH;each Rqis independently selected from C1-C6 alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0;k is an integer selected from 0, 1, and 2;q is an integer selected from 0, 1, and 2;m is an integer selected from 0, 1, 2, and 3;n is an integer selected from 1, 2, and 3.

[0117] In some embodiments, the compound is of Formula (VII-A-1):34.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0118] In some embodiments, the compound is of Formula (VII-A-l-a):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof

[0119] In some embodiments, the compound is of Formula (VII-A-I-b):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein Rqis Ci-Ce alkyl or C3-C7 cycloalkyl.

[0120] In some embodiments, the compound is of Formula (VII-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:35.ASBMondego.26.0001Q is selected from O, S, S(O)k, CH2, NH;each Rqis independently selected from Ci-Ce alkyl, OH, halogen, CN, and =0; k is an integer selected from 0, 1, and 2;q is an integer selected from 0, 1, and 2;m is an integer selected from 0, 1, 2, and 3;n is an integer selected from 1, 2, and 3.

[0121] In some embodiments, the compound is of Formula (VII-B-1):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0122] In some embodiments, the compound is of Formula (VII-B-l-a):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0123] In some embodiments, the compound is of Formula (VII-B-l-b):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein Rqis Ci-Ce alkyl or C3-C7 cycloalkyl.

[0124] In some embodiments the compound of Formula (A) is a compound of Formula (VIII).36.ASBMondego.26.0001

[0125] In some embodiments, the compound is of Formula (VIII):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;each from R25, R26and R27is independently selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy.

[0126] In some embodiments, the compound is of Formula (VIII- A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0127] In some embodiments, the compound is of Formula (VIII-B):37.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0128] In some embodiments the compound of Formula (A) is a compound of Formula (IX-X).

[0129] In some embodiments, the compound is of Formula (IX-X):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:each V is independently selected from CR26and N;each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;each from R25, R26and R27is independently selected from H, Ci-Ce alkyl, and Ci-Cr> alkoxy;R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl.

[0130] In some embodiments the compound of Formula (A) is a compound of Formula (IX).

[0131] In some embodiments, the compound is of Formula (IX):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:38.ASBMondego.26.0001each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;each from R25, R26and R27is independently selected from H, Ci-Ce alkyl, and Ci-C6 alkoxy.

[0132] In some embodiments, the compound is of Formula (IX-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0133] In some embodiments, the compound is of Formula (IX-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0134] In some embodiments the compound of Formula (A) is a compound of Formula (X).

[0135] In some embodiments, the compound is of Formula (X):39.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:each V is independently selected from CR26and N;each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;each from R25, R27, R42, and R44is independently selected from H, Ci-Ce alkyl, and Ci-C6alkoxy;each R26is independently selected from H, Ci-Ce alkyl, C3-C7 cycloalkyl, C4-C7 cycloalkenyl, -NHCi-Ce alkyl, and Ci-Ce alkoxy;R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl.

[0136] In some embodiments, the compound is of Formula (X-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0137] In some embodiments, the compound is of Formula (X-B):40.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0138] In some embodiments, the compound is of Formula (X-C):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0139] In some embodiments, the compound is of Formula (X-D):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0140] In some embodiments, the compound is of Formula (X-E):41.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0141] In some embodiments the compound of Formula (A) is a compound of Formula (XI).

[0142] In some embodiments, the compound is of Formula (XI):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy.

[0143] In some embodiments, the compound is of Formula (XI-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof42.ASBMondego.26.0001

[0144] In some embodiments the compound of Formula (A) is a compound of Formula (XII).

[0145] In some embodiments, the compound is of Formula (XII):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:Q* is selected from O, S(O)k, CH2, NR28;k is an integer selected from 0, 1, and 2;each R28is independently selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl; each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy.

[0146] In some embodiments, the compound is of Formula (XII- A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0147] In some embodiments, the compound is of Formula (XII-B):43.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0148] In some embodiments the compound of Formula (A) is a compound of Formula (XIII).

[0149] In some embodiments, the compound is of Formula (XIII):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R31is selected from Ci-Ce alkyl, C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl.

[0150] In some embodiments the compound of Formula (A) is a compound of Formula (XIV).

[0151] In some embodiments, the compound is of Formula (XIV):44.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:Q is selected from O, S(O)k, CH2, NH;R30is selected from H, halogen, Ci-Ce alkyl, wherein alkyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen;each R41is independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, Cs-Cs cycloalkyl, 3-7 membered heterocyclyl, aryl, 5-6 membered heteroaryl;b is an integer selected from 0, 1, 2 and 3;k is an integer selected from 0, 1, and 2;q is an integer selected from 0, 1 and 2.

[0152] In some embodiments, the compound is of Formula (XIV-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0153] In some embodiments, the compound is of Formula (XIV-A-1):45.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0154] In some embodiments, the compound is of Formula (XIV-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0155] In some embodiments the compound of Formula (A) is a compound of Formula (XV).

[0156] In some embodiments, the compound is of Formula (XV):46.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:each E is independently selected from CR52and N;R28is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R51is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl, wherein alkyl or cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, =0, Ci-Ce alkyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, aryl;each R52is independently selected from H, Ci-Ce alkyl;or two R52together with the atoms to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl.

[0157] In some embodiments, the compound is of Formula (XV-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0158] In some embodiments, the compound is of Formula (XV-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0159] In some embodiments the compound of Formula (A) is a compound of Formula (XVI).

[0160] In some embodiments, the compound is of Formula (XVI):47.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:each R* is H, or two R* form a bond;each R28is independently selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R61is selected from H, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, -C(O)N(R28)2, -C(O)OR28, wherein alkyl, cycloalkyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2;R62is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;or R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl, 5-10 membered heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, Ci-Ce alkyl-C(O)-, -C(O)N(R28)2.

[0161] In some embodiments, the compound is of Formula (XVI-A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0162] In some embodiments, the compound is of Formula (XVI-A-1):48.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0163] In some embodiments, the compound is of Formula (XVI-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R63is selected from Ci-C6alkyl, Ci-C6alkyl-C(O)-, -C(O)N(R28)2.

[0164] In some embodiments, the compound is of Formula (XVII):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R33is selected from H, halogen, -CN, Ci-Ce alkyl, Ca-Cs cycloalkyl;and all other variables are as defined herein.

[0165] In some embodiments, the compound is of Formula (XVII-A):49.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R33is selected from H, halogen, -CN, Ci-Ce alkyl, Ca-Cs cycloalkyl;and all other variables are as defined herein.

[0166] In some embodiments, the compound is of Formula (XVII-B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R33is selected from H, halogen, -CN, Ci-Ce alkyl, Ca-Cs cycloalkyl;and all other variables are as defined herein.

[0167] In some embodiments, the compound is of Formula (XVIII- A):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0168] In some embodiments, the compound is of Formula (XVIII-B):50.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R3is selected from H, -OH, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -OH, -CN, halogen, =0, -NR31R32, -C(O)NR31R32, and 3-10 membered heterocyclyl, or two substituents together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl;and all other variables are as defined herein.

[0169] In some embodiments, the compound is of Formula (B):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R28is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R31is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl51.ASBMondego.26.0001is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;R43is H; orR32and R43together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and aryl;R45is selected from halogen, -CN, -OH, and Ci-Ce alkyl;z is an integer selected from 0 and 1.

[0170] In some embodiments, the compound is of Formula (B-l):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0171] In some embodiments, the compound is of Formula (B-l-I):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0172] In some embodiments, the compound is of Formula (B-l-II):52.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof.

[0173] In some embodiments, the compound is of Formula (B-2):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:each R46is independently selected from halogen, OH, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and aryl;x is an integer selected from 1, 2, 3, and 4;y is an integer selected from 0, 1, and 2;and all other variables are as described herein.

[0174] In some embodiments, the compound is of Formula (B-3):53.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:each R46is independently selected from halogen, OH, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and aryl;y is an integer selected from 0, 1, and 2;and all other variables are as described herein.

[0175] In some embodiments, each E is independently selected from CR52and N.

[0176] In some embodiments, E is CR52.

[0177] In some embodiments, E is N.

[0178] In some embodiments, Q is selected from O, S(O)k, C(R21)2, NR22.

[0179] In some embodiments, Q is O.

[0180] In some embodiments, Q is S(O)k.

[0181] In some embodiments, Q is S.

[0182] In some embodiments, Q is S(O).

[0183] In some embodiments, Q is S(O)2.

[0184] In some embodiments, Q is C(R21)2.

[0185] In some embodiments, Q is CH2.

[0186] In some embodiments, Q is CHR21.

[0187] In some embodiments, Q is CHNR31R32.

[0188] In some embodiments, Q is CHNHR31.

[0189] In some embodiments, Q is CHNH(CH2)2CH(CH3)2.

[0190] In some embodiments,

[0191] In some embodiments,

[0192] In some embodiments, Q is NH.

[0193] In some embodiments, Q is NCH2CH(CH )2.

[0194] In some embodiments, Q is N(CH2)2CH(CH3)2.

[0195] In some embodiments, Q is NC(O)OCH2Aryl.

[0196] In some embodiments,54.ASBMondego.26.0001

[0197] In some embodiments, Q* is selected from O, S(O)k, CH2, NR28.

[0198] In some embodiments, Q* is S.

[0199] In some embodiments, Q* is NH.

[0200] In some embodiments, each V is independently selected from CR’ and N.

[0201] In some embodiments, V is CR’.

[0202] In some embodiments, V is N.

[0203] In some embodiments, W is 5-6 membered cycloalkyl, heterocyclyl or heteroaryl, wherein cycloalkyl, heterocyclyl or heteroaryl optionally substituted with one or more R23.

[0204] In some embodiments, W is 5-6 membered cycloalkyl optionally substituted with one or more R23.

[0205] In some embodiments, W is 5-6 membered cycloalkyl.

[0206] In some embodiments,

[0207] In some embodiments, W is heterocyclyl optionally substituted with one or more

[0208] In some embodiments, W is heterocyclyl.

[0209] In some embodiments, W is 5-6 membered heterocyclyl.

[0210] In some embodiments,

[0211] In some embodiments,

[0212] In some embodiments,

[0213] In some embodiments,

[0214] In some embodiments,55.ASBMondego.26.0001

[0215] In some embodiments,

[0216] In some embodiments,

[0217] In some embodiments,

[0218] In some embodiments, W is heteroaryl optionally substituted with one or more R23.

[0219] In some

[0220] In some

[0221] In some embodiments,

[0222] In some embodiments,

[0223] In some embodiments,

[0224] In some embodiments, Z is selected from O and NH.

[0225] In some embodiments, Z is O.

[0226] In some embodiments, Z is NH.56.ASBMondego.26.0001

[0227] In some embodiments, Rais selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl.

[0228] In some embodiments, Rais H.

[0229] In some embodiments, Rbis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl.

[0230] In some embodiments, Rbis H.

[0231] In some embodiments, Rbis OH.

[0232] In some embodiments, Rcis H.

[0233] In some embodiments, Raand Rcform a double bond.

[0234] In some embodiments, Rdis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl.

[0235] In some embodiments, Rdis H.

[0236] In some embodiments, Rdis Ci-Ce alkoxy.

[0237] In some embodiments, Rdis -OCH3.

[0238] In some embodiments, Reis H.

[0239] In some embodiments, Reand Rgform a double bond.

[0240] In some embodiments, Rfis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl.

[0241] In some embodiments, Rfis H.

[0242] In some embodiments, R1is Ci-Ce alkoxy.

[0243] In some embodiments, Rfis -OCH3.

[0244] In some embodiments, Rgis H.

[0245] In some embodiments, Rhis selected from Ci-Ce alkyl, 3-8 membered cycloalkyl.

[0246] In some embodiments, Rhis Ci-Ce alkyl.

[0247] In some embodiments, Rhis -(CH2)2CH(CH3)2.

[0248] In some embodiments, Rqis independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0.

[0249] In some embodiments, each R* is H.

[0250] In some embodiments, two R* form a bond.

[0251] In some embodiments, each R** is H.

[0252] In some embodiment, two R** form a bond.57.ASBMondego.26.0001

[0253] In some embodiments, each R* is H and each R** is H.

[0254] In some embodiments, two R* form a bond and two R** form a bond.

[0255] In some embodiments, R3is selected from H, halogen, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0.

[0256] In some embodiments, R3is selected from H, halogen.

[0257] In some embodiments, R3is H.

[0258] In some embodiments, R3is halogen.

[0259] In some embodiments, R3is F.

[0260] In some embodiments, R3is Cl.

[0261] In some embodiments, R3is Br.

[0262] In some embodiments, R3is Ci-Cg alkyl optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0.

[0263] In some embodiments, R3is -CH3.

[0264] In some embodiments, R3is -CHF2.

[0265] In some embodiments, R3is -CF3.

[0266] In some embodiments, R3is -CH2CH3.

[0267] In some embodiments, R3is -CH2CH2CH3.

[0268] In some embodiments, R3is -CH(CH3)2.

[0269] In some embodiments, R3is -CH2CH2CH2CH3.

[0270] In some embodiments, R3is -CH2CH(CH3)2.

[0271] In some embodiments, R3is -C(CH3)3.

[0272] In some embodiments, R3is C5 alkyl.

[0273] In some embodiments, R3is Ce alkyl.

[0274] In some embodiments, R3is 3-8 membered cycloalkyl optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0.

[0275] In some embodiments, R3is aryl optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0.58.ASBMondego.26.0001

[0276] In some embodiments, R3is 3-10 membered heterocyclyl optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0.

[0277] In some embodiments, R3is 5-10 membered heteroaryl optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0.

[0278] In some embodiments, R4is selected from H, -OH, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl.

[0279] In some embodiments, R4is H.

[0280] In some embodiments, R4is -OH.

[0281] In some embodiments, R4is halogen.

[0282] In some embodiments, R4is F.

[0283] In some embodiments, R4is Cl.

[0284] In some embodiments, R4is Br.

[0285] In some embodiments, R4is Ci-Ce alkyl.

[0286] In some embodiments, R4is -CH3.

[0287] In some embodiments, R4is -CH2CH3.

[0288] In some embodiments, R4is -CH2CH2CH3.

[0289] In some embodiments, R4is -CH(CH)2.

[0290] In some embodiments, R4is -CH2CH2CH2CH3.

[0291] In some embodiments, R4is -CH2CH(CH3)2.

[0292] In some embodiments, R4is -C(CH)3.

[0293] In some embodiments, R4is C5 alkyl.

[0294] In some embodiments, R4is Ce alkyl.

[0295] In some embodiments, R4is C2-C6 alkenyl.

[0296] In some embodiments,

[0297] In some embodiments,59.ASBMondego.26.0001

[0298] In some embodiments, each R5is independently selected from[,

[0300] In some embodiments,

[0301] In some embodiments,

[0302] In some embodiments,60.ASBMondego.26.0001

[0303] In some embodiments,

[0304] In some embodiments,

[0305] In some embodiments, each R6is independently selected from Ci-Ce alkyl, -OH, -

[0306] In some embodiments, R6is Ci-Ce alkyl.

[0307] In some embodiments, R6is -OH.

[0308] In some embodiments, R6is -NHCH2R24.

[0309] In some embodiments,

[0310] In some embodiments,

[0311] In some embodiments, two geminal or vicinal R6form C3-C10 cycloalkyl, 3-10 membered heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0.

[0312] In some embodiments, two geminal R6form C3-C10 cycloalkyl, 3-10 membered heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more61.ASBMondego.26.0001substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0.

[0313] In some embodiments, two vicinal R6form C3-C10 cycloalkyl, 3-10 membered heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0.

[0314] In some embodiments, two geminal R6form =0.

[0315] In some embodiments, R7is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl.

[0316] In some embodiments, R7is H.

[0317] In some embodiments, R7is Ci-Ce alkyl.

[0318] In some embodiments, R7is 3-8 membered cycloalkyl.

[0319] In some embodiments, R10is H.

[0320] In some embodiments, R11is H.

[0321] In some embodiments, R10and R11together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0.

[0322] In some embodiments, R10and R11together with the atom to which they areattached and any intervening atoms, form

[0323] In some embodiments, R10and R11together with the atom to which they areattached and any intervening atoms, form

[0324] In some embodiments, R10and R11together with the atom to which they areX N— (attached and any intervening atoms, form ''' X.

[0325] In some embodiments, R10and R11together with the atom to which they areattached and any intervening atoms, form 162.ASBMondego.26.0001

[0326] In some embodiments, R10and R11together with the atom to which they areattached and any intervening atoms, form

[0327] In some embodiments, R10and R11together with the atom to which they areattached and any intervening atoms, form

[0328] In some embodiments, R12is H.

[0329] In some embodiments, R13is H.

[0330] In some embodiments, R12and R13together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0.

[0331] In some embodiments, R12and R13together with the atom to which they areattached and any intervening atoms, form

[0332] In some embodiments, R12and R13together with the atom to which they areattached and any intervening atoms, form

[0333] In some embodiments, R12and R13together with the atom to which they areattached and any intervening atoms, form

[0334] In some embodiments, R12and R13together with the atom to which they areattached and any intervening atoms, form

[0335] In some embodiments, R12and R13together with the atom to which they areattached and any intervening atoms, form63.ASBMondego.26.0001

[0336] In some embodiments, R12and R13together with the atom to which they areattached and any intervening atoms, form

[0337] In some embodiments, each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl.

[0338] In some embodiments, R21is H.

[0339] In some embodiments, R21is -OH.

[0340] In some embodiments, R21is halogen.

[0341] In some embodiments, R21is F.

[0342] In some embodiments, R21is Cl.

[0343] In some embodiments, R21is Br.

[0344] In some embodiments, R21is Ci-Ce alkyl.

[0345] In some embodiments, R21is -CH3.

[0346] In some embodiments, R21is -CH2CH3.

[0347] In some embodiments, R21is -CH2CH2CH3.

[0348] In some embodiments, R21is -CH(CH3)2.

[0349] In some embodiments, R21is -CH2CH2CH2CH3.

[0350] In some embodiments, R21is -CH2CH(CH3)2.

[0351] In some embodiments, R21is -C(CH3)3.

[0352] In some embodiments, R21is Cs alkyl.

[0353] In some embodiments, R21is C>, alkyl.

[0354] In some embodiments, R21is -NR31R32.

[0355] In some embodiments, R21is -NH2.

[0356] In some embodiments, R21is -C(O)NR31R32.

[0357] In some embodiments, R21is -C(O)NHCH2CH2CH(CH3)2.

[0358] In some embodiments, R21is 3-10 membered heterocyclyl.

[0359] In some embodiments, two R21attached to two vicinal atoms form a double bond.

[0360] In some embodiments, two R21attached to geminal atom form =0.64.ASBMondego.26.0001

[0361] In some embodiments, two R21together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl optionally substituted with one or more R22.

[0362] In some embodiments, two R21together with the atoms to which they are attached and any intervening atoms, form cyclopropyl.

[0363] In some embodiments, two R21together with the atoms to which they are attached and any intervening atoms, form cyclobutyl.

[0364] In some embodiments, two R21together with the atoms to which they are attached and any intervening atoms, form pyrrolidine.

[0365] In some embodiments, two R21together with the atoms to which they are attached and any intervening atoms, form pyrrolidine substituted with one or more R22.

[0366] In some embodiments, each R22is independently selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl.

[0367] In some embodiments, R22is H.

[0368] In some embodiments, R22is Ci-Ce alkyl.

[0369] In some embodiments, R22is -CH3.

[0370] In some embodiments, R22is -CH2CH3.

[0371] In some embodiments, R22is -CH2CH2CH3.

[0372] In some embodiments, R22is -CH(CH3)2.

[0373] In some embodiments, R22is -CH2CH2CH2CH3.

[0374] In some embodiments, R22is -CH2CH(CH3)2.

[0375] In some embodiments, R22is -C(CH3)3.

[0376] In some embodiments, R22is C5 alkyl.

[0377] In some embodiments, R22is -CH2CH2CH(CH3)2.

[0378] In some embodiments, R22is Ce alkyl.

[0379] In some embodiments, R22is -C(O)OCH2Aryl.

[0380] In some embodiments,65.ASBMondego.26.0001

[0381] In some embodiments,

[0382] In some embodiments, R23is selected from Ci-Ce alkyl, Ci-Ce alkoxy.

[0383] In some embodiments, R23is Ci-Ce alkyl.

[0384] In some embodiments, R23is -CH3.

[0385] In some embodiments, R23is Ci-Ce alkoxy.

[0386] In some embodiments, R23is -OCH3.

[0387] In some embodiments, R24is selected from Ci-Ce alkyl and C2-C6 alkenyl, wherein alkyl or alkenyl is optionally substituted with one or more substituents independently selected from halogen, OH, CN.

[0388] In some embodiments, R24is Ci-Ce alkyl optionally substituted with one or more substituents independently selected from halogen, OH, CN.

[0389] In some embodiments, R24is -CH2CH(CH3)2.

[0390] In some embodiments, R24is -CF3.

[0391] In some embodiments, R24is C2-C6 alkenyl optionally substituted with one or more substituents independently selected from halogen, OH, CN.

[0392] In some embodiments, R24is -CH=CF2.

[0393] In some embodiments, R25is selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy.

[0394] In some embodiments, R25is H.

[0395] In some embodiments, R25is Ci-Ce alkyl.

[0396] In some embodiments, R25is -CH3.

[0397] In some embodiments, R25is Ci-Ce alkoxy.

[0398] In some embodiments, R25is -OCH3.

[0399] In some embodiments, each R26is independently selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy.

[0400] In some embodiments, R26is H.

[0401] In some embodiments, R26is Ci-Ce alkyl.

[0402] In some embodiments, R26is -CH3.

[0403] In some embodiments, R26is Ci-Ce alkoxy.

[0404] In some embodiments, R26is -OCH3.66.ASBMondego.26.0001

[0405] In some embodiments, R27is selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy.

[0406] In some embodiments, R27is H.

[0407] In some embodiments, R27is Ci-Ce alkyl.

[0408] In some embodiments, R27is -CH3.

[0409] In some embodiments, R27is Ci-Ce alkoxy.

[0410] In some embodiments, R27is -OCH3.

[0411] In some embodiments, R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl.

[0412] In some embodiments, R28is H.

[0413] In some embodiments, R28is Ci-Ce alkyl.

[0414] In some embodiments, R28is C3-C8 cycloalkyl.

[0415] In some embodiments, each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy.

[0416] In some embodiments, R29is H.

[0417] In some embodiments, R29is -OH.

[0418] In some embodiments, R29is -OCH3.

[0419] In some embodiments, R30is selected from H, halogen, Ci-Ce alkyl, wherein alkyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen.

[0420] In some embodiments, R30is H.

[0421] In some embodiments, R30is -CF3.

[0422] In some embodiments, R31is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl.

[0423] In some embodiments, R31is H.

[0424] In some embodiments, R31is Ci-Ce alkyl.

[0425] In some embodiments, R31is -CH3.

[0426] In some embodiments, R31is -CH2CH3.

[0427] In some embodiments, R31is -CH2CH2CH3.

[0428] In some embodiments, R31is -CH(CH3)2.

[0429] In some embodiments, R31is -CH2CH2CH2CH3.

[0430] In some embodiments, R31is -CH2CH(CH3)2.

[0431] In some embodiments, R31is -C(CH3)3.

[0432] In some embodiments, R31is C5 alkyl.67.ASBMondego.26.0001

[0433] In some embodiments, R31is -CH2CH2CH(CH3)2.

[0434] In some embodiments, R31is C3-C8 cycloalkyl.

[0435] In some embodiments, R32is selected from H, Ci-Ce alkyl.

[0436] In some embodiments, R32is H.

[0437] In some embodiments, R32is Ci-Ce alkyl.

[0438] In some embodiments, R31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl.

[0439] In some embodiments, R31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl.

[0440] In some embodiments, R31and R32together with the atom to which they are attached and any intervening atoms, form piperidine.

[0441] In some embodiments, each R41is independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, C3-C8 cycloalkyl, 3-7 membered heterocyclyl, aryl, 5-6 membered heteroaryl.

[0442] In some embodiments, R41is Ci-Ce alkyl.

[0443] In some embodiments, R41is -CH3.

[0444] In some embodiments, R43is H.

[0445] In some embodiments, R32and R43together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and aryl.

[0446] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0447] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form68.ASBMondego.26.0001

[0448] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0449] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0450] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0451] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0452] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0453] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0454] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form69.ASBMondego.26.0001

[0455] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0456]

[0457] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0458] In some embodiments, R32and R43together with the atoms to which they areattached and any intervening atoms, form

[0459] In some embodiments, R45is selected from halogen, -CN, -OH, and Ci-Ce alkyl.

[0460] In some embodiments, R45is halogen.

[0461] In some embodiments, R45is -CN.

[0462] In some embodiments, R45is -OH.

[0463] In some embodiments, R45is Ci-Ce alkyl.

[0464] In some embodiments, R45is -CH3.

[0465] In some embodiments, R43is -CH2CH2CH3.

[0466] In some embodiments, R45is -CH2CH2CH(CH3)2.

[0467] In some embodiments, R31is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl, wherein alkyl or cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, =0, Ci-Ce alkyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, aryl.

[0468] In some embodiments, R51is -CH3.

[0469] In some embodiments,

[0470] In some embodiments,

[0471] In some embodiments,

[0472] In some embodiments, each R52is independently selected from H, Ci-Ce alkyl.

[0473] In some embodiments, R52is H.70.ASBMondego.26.0001

[0474] In some embodiments, R2is Ci-Ce alkyl.

[0475] In some embodiments, R52is -CH3.

[0476] In some embodiments, R61is selected from H, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, -C(O)N(R28)2, -C(O)OR28, wherein alkyl, cycloalkyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2.

[0477] In some embodiments, R61is H.

[0478] In some embodiments, R61is Ci-Ce alkyl, wherein alkyl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2.

[0479] In some embodiments, R61is -CH3.

[0480] In some embodiments, R61is -CF3.

[0481] In some embodiments, R61is -C(CH3)3.

[0482] In some embodiments, R61is -CH2CH2CH(CH3)2.

[0483] In some embodiments, R61is C3-C10 cycloalkyl, wherein cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2.

[0484] In some embodiments, R61is cyclopentyl.

[0485] In some embodiments, R61is cyclohexyl.

[0486] In some embodiments, R61is cycloheptyl.

[0487] In some embodiments, R61is aryl, wherein aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2.

[0488] In some embodiments, R61is phenyl.

[0489] In some embodiments, R61is -C(O)N(R28)2.

[0490] In some embodiments, R61is -C(O)NH2.

[0491] In some embodiments, R61is -C(O)NHCH3.

[0492] In some embodiments, R61is -C(O)N(CH3)2.

[0493] In some embodiments, R61is -C(O)NHCH2CH2CH(CH3)2.

[0494] In some embodiments, R61is -C(O)OR28.

[0495] In some embodiments, R61is -C(O)OCH2CH3.

[0496] In some embodiments, R62is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl.

[0497] In some embodiments, R62is H.

[0498] In some embodiments, R62is Ci-Ce alkyl.71.ASBMondego.26.0001

[0499] In some embodiments, R62is CH3.

[0500] In some embodiments, R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl, 5-10 membered heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-C6alkyl, Ci-C6alkyl-C(O)-, -C(O)N(R28)2.

[0501] In some embodiments, R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl, wherein cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-C6alkyl, Ci-C6alkyl-C(O)-, -C(O)N(R28)2.

[0502] In some embodiments, R61and R62together with the atom to which they are attached and any intervening atoms, form cyclohexyl optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, Ci-Ce alkyl-C(O)-, -C(O)N(R28)2.

[0503] In some embodiments, R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-C6alkyl, Ci-C6alkyl-C(O)-, -C(O)N(R28)2.

[0504] In some embodiments, R61and R62together with the atom to which they areattached and any intervening atoms, form

[0505] In some embodiments, R61and R62together with the atom to which they areattached and any intervening atoms, form

[0506] In some embodiments, R61and R62together with the atom to which they are attached and any intervening atoms, form aryl optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, Ci-Ce alkyl-C(O)-, -C(O)N(R28)2.72.ASBMondego.26.0001

[0507] In some embodiments, R61and R62together with the atom to which they areattached and any intervening atoms, form

[0508] In some embodiments, b is an integer selected from 0, 1, 2 and 3.

[0509] In some embodiments, b is 0.

[0510] In some embodiments, b is 1.

[0511] In some embodiments, b is 2.

[0512] In some embodiments, b is 3.

[0513] In some embodiments, k is an integer selected from 0, 1, and 2.

[0514] In some embodiments, k is 0.

[0515] In some embodiments, k is 1.

[0516] In some embodiments, k is 2.

[0517] In some embodiments, m is an integer selected from 0, 1, 2, and 3.

[0518] In some embodiments, m is 0.

[0519] In some embodiments, m is 1.

[0520] In some embodiments, m is 2.

[0521] In some embodiments, m is 3.

[0522] In some embodiments, n is an integer selected from 1, 2, and 3.

[0523] In some embodiments, n is 1.

[0524] In some embodiments, n is 2.

[0525] In some embodiments, n is 3.

[0526] In some embodiments, p is an integer selected from 1, 2 and 3.

[0527] In some embodiments, p is 1.

[0528] In some embodiments, p is 2.

[0529] In some embodiments, p is 3.

[0530] In some embodiments, r is an integer selected from 0 and 1.

[0531] In some embodiments, r is 0.

[0532] In some embodiments, r is 1.

[0533] In some embodiments, q is an integer selected from 0, 1, and 2.

[0534] In some embodiments, q is 0.73.ASBMondego.26.0001

[0535] In some embodiments, q is 1.

[0536] In some embodiments, q is 2.

[0537] In some embodiments, t is an integer selected from 0 and 1.

[0538] In some embodiments, t is 0.

[0539] In some embodiments, t is 1.

[0540] In some embodiments, z is an integer selected from 0 and 1.

[0541] In some embodiments, z is 0.

[0542] In some embodiments, z is 1.

[0543] In some embodiments, the compound is selected from the compounds described in Table 1 and pharmaceutically acceptable salts, stereoisomers, solvates, prodrugs, isotopic derivatives, or tautomers thereof.

[0544] In some embodiments, the compound is selected from the compounds described in Table 1 and prodrugs and pharmaceutically acceptable salts thereof.

[0545] In some embodiments, the compound is selected from the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

[0546] In some embodiments, the compound is selected from the prodrugs of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

[0547] In some embodiments, the compound is selected from the compounds described in Table 1

[0548] Table 1 Certain examples of the compound of Formula (A)74.ASBMondego.26.000175.ASBMondego.26.000176.ASBMondego.26.000177.ASBMondego.26.000178.ASBMondego.26.000179.ASBMondego.26.000180.ASBMondego.26.000181.ASBMondego.26.000182.ASBMondego.26.000183.ASBMondego.26.000184.ASBMondego.26.000185.ASBMondego.26.000186.ASBMondego.26.000187.ASBMondego.26.000188.ASBMondego.26.000189.ASBMondego.26.000190.ASBMondego.26.000191.ASBMondego.26.000192.ASBMondego.26.000193.ASBMondego.26.000194.ASBMondego.26.000195.ASBMondego.26.000196.ASBMondego.26.000197.ASBMondego.26.000198.ASBMondego.26.000199.ASBMondego.26.0001100.ASBMondego.26.0001101.ASBMondego.26.0001102.ASBMondego.26.0001103.ASBMondego.26.0001104.ASBMondego.26.0001105.ASBMondego.26.0001106.ASBMondego.26.0001107.ASBMondego.26.0001108.ASBMondego.26.0001109.ASBMondego.26.0001110.ASBMondego.26.0001111.ASBMondego.26.0001112.ASBMondego.26.0001113.ASBMondego.26.0001114.ASBMondego.26.0001115.ASBMondego.26.0001116.ASBMondego.26.0001117.ASBMondego.26.0001

[0549] In some embodiments, the compound is a pharmaceutically acceptable salt of any one of the compounds described in Table 1.

[0550] In some embodiments, the compound is a lithium salt, sodium salt, potassium salt, calcium salt, or magnesium salt of any one of the compounds described in Table 1.

[0551] In some embodiments, the compound is a salt of any one of acid described in the Table 2 and any one of the compounds described in Table 1.118.ASBMondego.26.0001

[0552] Table 2 Pharmaceutical acceptable acid forming salts with the Compound of Formula (A).

[0553] In some embodiments, the compound is a salt of acetic acid and any one of the compounds described in Table 1.

[0554] In some embodiments, the compound is a salt of adipic acid and any one of the compounds described in Table 1.

[0555] In some embodiments, the compound is a salt of ascorbic acid (L) and any one of the compounds described in Table 1.

[0556] In some embodiments, the compound is a salt of hydrobromic acid and any one of the compounds described in Table 1.

[0557] In some embodiments, the compound is a salt of hydrochloric acid and any one of the compounds described in Table 1.

[0558] In some embodiments, the compound is a salt of citric acid and any one of the compounds described in Table 1.

[0559] In some embodiments, the compound is a salt of glutamic acid and any one of the compounds described in Table 1.

[0560] In some embodiments, the compound is a salt of oxalic acid and any one of the compounds described in Table 1.119.ASBMondego.26.0001

[0561] In some embodiments, the compound is a salt of formic acid and any one of the compounds described in Table 1.

[0562] In some embodiments, the compound is a salt of sulfuric acid and any one of the compounds described in Table 1.

[0563] In some aspects, the present disclosure provides a compound being an isotopic derivative (e.g., isotopically labeled compound) of any one of the compounds of the Formulae disclosed herein.

[0564] In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Table 1 and prodrugs and pharmaceutically acceptable salts thereof.

[0565] In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

[0566] In some embodiments, the compound is an isotopic derivative of any one of prodrugs of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

[0567] In some embodiments, the compound is an isotopic derivative of any one of the compounds described in Table 1.

[0568] It is understood that the isotopic derivative can be prepared using any of a variety of art-recognized techniques. For example, the isotopic derivative can generally be prepared by carrying out the procedures disclosed in the Schemes and / or in the Examples described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0569] In some embodiments, the isotopic derivative is a deuterium labeled compound.

[0570] In some embodiments, the isotopic derivative is a deuterium labeled compound of any one of the compounds of the Formulae disclosed herein.

[0571] The term “isotopic derivative”, as used herein, refers to a derivative of a compound in which one or more atoms are isotopically enriched or labelled. For example, an isotopic derivative of a compound of Formula (A) is isotopically enriched with regard to, or labelled with, one or more isotopes as compared to the corresponding compound of Formula (A). In some embodiments, the isotopic derivative is enriched with regard to, or labelled with, one or more atoms selected from2H,13C,14C,15N,18O,29Si,31P, and34S. In some120.ASBMondego.26.0001embodiments, the isotopic derivative is a deuterium labeled compound (i.e., being enriched with2H with regard to one or more atoms thereof).

[0572] In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Table 1 and prodrugs and pharmaceutically acceptable salts thereof.

[0573] In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

[0574] In some embodiments, the compound is a deuterium labeled compound of any one of the prodrugs of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

[0575] In some embodiments, the compound is a deuterium labeled compound of any one of the compounds described in Table 1.

[0576] It is understood that the deuterium labeled compound comprises a deuterium atom having an abundance of deuterium that is substantially greater than the natural abundance of deuterium, which is 0.015%.

[0577] In some embodiments, the deuterium labeled compound has a deuterium enrichment factor for each deuterium atom of at least 3500 (52.5% deuterium incorporation at each deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). As used herein, the term “deuterium enrichment factor” means the ratio between the deuterium abundance and the natural abundance of a deuterium.

[0578] It is understood that the deuterium labeled compound can be prepared using any of a variety of art-recognized techniques. For example, the deuterium labeled compound can generally be prepared by carrying out the procedures disclosed in the Schemes and / or in the Examples described herein, by substituting a deuterium labeled reagent for a nondeuterium labeled reagent.

[0579] A compound of the disclosure or a pharmaceutically acceptable salt or solvate thereof that contains the aforementioned deuterium atom(s) is within the scope of the121.ASBMondego.26.0001disclosure. Further, substitution with deuterium (z.e.,2H) may afford certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements.

[0580] In some embodiments, the compound is a18F labeled compound.

[0581] In some embodiments, the compound is a123I labeled compound, a124I labeled compound, a125I labeled compound, a129I labeled compound, a131I labeled compound, a135I labeled compound, or any combination thereof.

[0582] In some embodiments, the compound is a33S labeled compound, a34S labeled compound, a35S labeled compound, a36S labeled compound, or any combination thereof.

[0583] It is understood that the18F,123I,124I,125I,129I,131I,135I,33S,34S,35S, and / or36S labeled compound, can be prepared using any of a variety of art-recognized techniques. For example, the deuterium labeled compound can generally be prepared by carrying out the procedures disclosed in the Schemes and / or in the Examples described herein, by substituting a18F,1231,124I,1251,129I,131I,1351,33S,34S,35S, and / or36S labeled reagent for a non-isotope labeled reagent.

[0584] A compound of the disclosure or a pharmaceutically acceptable salt or solvate thereof that contains one or more of the aforementioned18F,1231,1241,1251,1291,1311,1351,33S,34S,35S, and36S atom(s) is within the scope of the disclosure. Further, substitution with isotope e.g,,18F,123I,124I,125I,129I,131I,1351,33S,34S,35S, and / or36S) may afford certain therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements.

[0585] For the avoidance of doubt, it is to be understood that, where in this specification a group is qualified by “described herein”, the said group encompasses the first occurring and broadest definition as well as each and all of the particular definitions for that group.

[0586] The various functional groups and substituents making up the compounds of the Formula (I) are typically chosen such that the molecular weight of the compound does not exceed 1000 Daltons. More usually, the molecular weight of the compound will be less than 700, for example less than 600, or less than 550, or less than 500, or less than 450 Daltons. More conveniently, the molecular weight is less than 600 and, for example, is 550 Daltons or less, for example 500 Daltons or less, for example 450 Daltons or less, for example 400 Daltons or less.122.ASBMondego.26.0001

[0587] A suitable pharmaceutically acceptable salt of a compound of the disclosure is, for example, an acid-addition salt of a compound of the disclosure, which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid. In addition, a suitable pharmaceutically acceptable salt of a compound of the disclosure which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

[0588] It will be understood that the compounds of any one of the Formulae disclosed herein and any pharmaceutically acceptable salts thereof, comprise stereoisomers, mixtures of stereoisomers, polymorphs of all isomeric forms of said compounds.

[0589] As used herein, the term “isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture.”

[0590] As used herein, the term “chiral center” refers to a carbon atom bonded to four nonidentical substituents.

[0591] As used herein, the term “chiral isomer” means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.” When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit. 1966,123.ASBMondego.26.00015, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ.1964, 41, 116).

[0592] As used herein, the term “geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

[0593] It is to be understood that the compounds of the present disclosure may be depicted as different chiral isomers or geometric isomers. It is also to be understood that when compounds have chiral isomeric or geometric isomeric forms, all isomeric forms are intended to be included in the scope of the present disclosure, and the naming of the compounds does not exclude any isomeric forms, it being understood that not all isomers may have the same level of activity.

[0594] It is to be understood that the structures and other compounds discussed in this disclosure include all atropic isomers thereof. It is also to be understood that not all atropic isomers may have the same level of activity.

[0595] As used herein, the term “atropic isomers” are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.

[0596] As used herein, the term “tautomer” is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerisation is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertible by tautomerisations is called tautomerism. Of the various types of tautomerism that are124.ASBMondego.26.0001possible, two are commonly observed. In keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs. Ring-chain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.

[0597] It is to be understood that the compounds of the present disclosure may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be included in the scope of the present disclosure, and the naming of the compounds does not exclude any tautomer form. It will be understood that certain tautomers may have a higher level of activity than others.

[0598] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric centre, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterised by the absolute configuration of its asymmetric centre and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarised light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.

[0599] The compounds of this disclosure may possess one or more asymmetric centres; such compounds can therefore be produced as individual (R)- or (5)-stereoi somers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. Some of the compounds of the125.ASBMondego.26.0001disclosure may have geometric isomeric centres (E- and Z- isomers). It is to be understood that the present disclosure encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess inflammasome inhibitory activity.

[0600] The present disclosure also encompasses compounds of the disclosure as defined herein which comprise one or more isotopic substitutions.

[0601] It is to be understood that the compounds of any Formula described herein include the compounds themselves, as well as their salts, and their solvates, if applicable. A salt, for example, can be formed between an anion and a positively charged group (e.g., amino) on a substituted compound disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).

[0602] As used herein, the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt. Likewise, a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a substituted compound disclosed herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion or diethylamine ion. The substituted compounds disclosed herein also include those salts containing quaternary nitrogen atoms.

[0603] It is to be understood that the compounds of the present disclosure, for example, the salts of the compounds, can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules. Nonlimiting examples of hydrates include monohydrates, dihydrates, etc. Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.

[0604] As used herein, the term “solvate” means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of126.ASBMondego.26.0001one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.

[0605] As used herein, the term “analog” refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group). Thus, an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.

[0606] As used herein, the term “derivative” refers to compounds that have a common core structure and are substituted with various groups as described herein.

[0607] As used herein, the term “bioisostere” refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound. The bioisosteric replacement may be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonamides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.

[0608] It is also to be understood that certain compounds of any one of the Formulae disclosed herein may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. A suitable pharmaceutically acceptable solvate is, for example, a hydrate such as hemi-hydrate, a mono-hydrate, a di-hydrate or a tri-hydrate. It is to be understood that the disclosure encompasses all such solvated forms that possess inflammasome inhibitory activity.

[0609] It is also to be understood that certain compounds of any one of the Formulae disclosed herein may exhibit polymorphism, and that the disclosure encompasses all such forms, or mixtures thereof, which possess inflammasome inhibitory activity. It is generally known that crystalline materials may be analyzed using conventional techniques such as X-Ray Powder Diffraction analysis, Differential Scanning Calorimetry, Thermal Gravimetric Analysis, Diffuse Reflectance Infrared Fourier Transform (DRIFT) spectroscopy, Near Infrared (NIR) spectroscopy, solution and / or solid state nuclear127.ASBMondego.26.0001magnetic resonance spectroscopy. The water content of such crystalline materials may be determined by Karl Fischer analysis.

[0610] Compounds of any one of the Formulae disclosed herein may exist in a number of different tautomeric forms and references to compound of Formula (A) include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by Formula (A). Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.keto enol enolate

[0611] Compounds of any one of the Formulae disclosed herein containing an amine function may also form A-oxides. A reference herein to a compound of Formula (A) that contains an amine function also includes the A-oxide. Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidized to form an A-oxide. Particular examples of A-oxides are the A-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle. A-oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, A-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with meta-chloroperoxybenzoic acid (m-CPBA), for example, in an inert solvent such as di chloromethane.

[0612] The compounds of any one of the Formulae disclosed herein may be administered in the form of a prodrug which is broken down in the human or animal body to release a compound of the disclosure. A prodrug may be used to alter the physical properties and / or the pharmacokinetic properties of a compound of the disclosure. A prodrug can be formed when the compound of the disclosure contains a suitable group or substituent to which a128.ASBMondego.26.0001property-modifying group can be attached. Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents at the ester or amide group in any one of the Formulae disclosed herein.

[0613] Accordingly, the present disclosure includes those compounds of any one of the Formulae disclosed herein as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a prodrug thereof. Accordingly, the present disclosure includes those compounds of any one of the Formulae disclosed herein that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of any one of the Formulae disclosed herein may be a synthetically produced compound or a metabolically-produced compound.

[0614] A suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein is one that is based on reasonable medical judgment as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity. Various forms of prodrug have been described, for example in the following documents: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f)N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A. C. S. Symposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0615] A suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof. An in vivo cleavable ester or ether of a compound of any one of the Formulae disclosed herein containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically acceptable ester129.ASBMondego.26.0001forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically acceptable ester forming groups for a hydroxy group include C1-C10 alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, C1-C10 alkoxycarbonyl groups such as ethoxycarbonyl, JV, JV-(Ci-Ce alkyl)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, A-alkylaminomethyl, N, N-dialkylaminomethyl, morpholinomethyl, piperazin- 1-ylmethyl and 4-(CI-C4 alkyl)piperazin-l-ylmethyl. Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include oc-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.

[0616] A suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a Ci-4alkylamine such as methylamine, a (C1-C4 alkyl)2amine such as dimethylamine, N-ethyl-A-methylamine or diethylamine, a C1-C4 alkoxy-C2-C4 alkylamine such as 2-methoxyethylamine, a phenyl-Ci-C4 alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.

[0617] A suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C1-C10 alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, A-alkylaminomethyl, A, A-dialkylaminomethyl, morpholinomethyl, piperazin- 1-ylmethyl and 4-(CI-C4 alkyl)piperazin- 1-ylmethyl.

[0618] The in vivo effects of a compound of any one of the Formulae disclosed herein may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of any one of the Formulae disclosed herein. As stated hereinbefore, the in vivo effects of a compound of any one of the Formulae disclosed herein may also be exerted by way of metabolism of a precursor compound (a prodrug).130.ASBMondego.26.0001Method of Synthesizing the Compounds

[0619] The compounds of the present invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the Schemes given below.

[0620] The compounds of Formula (A) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, " Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of those skilled in the art will recognize if a stereocenter exists in the compounds of Formula (A). Accordingly, the present invention includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and / or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, " Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994).

[0621] The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and / or enzymatic processes.Preparation of Compounds

[0622] The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Suitable methods include but are not limited to those131.ASBMondego.26.0001methods described below. Compounds of the present invention can be synthesized by following the steps outlined in General Procedures which comprise different sequences of assembling intermediates or compounds. Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated below.

[0623] All reagents may be commercially available compounds itself or products of synthesis from commercially available reagents. For preparation these reagents may be used one step or multi step synthetic procedures, including but not limited procedures described herein in preparative part.

[0624] It should be obvious for specialist in this field that any of compound of Formula (A) obtained according to the procedures described above may be a subject for further transformation and modification that will lead to other compound of Formula (A).Biological Assays

[0625] Compounds designed, selected and / or optimized by methods described above, once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity. For example, the molecules can be characterized by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and / or binding specificity.

[0626] Furthermore, high-throughput screening can be used to speed up analysis using such assays. As a result, it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art. General methodologies for performing high-throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U. S. Patent No. 5,763,263. High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.

[0627] Various in vitro or in vivo biological assays may be suitable for detecting the effect of the compounds of the present disclosure. These in vitro or in vivo biological assays can include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and the assays described herein. Pharmaceutical Compositions

[0628] In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure as an active ingredient. In some132.ASBMondego.26.0001embodiments, the present disclosure provides a pharmaceutical composition comprising at least one compound of each of the formulae described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the present disclosure provides a pharmaceutical composition comprising at least one compound selected from Table 1.

[0629] As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

[0630] Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

[0631] Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins,133.ASBMondego.26.0001methylcellulose, sodium carboxymethyl cellulose, and other well-known suspending agents.

[0632] The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-fdled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

[0633] The compounds of present disclosure can be formulated for oral administration in forms such as tablets, capsules (each of which includes sustained release or timed-release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions. The compounds of present disclosure on can also be formulated for intravenous (bolus or in-fusion), intraperitoneal, topical, subcutaneous, intramuscular or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.

[0634] The formulation of the present disclosure may be in the form of an aqueous solution comprising an aqueous vehicle. The aqueous vehicle component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from the group consisting of a solubility enhancing agent, chelating agent, preservative, tonicity agent, viscosity / suspending agent, buffer, and pH modifying agent, and a mixture thereof.

[0635] Any suitable solubility enhancing agent can be used. Examples of a solubility enhancing agent include cyclodextrin, such as those selected from the group consisting of hydroxypropyl-P-cyclodextrin, methyl-P-cyclodextrin, randomly methylated-P-cyclodextrin, ethylated-P-cyclodextrin, triacetyl-P-cyclodextrin, peracetylated-P-134.ASBMondego.26.0001cyclodextrin, carboxymethyl-P-cyclodextrin, hydroxy ethyl-P-cyclodextrin, 2-hydroxy-3-(trimethylammonio)propyl-P-cyclodextrin, glucosyl-P-cyclodextrin, sulfated P-cyclodextrin (S-P-CD), maltosyl-P-cyclodextrin, P-cyclodextrin sulfobutyl ether, branched-P-cyclodextrin, hydroxypropyl-y-cyclodextrin, randomly methylated-y-cyclodextrin, and trimethyl-y-cyclodextriri, and mixtures thereof.

[0636] Any suitable chelating agent can be used. Examples of a suitable chelating agent include those selected from the group consisting of ethylenedi aminetetraacetic acid and metal salts thereof, disodium edetate, trisodium edetate, and tetrasodium edetate, and mixtures thereof.

[0637] Any suitable preservative can be used. Examples of a preservative include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate, phenylmercury acetate, phenylmercury neodecanoate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, and butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.

[0638] In some embodiments, examples of a preservative include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chlorhexidine gluconate, benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propylaminopropyl biguanide, and butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.

[0639] The aqueous vehicle may also include a tonicity agent to adjust the tonicity (osmotic pressure). The tonicity agent can be selected from the group consisting of a glycol (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and a mixture thereof. In some embodiments, the tonicity agent is selected from the group consisting of a glycol (such as propylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and a mixture thereof.135.ASBMondego.26.0001

[0640] The aqueous vehicle may also contain a viscosity / suspending agent. Suitable viscosity / suspending agents include those selected from the group consisting of cellulose derivatives, such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose, polyethylene glycols (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethyl cellulose, hydroxypropylmethyl cellulose, and cross-linked acrylic acid polymers (carbomers), such as polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol (Carbopols - such as Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974 and Carbopol 974P), and a mixture thereof.

[0641] In order to adjust the formulation to an acceptable pH (typically a pH range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH modifying agent. The pH modifying agent is typically a mineral acid or metal hydroxide base, selected from the group of potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, and preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or basic pH modifying agents are added to adjust the formulation to the target acceptable pH range. Hence it may not be necessary to use both acid and base - depending on the formulation, the addition of one of the acid or base may be sufficient to bring the mixture to the desired pH range.

[0642] The aqueous vehicle may also contain a buffering agent to stabilize the pH. When used, the buffer is selected from the group consisting of a phosphate buffer (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), a borate buffer (such as boric acid, or salts thereof including disodium tetraborate), a citrate buffer (such as citric acid, or salts thereof including sodium citrate), and s-aminocaproic acid, and mixtures thereof.

[0643] The formulation may further comprise a wetting agent. Suitable classes of wetting agents include those selected from the group consisting of polyoxypropylenepolyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oils, polyoxyethylenated sorbitan esters (polysorbates), polymers of oxyethylated octyl phenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty esters, and polyoxyethylene fatty esters, and mixtures thereof.

[0644] Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For136.ASBMondego.26.0001the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0645] According to a further aspect of the disclosure there is provided a pharmaceutical composition which comprises a compound of the disclosure as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0646] In some embodiments, a pharmaceutical composition described herein may further comprise one or more additional pharmaceutically active agents.

[0647] The compositions of the disclosure may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).

[0648] The compositions of the disclosure may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring, sweetening, flavoring and / or preservative agents.137.ASBMondego.26.0001

[0649] A therapeutically effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat or prevent a PTPN2 related condition referred to herein, slow its progression and / or reduce the symptoms associated with the condition.

[0650] A therapeutically effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat an PTPN2 related condition referred to herein, slow its progression and / or reduce the symptoms associated with the condition.

[0651] The size of the dose for therapeutic or prophylactic purposes of a compound of Formula (A) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or subject and the route of administration, according to well-known principles of medicine.Methods of Use

[0652] In some aspects, the present disclosure provides a method of inhibiting of PTPN2 (e.g., in vitro or in vivo), comprising contacting a cell with a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.

[0653] In some aspects, the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0654] In some aspects, the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0655] In some embodiments, the disease or disorder is associated with PTPN2. In some embodiments, the disease or disorder is a disease or disorder in which PTPN2 is implicated.

[0656] The compounds of the invention are also useful in treating diseases associated with PTPN2. For example, diseases and conditions treatable according to the methods of the invention include Cancer; Oligoarticular Juvenile Idiopathic Arthritis; Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis; Inflammatory Bowel Disease 20138.ASBMondego.26.0001(IBD20); Crohn's Disease; Immunodeficiency 31c (IMD31C); T-Cell Acute Lymphoblastic Leukemia; Inflammatory Bowel Disease; Inflammatory Bowel Disease 1 (IBD1); Celiac Disease 1 (CELIAC1); Body Mass Index Quantitative Trait Locus 11 (BMIQ11); Diabetes Mellitus; Type 2 Diabetes Mellitus (T2D); Rasopathy; Ovarian Cancer (OC); Bubonic Plague; Primary Mediastinal B-Cell Lymphoma; Leptin Deficiency or Dysfunction; Alzheimer Disease; Ovemutrition; Noonan Syndrome; Noonan Syndrome With Multiple Lentigines; Rasopathy; Hypertension, Essential.

[0657] The method of treatment comprises administering to a patient suffering from at least one of said diseases or disorders a compound of Formula (A), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or pharmaceutical composition thereof.

[0658] In some embodiments, the disease or disorder is Cancer.

[0659] As used herein, "cancer" refers to human cancers and carcinomas, sarcomas, adenocarcinomas (e.g., papillary adenocarcinomas), lymphomas, leukemias, melanomas, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, liver cancer, including hepatocarcinoma, lymphoma, including Bacute lymphoblastic lymphoma, non-Hodgkin's lymphomas (e.g., Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including AML, ALL, and CML), and / or multiple myeloma. In some further instances, "cancer" refers to lung cancer, breast cancer, ovarian cancer, epithelial ovarian cancer, leukemia, lymphoma, melanoma, pancreatic cancer, sarcoma, bladder cancer, bone cancer, biliary tract cancer, adrenal gland cancer, salivary gland cancer, bronchus cancer, oral cancer, cancer of the oral cavity or pharynx, laryngeal cancer, renal cancer, gynecologic cancers, brain cancer, central nervous system cancer, peripheral nervous system cancer, cancer of the hematological tissues, small bowel or appendix cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, liver cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, prostate cancer, metastatic cancer, or carcinoma.

[0660] As used herein, the term "cancer" refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemia, lymphoma, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound, pharmaceutical139.ASBMondego.26.0001composition, or method provided herein include lymphoma, B-cell lymphoma, heavy chain disease, alpha chain disease, gamma chain disease, mu chain disease, Waldenstrom’s macroglobulinemia, benign monoclonal gammopathy, sarcoma, bladder cancer, bone cancer, brain tumor, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., ER positive, ER negative, chemotherapy resistant, herceptin resistant, HERZ positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), glioblastoma multiforme, acoustic neuroma, retinoblastoma, astrocytoma, craniopharyngioma, hemangioblastoma, pinealoma, ependymoma, oligodendroglioma, meningioma, glioma, or melanoma. Additional examples include, cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, nonsmall cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus or Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, immunocytic amyloidosis, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget’ s Disease of the Nipple, Phyllodes Tumors, Lobular Carcinoma, Ductal Carcinoma, cancer of the pancreatic stellate cells, cancer of the hepatic stellate cells, or prostate cancer.

[0661] In some embodiments, the diseases or disorder is Ovarian Cancer (OC).

[0662] In some embodiments, the disease or disorder is Leukemia.

[0663] In some embodiments, the disease or disorder is T-Cell Acute Lymphoblastic Leukemia.140.ASBMondego.26.0001

[0664] The term "leukemia" refers broadly to progressive, malignant diseases of the bloodforming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the diseaseacute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound, pharmaceutical composition, or method provided herein include, for example, chronic leukemia, acute nonlymphocytic leukemia, acute lymphocytic leukemia, 8-cell chronic byniphoeytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, acute myelocytic leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, erythroleukemia, Gross’ leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocyte leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblasts leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, polycythemia vera, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.

[0665] In some embodiments, the disease or disorder is Oligoarticular Juvenile Idiopathic Arthritis.

[0666] In some embodiments, the disease or disorder is Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis.

[0667] In some embodiments, the diseases or disorder is Inflammatory Bowel Disease 20 (IBD20).

[0668] In some embodiments, the diseases or disorder is Crohn's Disease.141.ASBMondego.26.0001

[0669] In some embodiments, the diseases or disorder is Immunodeficiency 31c (IMD31C).

[0670] In some embodiments, the diseases or disorder is Inflammatory Bowel Disease.

[0671] In some embodiments, the diseases or disorder is Inflammatory Bowel Disease 1 (IBD1).

[0672] In some embodiments, the diseases or disorder is Celiac Disease 1 (CELIAC1).

[0673] In some embodiments, the diseases or disorder is Body Mass Index Quantitative Trait Locus 11 (BMIQ11).

[0674] In some embodiments, the diseases or disorder is Diabetes Mellitus.

[0675] In some embodiments, the diseases or disorder is Type 2 Diabetes Mellitus (T2D).

[0676] In some embodiments, the diseases or disorder is Rasopathy.

[0677] In some aspects, the present disclosure provides a method of treating or preventing a Cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0678] In some aspects, the present disclosure provides a method of treating or preventing a Leukemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0679] In some aspects, the present disclosure provides a method of treating or preventing a T-Cell Acute Lymphoblastic Leukemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0680] In some aspects, the present disclosure provides a method of treating or preventing a Oligoarticular Juvenile Idiopathic Arthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.142.ASBMondego.26.0001

[0681] In some aspects, the present disclosure provides a method of treating or preventing a Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0682] In some aspects, the present disclosure provides a method of treating or preventing a Inflammatory Bowel Disease 20 (IBD20) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0683] In some aspects, the present disclosure provides a method of treating or preventing a Crohn's Disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0684] In some aspects, the present disclosure provides a method of treating or preventing a Immunodeficiency 31c (IMD31C) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0685] In some aspects, the present disclosure provides a method of treating or preventing a Celiac Disease 1 (CELIAC1) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0686] In some aspects, the present disclosure provides a method of treating or preventing a Body Mass Index Quantitative Trait Locus 11 (BMIQ11) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.143.ASBMondego.26.0001

[0687] In some aspects, the present disclosure provides a method of treating or preventing a Diabetes Mellitus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0688] In some aspects, the present disclosure provides a method of treating or preventing a Type 2 Diabetes Mellitus (T2D) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0689] In some aspects, the present disclosure provides a method of treating or preventing a Rasopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0690] In some aspects, the present disclosure provides a method of treating or preventing a Ovarian Cancer (OC) in a subject in need thereof, comprising administering to the subj ect a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0691] In some aspects, the present disclosure provides a method of treating a Cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0692] In some aspects, the present disclosure provides a method of treating a Leukemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0693] In some aspects, the present disclosure provides a method of treating a T-Cell Acute Lymphoblastic Leukemia in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a144.ASBMondego.26.0001pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0694] In some aspects, the present disclosure provides a method of treating a Oligoarticular Juvenile Idiopathic Arthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0695] In some aspects, the present disclosure provides a method of treating a Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0696] In some aspects, the present disclosure provides a method of treating an Inflammatory Bowel Disease 20 (IBD20) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0697] In some aspects, the present disclosure provides a method of treating a Crohn's Disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0698] In some aspects, the present disclosure provides a method of treating an Immunodeficiency 31c (IMD31C) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0699] In some aspects, the present disclosure provides a method of treating an Inflammatory Bowel Disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a145.ASBMondego.26.0001pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0700] In some aspects, the present disclosure provides a method of treating an Inflammatory Bowel Disease 1 (IBD1) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0701] In some aspects, the present disclosure provides a method of treating a Celiac Disease 1 (CELIAC1) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0702] In some aspects, the present disclosure provides a method of treating a Body Mass Index Quantitative Trait Locus 11 (BMIQ11) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0703] In some aspects, the present disclosure provides a method of treating a Diabetes Mellitus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0704] In some aspects, the present disclosure provides a method of treating a Type 2 Diabetes Mellitus (T2D) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0705] In some aspects, the present disclosure provides a method of treating a Rasopathy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.146.ASBMondego.26.0001

[0706] In some aspects, the present disclosure provides a method of treating an Ovarian Cancer (OC) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0707] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in inhibiting of PTPN1 / PTPN2 (e.g., in vitro or in vivo).

[0708] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease or disorder disclosed herein.

[0709] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder disclosed herein.

[0710] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a Cancer in a subject in need thereof.

[0711] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a Leukemia in a subject in need thereof.

[0712] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a T-Cell Acute Lymphoblastic Leukemia in a subject in need thereof.

[0713] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing an Oligoarticular Juvenile Idiopathic Arthritis in a subject in need thereof.

[0714] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing an Inflammatory Bowel Disease 20 (IBD20) in a subject in need thereof.147.ASBMondego.26.0001

[0715] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a Crohn's Disease in a subject in need thereof.

[0716] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating an Immunodeficiency 31c (IMD31 C) in a subject in need thereof.

[0717] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating an Inflammatory Bowel Disease in a subject in need thereof.

[0718] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating an Inflammatory Bowel Disease 1 (IBD1) in a subject in need thereof.

[0719] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Celiac Disease 1 (CELIAC 1) in a subject in need thereof.

[0720] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Body Mass Index Quantitative Trait Locus 11 (BMIQ11) in a subject in need thereof.

[0721] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Diabetes Mellitus in a subject in need thereof.

[0722] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Type 2 Diabetes Mellitus (T2D) in a subject in need thereof.

[0723] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a Rasopathy in a subject in need thereof.

[0724] In some aspects, the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating an Ovarian Cancer (OC) in a subject in need thereof.148.ASBMondego.26.0001

[0725] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inhibiting of PTPN2 (e.g., in vitro or in vivo).

[0726] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.

[0727] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder disclosed herein.

[0728] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a Leukemia in a subject in need thereof.

[0729] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a T-Cell Acute Lymphoblastic Leukemia in a subj ect in need thereof.

[0730] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a Cancer in a subject in need thereof.

[0731] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing an Oligoarticular Juvenile Idiopathic Arthritis in a subject in need thereof.

[0732] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis in a subject in need thereof.

[0733] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing an Inflammatory Bowel Disease 20 (IBD20) in a subject in need thereof.149.ASBMondego.26.0001

[0734] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Crohn's Disease in a subject in need thereof.

[0735] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an Immunodeficiency 31c (IMD31 C) in a subject in need thereof.

[0736] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an Inflammatory Bowel Disease in a subject in need thereof.

[0737] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an Inflammatory Bowel Disease 1 (IBD1) in a subject in need thereof.

[0738] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Celiac Disease 1 (CELIAC 1) in a subject in need thereof.

[0739] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Body Mass Index Quantitative Trait Locus 11 (BMIQ11) in a subject in need thereof.

[0740] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Diabetes Mellitus in a subject in need thereof.

[0741] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Type 2 Diabetes Mellitus (T2D) in a subject in need thereof.

[0742] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Rasopathy in a subject in need thereof.150.ASBMondego.26.0001

[0743] In some aspects, the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a Ovarian Cancer (OC) in a subject in need thereof.

[0744] The present disclosure provides compounds that function as inhibitors of PTPN2 (e.g., in vitro or in vivo). The present disclosure therefore provides a method of inhibiting of PTPN2 in vitro or in vivo, said method comprising contacting a cell with a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as defined herein.

[0745] In some embodiments, the inhibitor of PTPN2 is a compound of the present disclosure.

[0746] Effectiveness of compounds of the disclosure can be determined by industry-accepted assays / disease models according to standard practices of elucidating the same as described in the art and are found in the current general knowledge.

[0747] The present disclosure also provides a method of treating a disease or disorder in which PTPN2 are implicated in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

[0748] In sore embodiments, the compounds described herein and compositions (e.g., compositions comprising a compound described herein) are used with a cancer immunotherapy (e.g., a checkpoint blocking antibody) to treat a subject (e.g., a human subject), e.g., suffering from a disease or disorder described herein (e.g., abnormal cell growth, e.g., cancer (e.g., a cancer described herein)). The methods described herein comprise administering a compound described herein and an immunotherapy to a subject having abnormal cell growth such as cancer.

[0749] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.Routes of Administration

[0750] The compounds of the disclosure or pharmaceutical compositions comprising these compounds may be administered to a subject by any convenient route of administration, whether systemically / peripherally or topically (i.e., at the site of desired action).151.ASBMondego.26.0001

[0751] Routes of administration include, but are not limited to, oral (e.g. by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.EXAMPLESSynthetical procedures and examples of the compound’s preparation.

[0752] All reagents were commercial and were used without further purification. Yields refer to purified and spectroscopically pure compounds. Thin layer chromatography (TLC) was performed using Merck TLC Aluminum sheets silica gel 60 F254 plates and visualized by fluorescence quenching under UV light. Flash chromatography was performed using silica gel (Chromatorex, MB 70-40 / 75, 40-75 μm) purchased by Fuji Silysia Chemicals. NMR spectra were recorded using Bruker AVANCE III 400 MHz and TMS was used as an internal standard operating at 400 MHz for1H. Chemical shifts are reported in ppm with the solvent resonance as the internal standard. Data is reported as follows: s = singlet, br. = broad, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets; coupling constants in Hz; integration. The purities were recorded on Waters e2695 separations Module / 2998 PDA Detector HPLC system (Column: XBridge C18, 5 pm, 4.6 mm (ID) x 150 mm (L), Eluent: the mixture of mobile phase A and B, mobile phase A: 100% acetonitrile; mobile phase B: pure water containing 0.1% formic acid and 10 mM NH4OAC, Flow rate: 0.5 mL / min. detection: UV, 254 nm). The LCMS measurement was performed using Agilent 1260 series LC / Mass system operating in ES (+) or (-) ionization mode; T = 30°C; flow rate = 1.5 mL / min; detected wavelength: 214 nm and 254nm. LC detector: diode-array detector (DAD) or photo-diode array detector (PDA) or variable wavelength detector (VWD); Mass detector: SQ Detector or SQ Detector 2 (electrospray152.ASBMondego.26.0001ionization source); Column: Sunfire Cl 8 column (5 m, 4.6 x 50 mm) or Waters Acquity UPLC BEH C18 column (1.7 pm, 2.1 x 50 mm).

[0753] Abbreviations used in the following examples and elsewhere herein are:ACN acetonitrileAcOH acetic acidaq. aqueousanh. anhydrousatm. atmosphereBnOH benzyl alcoholbr. broadBSA bovine serum albumincalc. calculatedCbz-OSu N-(b enzy 1 oxy carb ony 1 oxy) succi ni mi decone. concentratedCSI chlorosulfonyl isocyanated dupletDCM dichloromethaneDiFMUP 6, 8-difluoro-4-methy lumb elliferyl phosphateDMEM Dulbecco's modified eagle mediumDMF A' W-di methyl formamideDMSO dimethyl sulfoxideDPPA diphenylphosphoryl azideDTT dithiothreitolEA ethyl acetateEDTA ethylenediaminetetraacetic acideq equivalentESI electro sprayFA formic acidFBS fetal bovine serumh hour(s)HEPES Na salt 4-(2-hydroxyethyl)piperazine-l -ethanesulfonic acid sodium salt HPLC high pressure (or performance) liquid chromatography LCMS liquid chromatography mass spectrometryLDA lithium diisopropylamidem multipletM molarMHz megahertzmin minutesMTBE methyl / cvZ-butyl ether153.ASBMondego.26.0001NBS A-bromosuccinimideNMP A-methyl-2-pyrrolidoneNMR nuclear magnetic resonancePE petroleum etherq quadrupletrt room temperatureRT retention times singlet, solidsat. saturatedt triplet, temperatureTBAF tetrabutylammonium fluorideTEA triethylamineTFA trifluoroacetic acidTFE tetrafluoroethyleneTHF tetrahydrofuranTLC thin layer chromatographyTMSC1 trimethyl silyl chlorideSynthesis of Building BlocksSynthesis of / c / 7-butyl 2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-7- azabicyclo[2.2. l]hept-2-ene-7-carboxylate (P2)

[0754] Preparation 1. / e / V-Butyl 2-(((trifluoromethyl)sulfonyl)oxy)-7-azabicyclo[2.2. l]hept-2-ene-7-carboxylate (Pl).To a solution of / -butyl 2-oxo-7-azabicyclo[2.2.1]heptane-7-carboxylate (2.0 g, 9.47 mmol) in THF (40 mL) was slowly added potassium bis(trimethylsilyl)amide (14.2 mL, 1.0 M, 14.2 mmol) at -70°C and then the reaction mixture was stirred at -70°C for 2 h. N-(5-Chloropyridin-2-yl)- 1,1, 1 -trifluoro-A-((trifluoromethyl)sulfonyl)methanesulfonamide (3.77 g, 24.06 mmol) as solid was added to the solution at -70°C, the reaction mixture was stirred at -70°C to rt for 16 h. The reaction mixture was quenched with ammonium chloride solution (100 mL), extracted with EA (100 mL><3). Organic layer was washed with brine, 154.ASBMondego.26.0001dried over Na2SO4(s). filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (ethyl acetate in petroleum = 0 to 10%) to afford the desired product Pl (2.5 g, 76.9% yield) as colorless oil. ’H-NMR (400 MHz, CDCh), 8: 5.96 (s, 1H), 4.81 -4.75 (m, 1H), 4.71 - 4.63 (m, 1H), 2.10 - 1.98 (m, 2H), 1.43 (s, 9H), 1.37 - 1.23 (m, 2H).

[0755] Preparation 2. tert-Butyl 2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-7-azabicyclo[2.2. l]hept-2-ene-7-carboxylate (P2).A mixture of Pl (500 mg, 1.46 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (739.7 mg, 2.91 mmol), potassium acetate (285.9 mg, 2.91 mmol) and [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (106.6 mg, 0.15 mmol) in 1,4-di oxane (10 mL) was degassed with nitrogen atm., and then the mixture was stirred at 80°C for 4 h. The mixture was filtered and concentrated to get a residue, which was purified by silica gel column chromatography (EA in PE = 0 to 10%) to afford the solid (400 mg), and the solid was purified by C18 (ACN: 0.1% ammonium bicarbonate aq. solution = 0% to 90%) to give the title compound P2 (80 mg, 15.4% yield) as white solids. LCMS (ESI): RT = 1.627 min, mass calc, for Ci7H28BNO4321.21, m / z found 222.1 [M+H-100]+. 'H-NMR (400 MHz, CDCh), 8: 6.88 (s, 1H), 4.83 (s, 1H), 4.70 (s, 1H), 1.88 - 1.79 (m, 2H), 1.41 (s, 9H), 1.27 (d, J = 6.0 Hz, 12H), 1.10 - 1.01 (m, 2H).Synthesis of tert-butyl 2-(3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-4- hydroxy-6-methylphenyl)-7-azabicyclo[2.2.1]heptane-7-carboxylate (P12)155.ASBMondego.26.0001100 °C, 3 h P11 P12

[0756] Preparation 3. l-(Benzyloxy)-3-fluoro-5-methyl-2-nitrobenzene (P3).To a solution of l,3-difluoro-5-methyl-2-nitrobenzene (5.0 g, 28.9 mmol) and BnOH (3.75 g, 34.7 mmol) in THF (100 mL) was slowly added fert-BuOK (34.7 mL, 1.0 M, 34.7 mmol) at -70°C. After stirred at -70°C for 2 h, the reaction mixture warmed to rt for 1 h and then quenched with ammonium chloride solution (100 mL), extracted with ethyl acetate (100 mL*3). Organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in petroleum = 0 to 20%) to afford the desired product P3 (5.2 g, 62.2% yield) as a white solid. ’H-NMR (400 MHz, CDC13), 5: 7.39 - 7.34 (m, 5H), 6.66 - 6.62 (m, 2H), 5.16 (s, 2H), 2.53 (s, 3H).

[0757] Preparation 4. l-(Benzyloxy)-4-bromo-3-fluoro-5-methyl-2-nitrobenzene (P4).To a solution of P3 (5.2 g, 17.9 mmol) in AcOH (80 mb) was slowly added Br (11.5 g, 71.7 mmol) and then the reaction mixture was stirred at 50°C for 2 h. After cooling down to rt for 1 h, the reaction mixture was quenched with cold sodium bicarbonate solution (200 mL), extracted with EA (200 mL><3). Organic layers were washed with brine, dried over 156.ASBMondego.26.0001Na2SO4(s). filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in petroleum = 0 to 20%) to afford the desired product P4 (3.5 g, 51.7% yield) as a light-yellow solid. 'H-NMR (400 MHz, CDCh), 8: 7.39 - 7.36 (m, 5H), 6.79 (s, 1H), 5.17 (s, 2H), 2.43 (s, 3H).

[0758] Preparation 5. 6-(Benzyloxy)-3-bromo-2-fluoro-4-methylaniline (P5).To a solution of P4 (3.5 g, 9.26 mmol) in EtOH (80 mL) and water (40 mL) was added NH4CI (3.96 g, 74.1 mmol) and Fe (2.59 g, 46.3 mmol), then the reaction mixture was stirred at 70°C for 2 h. The reaction mixture was filtered, and the filtrate was quenched with water (100 mL), extracted with EA (100 mL*3). Organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in petroleum = 0 to 20%) to afford the desired product P5 (3.1 g, 97.1% yield) as a colorless oil. 'H-NMR (400 MHz, CDCh), 8: 7.41 -7.36 (m, 5H), 6.58 (s, 1H), 5.06 (s, 2H), 3.64 (s, 2H), 2.30 (s, 3H).

[0759] Preparation 6. tert- vy\ (A-(6-(benzyloxy)-3-bromo-2-fluoro-4-methylphenyl)sulfamoyl)carbamate (P6).To a solution of tert-BuOH (2.00 g, 14.1 mmol) in DCM (10 mL) was added CS1 (1.05 g, 14.1 mmol) at 0°C. After stirred for 0.5 h the reaction mixture was dropped into the mixture of benzyloxy )-3-bromo-2-fluoro-4-m ethylaniline P5 (3.1 g, 9.00 mmol) and TEA (1.91 g, 18.8 mmol) in DCM. The reaction mixture was stirred at 20°C for 2 h. The reaction mixture was quenched with water (100 mL), extracted with DCM (100 mL*3). Organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in petroleum = 0 to 20%) to afford the desired product P6 (4.0 g, 80.4% yield) as a colorless oil.111-NMR (400 MHz, CDCh), 8: 7.41 - 7.32 (m, 5H), 7.17 (s, 1H), 6.69 (s, 2H), 5.13 (s, 2H), 2.37 (s, 3H), 1.48 (s, 9H).

[0760] Preparation 7. A-[6-(Benzyloxy)-3-bromo-2-fluoro-4-methylphenyl]aminosulfonamide (P7).To a solution of P6 (4.0 g, 7.36 mmol) in DCM (40 mL) was added TFA (15 mL). After stirred at 20°C for 4 h, the reaction mixture was concentrated in vacuum. The crude was purified by silica gel column chromatography (EA in DCM = 0 to 10%) to afford the desired product P7 (3.1 g, 97.4% yield) as a colorless oil. 'H-NMR (400 MHz, DMSO-t / e),157.ASBMondego.26.00018: 8.48 (s, 1H), 7.55 - 7.53 (m, 2H), 7.40 - 7.32 (m, 3H), 7.00 (s, 1H), 6.70 (s, 2H), 5.17 (s, 2H), 2.34 (s, 3H).

[0761] Preparation 8. te / 7-Butyl? / -(6-(benzyloxy)-3-bromo-2-fluoro-4-methylphenyl)-jV-sulfamoylglycinate (P8).To a solution of P7 (3.1 g, 7.17 mmol) in ACN (40 mL) was added K2CO3 (3.96 g, 28.7 mmol) and / e / 7-butyl 2-bromoacetate (1.4 g, 7.17 mmol), then the reaction mixture was stirred at 20°C for 16 h. The reaction mixture was quenched with water (100 mL), extracted with EA (100 mL><3). Organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in petroleum = 0 to 20%) to afford the desired product P8 (2.6 g, 64.9% yield) as a white solid. 'H-NMR (400 MHz, DMSO-6), 8: 7.52 - 7.50 (m, 2H), 7.38 - 7.31 (m, 3H), 7.08 (s, 1H), 7.02 (s, 2H), 5.17 (s, 2H), 4.13 (q, J= 17.2, 78.0 Hz 2H), 2.37 (s, 3H), 1.30 (s, 9H).

[0762] Preparation 9. A-(6-(Benzyloxy)-3-bromo-2-fluoro-4-methylphenyl)-A-sulfamoylglycine (P9).To a solution of P8 (2.6 g, 4.65 mmol) in DCM (30 mL) was added TFA (10 mL). After stirred at 20°C for 4 h the reaction mixture was concentrated in vacuum, the crude was purified by silica gel column chromatography (EA in DCM = 0 to 10%) to afford the desired product P9 (1.6 g, 77.0% yield) as a light-yellow solid. 'H-NMR (400 MHz, DMSO-d6), 8: 7.53 -7.33 (m, 5H), 7.08 (s, 1H), 6.98 (s, 2H), 5.17 (s, 2H), 4.23 (d, J= 10.0 Hz, 1H), 4.14 (d, J= 10.0 Hz, 1H), 2.37 (s, 3H).

[0763] Preparation 10. 5-(6-(Benzyloxy)-3-bromo-2-fluoro-4-methylphenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P10).To a solution of P9 (1.6 g, 3.69 mmol) in DCM (20 mL) was added Et₃N (1.12 g, 11.1 mmol) and T4P (5.32 g, 50% in EA, 7.39 mmol), then the reaction mixture was stirred at 20°C for 16 h. The reaction mixture was quenched with water (100 mL), extracted with EA (100 mL*3). Organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (MeOH in DCM = 0 to 15%) to afford the desired product P10 (1.2 g, 78.3% yield) as a158.ASBMondego.26.0001white solid. ’H-NMR (400 MHz, DMSO-6), 8: 7.47 - 7.33 (m, 5H), 7.19 (s, 1H), 5.19 (s, 2H), 4.43 (s, 2H), 2.40 (s, 3H).

[0764] Preparation 11. / c / 'Z-Butyl 2-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadi azolidin-2 -yl)-2-fluoro-6-methylphenyl)-7-azabicyclo[2.2. l]hept-2-ene-7-carb oxy late (PH).The mixture of PIO (100 mg, 0.21 mmol), P2 (80 mg, 0.25 mmol), cataCXium A-Pd G3 (15.3 mg, 20.96 pmol) and potassium phosphate tribasic (133.5 mg, 0.63 mmol) in 1,4-di oxane (3 mb) and water (1 mL) was degassed with nitrogen atm. and stirred at 100°C for 3 h. The reaction mixture was poured into water (20 mL) and extracted with EA (20 mL><3). The combined organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated. The residue was purified by prep-TLC (DCM: MeOH = 10:1) to give the compound PH (80 mg, 68.6% yield) as a white solid, which was combined with 2 batches to give (120 mg) of desired product. LCMS (ESI): RT = 1.379 min, mass calc, for C27H30FN3O6S 543.18 m / z found 444.0 [M+H-100]+. 'II-NMR (400 MHz, CDCI3), 8: 7.42 - 7.36 (m, 2H), 7.34 - 7.32 (m, 1H), 7.22 - 7.15 (m, 2H), 6.63 (s, 1H), 6.16 (s, 1H), 5.21 -5.04 (m, 2H), 4.83 - 4.67 (m, 2H), 4.40 - 4.18 (m, 2H), 2.26 (s, 3H), 1.97 - 1.77 (m, 4H), 1.40 (s, 9H).

[0765] Preparation 12. / / 7-Buty] 2-(3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-4-hydroxy-6-methylphenyl)-7-azabicyclo[2.2.1 ]heptane-7-carboxylate (P12). To a solution of PH (120 mg, 0.22 mmol) in EA (8 mL) was added platinum (IV) oxide (9.8 mg, 43.1 pmol). The reaction mixture was degassed with H2 and stirred at rt (15 psi) for 1 h. The reaction mixture was filtered and concentrated in vacuum to leave a residue which was purified by C18 (ACN: 0.1% ammonium bicarbonate aq. solution = 0% to 90%) to give the title compound P12 (37 mg, 34.3% yield) as a white solid. LCMS (ESI): RT = 1.234 min, mass calc, for C20H26FN3O6S 455.15, m / z found 400.0 [M+H-56]+. 'H-NMR (400 MHz, DMSO-C / 6), 8: 9.16 (br. s, 1H), 7.11 (br. s, 1H), 6.56 (s, 1H), 4.16 (t, J=4.0Hz, 1H), 4.06 - 4.00 (m, 2H), 3.92 (s, 2H), 2.24 (s, 3H), 2.09 - 2.04 (m, 1H), 1.99 - 1.91 (m, 1H), 1.71 - 1.58 (m, 2H), 1.55 - 1.47 (m, 2H), 1.42 (s, 9H).Synthesis of benzyl l-(trifluoro-14-boraneyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate potassium salt (P15)159.ASBMondego.26.0001CbzP15

[0766] Preparation 13. Benzyl 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydro- IH-pyrrole- 1 -carboxylate (P13).To a solution of tert-butyl 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,5-dihydro- IH-pyrrole-l-carboxylate (5.0 g, 16.9 mmol) in DCM (20 mL) was added TFA (6.4 mL) and stirred at rt for 5 h. The reaction mixture was concentrated, and the residue was dissolved in THF (50 mL). TEA (11.8 mL, 84.5 mmol) and Cbz-OSu (5.06 g, 20.3 mmol) were added, and the resulting mixture was stirred overnight. The reaction mixture was poured into water (200 mL) and extracted with EA (80 mL x 3). The combined organic layers were washed with brine, dried overNa2SC>4, filtered and concentrated. The residue was purified by silica gel column (PE: EA = 10:1 to 5:1) to give the desired compound P13 (3.3 g, 59% yield) as a white solid. 'H-NMR (400 MHz, CDCh), 5: 7.47 - 7.29 (m, 5H), 6.48 (s, 1H), 5.15 (s, 2H), 4.29 (s, 4H), 1.27 (s, 12H).

[0767] Preparation 14. Benzyl l-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P14).To a solution ofEt2Zn (1.0 M in hexane, 53.6 mL, 53.6 mmol) in DCM (50 mL) was added CH2I2 (28.7 g, 107 mmol) dropwise at -40°C to -35°C. The resulting white suspension was stirred at -40°C to -35°C for 1 h. TFA (4.1 mL, 53.6 mmol) was added and stirred at -20°C to -15°C for 1 h. Then P13 (2.2 g, 6.7 mmol) in DCM (10 mL) was added and the resulting mixture was stirred at rt overnight. The reaction mixture was quenched with NaHCCh (aq., 200 mL) and filtered through Celite. The filtrate was extracted with DCM (100 mL * 2). The combined organic layers were washed with brine, dried over Na2SC>4, filtered and concentrated. The crude was purified by silica gel column (PE: EA = 10:1 to 5:1) to give the desired compound P14 (1.77 g, 77% yield) as colorless oil. 'H-NMR. (400 MHz,160.ASBMondego.26.0001CDC13), 8: 7.42 - 7.28 (m, 5H), 5.18 - 4.96 (m, 2H), 3.73 - 3.67 (m, 1H), 3.61 - 3.41 (m, 3H), 1.71 - 1.66 (m, 1H), 1.22 (s, 12H), 0.99 (dd, J = 7.5, 4.2 Hz, 1H), 0.43 (t, J= 3.8 Hz, 1H).

[0768] Preparation 15. Benzyl l-(trifluoro-14-boraneyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate potassium salt (P15).A suspension of P14 (1.77 g, 5.16 mmol) and KHF2 (2.82 g, 36.1 mmol) in MeOH (30 mL) was stirred at 75°C for 14 h. The mixture was concentrated, and the residue was triturated with ACN (30 mL) at 50°C for 20 min and then cooled and filtered. The filtrate was concentrated to give the desired compound P15 (2.0 g, crude) as a white solid. 'H-NMR(400MHz, DMSO-d6), 8: 7.45 - 7.22 (m, 5H), 5.00 (s, 2H), 3.46 - 3.39 (m, 1H), 3.31 - 3.09 (m, 3H), 1.03 - 0.96 (m, 1H), 0.40 - 0.37 (m, 1H), -0.36 (s, 1H).Synthesis of benzyl l-(2-allyl-5-(benzyloxy)-4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin- 2-yl)-3-fhiorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P25)161.ASBMondego.26.0001

[0769] Preparation 16. 1 -(Benzyloxy )-5-bromo-3-fluoro-2-nitrobenzene (P16).To a solution of 5-bromo-l,3-difluoro-2-nitrobenzene (23.8 g, 100 mmol) in DMF (200 mb) was added BnOH (10.8 g, 100 mmol) and K2CO3 (27.6 g, 200 mmol). The resulting mixture was stirred at 80°C for 40 h. The reaction mixture was filtered, and the filtrate was poured into was water (1 L) and extracted with EA (300 mb x 3). The combined organic layers were washed with water, brine, dried over Na? SO4, filtered and concentrated. The crude was triturated with PE and filtered. The cake was evaporated to give the desired compound P16 (16.5 g, 50% yield) as a pale-yellow solid. 'H-NMR (400 MHz, CDCI3), 8: 7.54 - 7.29 (m, 5H), 7.05 - 7.03 (m, 2H), 5.18 (s, 2H).162.ASBMondego.26.0001

[0770] Preparation 17. Benzyl l-(3-(benzyloxy)-5-fluoro-4-nitrophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P17).A suspension of benzyl l-(trifluoro-14-boraneyl)-3-azabicyclo[3. L0]hexane-3-carboxylate potassium salt P15 (2.0 g crude, 5.16 mmol), P16 (1.85 g, 5.68 mmol), cataCXium A Pd G3 (188 mg, 0.258 mmol) and CS2CO3 (5.05 g, 15.5 mmol) in toluene / water (40 mL / 4 mL) was degassed with N2 and stirred at 90°C for 18 h. The reaction mixture was cooled, poured into water (150 mL) and extracted with EA (50 mL x 3). The combined organic layers were washed with brine, dried over Na2SC>4, filtered and concentrated. The crude was purified by silica gel column (PE: EA = 5:1 to 2:1) to give the desired compound P17 (1.4 g, 59% yield for 2 steps) as a brown oil. 'H-NMR (400 MHz, DMSO-d6), 8: 7.42 - 7.33 (m, 10H), 7.09 (d, J= 9.2 Hz, 1H), 7.04 (dd, J= 11.4, 5.0 Hz, 1H), 5.36 (d, J= 4.7 Hz, 2H), 5.15 -5.03 (m, 2H), 4.01 - 3.95 (m, 1H), 3.73 - 3.47 (m, 3H), 2.28 - 2.14 (m, 1H), 1.25 - 1.19 (m, 1H), 0.97 - 0.88 (m, 1H).

[0771] Preparation 18. Benzyl l-(5-(benzyloxy)-2-bromo-3-fluoro-4-nitrophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P18).To a solution of P17 (1.4 g, 3.03 mmol) and AcOH (46 mg, 0.76 mmol) in ACN (15 mL) was added NBS (810 mg, 4.55 mmol) and TMSC1 (0.19 mL, 1.52 mmol) under ice bath and the mixture was stirred under ice bath for 1 h. The reaction mixture was poured into NaHCCh (aq., 80 mL) and extracted with EA (30 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude was purified by silica gel column (PE: EA = 5:1 to 2:1) to give the desired compound P18 (1.5 g, 91% yield) as a brown oil. 'H-NMR (400 MHz, DMSO-6), 8: 7.47 (s, 1H), 7.46 - 7.16 (m, 10H), 5.36 (d, J= 2.3 Hz, 2H), 5.16 - 4.98 (m, 2H), 3.91 - 3.61 (m, 3H), 3.46 - 3.39 (m, 1H), 1.99 -1.93 (m, 1H), 1.26 - 1.22 (m, 1H), 0.94 - 0.91 (m, 1H).

[0772] Preparation 19. Benzyl l-(4-amino-5-(benzyloxy)-2-bromo-3-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P19).To a solution of P18 (1.3 g, 2.4 mmol) and AcOH (144 mg, 2.4 mmol) in EtOH / HoO / THF (14 mL / 7 mL / 7mL) was added Fe (671 mg, 12.0 mmol) and stirred at 85°C for 40 min. The reaction mixture was filtered through Celite and the filtrate was poured into NaHCOs (aq., 100 mL) and extracted with EA (70 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated to give the desire compound P19 (1.2 g,163.ASBMondego.26.000198% yield) as a brown oil. LCMS (ESI): RT = 1.520 min, mass calc, for C26H24BrFN2Ch 510.1 m / z found 511.1 [M+H]+.

[0773] Preparation 20. Benzyl l-(5-(benzyloxy)-2-bromo-4-((N-(tert-butoxycarbonyl)sulfamoyl)amino)-3-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P20).CSI (0.31 mL, 3.53 mmol) was added dropwise to a solution of te / 7-BuOH (0.34 mL, 3.35 mmol) in DCM (7 mL) and stirred at 25°C for 30 min. Then this solution was added to solution of P19 (1.2 g, 2.35 mmol) and TEA (0.65 mL, 4.70 mmol) in DCM (7 mL) at rt and stirred overnight. The reaction mixture was concentrated and purified by silica gel column (DCM: MeOH = 50:1 to 20:1) to give the desired compound P20 (1.36 g, 84% yield) as a white solid. 'H-NMR (400 MHz, CDCh), 8: 7.50 - 7.27 (m, 10H), 7.24 (d, J = 5.2 Hz, 1H), 6.79 (s, 2H), 5.22 - 4.97 (m, 4H), 3.87 - 3.78 (m, 3H), 3.50 (d, J= 10.6 Hz, 1H), 1.77 - 1.66 (m, 1H), 1.48 (s, 9H), 1.05 - 0.98 (m, 1H), 0.91 - 0.85 (m, 1H).

[0774] Preparation 21. Benzyl l-(5-(benzyloxy)-2-bromo-3-fluoro-4-(sulfamoylamino)phenyl)-3-azabicyclo[3.1.0]hexane-3 -carboxylate (P21).To a solution of P20 (1.36 g, 1.97 mmol) in DCM (15 mL) was added TFA (1.51 mL) at rt and stirred for 16 h. The reaction mixture was poured into NaHCOa (aq., 30 mL) and extracted with DCM (20 mL) 3 times. The combined organic layers were washed with brine, dried over Na2SC>4, filtered and concentrated to give the desired compound P21 (1.06 g, 91% yield) as a white solid. 'H-NMR. (400 MHz, DMSO-c / 6), 6: 8.57 (s, 1H), 7.60 - 7.54 (m, 2H), 7.50 - 7.18 (m, 8H), 7.07 (s, 1H), 6.77 (d, J= 4.7 Hz, 2H), 5.21 (s, 2H), 5.14 -4.98 (m, 2H), 3.83 - 3.65 (m, 3H), 3.39 - 3.33 (m, 1H), 1.93 - 1.74 (m, 1H), 1.12 - 1.07 (m, 1H), 0.85 - 0.82 (m, 1H).

[0775] Preparation 22. Benzyl l-(5-(benzyloxy)-2-bromo-4-((2-(tert-butoxy)-2-oxoethyl)(sulfamoyl)amino)-3-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P22).To a solution of P21 (1.06 g, 1.80 mmol) in ACN (30 mL) was added K2CO3 (995 mg, 7.20 mmol) and a solution of / c / 'Z-butyl 2-bromoacetate (219 mg, 1.80 mmol) in ACN (15 mL) at rt. The resulting mixture was stirred overnight, filtered and concentrated. The residue was purified by silica gel column (DCM: MeOH = 50: 1 to 10: 1) to give the desired164.ASBMondego.26.0001compound P22 (756 mg, 60% yield) as a white solid. 'H-NMR (400 MHz, DMSO-r / e), 8: 7.52 (d, J = 1A Hz, 2H), 7.41 - 7.35 (m, 8H), 7.14 - 7.10 (m, 3H), 5.21 (s, 2H), 5.07 (s, 2H), 4.26 (d, J= 17.1 Hz, 1H), 4.08 - 4.04 (m, 1H), 3.91 - 3.61 (m, 3H), 3.42 - 3.34 (m, 1H), 1.87 (br. s, 1H), 1.29 (s, 9H), 1.17 - 1.04 (m, 1H), 0.90 - 0.83 (m, 1H).

[0776] Preparation 23. A-(6-(Benzyloxy)-4-(3-((benzyloxy)carbonyl)-3-azabicyclo[3.1 0]hexan-l -yl)-3-bromo-2-fluorophenyl)-A-sulfamoylglycine (P23).To a solution of P22 (756 mg, 1.07 mmol) in DCM (8 mb) was added TFA (0.82 mL, 10.7 mmol) at rt and stirred for 16 h. The reaction mixture was concentrated to give the desired compound P23 (744 mg, 100% yield) as a white solid. 'H-NMR (400 MHz, DMSO-tZe), 8: 7.53 - 7.52 (m, 2H), 7.42 - 7.35 (m, 8H), 7.14 (s, 1H), 7.05 (s, 2H), 5.21 (s, 2H), 5.07 (s, 2H), 4.32 (d, J= 18.1 Hz, 1H), 4.13 (d, J= 18.3 Hz, 1H), 3.83 - 3.67 (m, 3H), 3.39 (dd, J = 23.7, 10.4 Hz, 1H), 1.93 - 1.83 (s, 1H), 1.19 - 1.11 (s, 1H), 0.89 - 0.83 (m, 1H).

[0777] Preparation 24. Benzyl l-(5-(benzyloxy)-2-bromo-4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (P24). To a solution of P23 (740 mg, 1.14 mmol) and TEA (0.48 mL, 3.42 mmol) in DCM (15 mL) was added T4P (50% in EA, 1.64 g, 2.28 mmol) at rt and stirred overnight. The mixture was diluted with DCM (20 mL), washed with water, brine, dried over Na2SC>4 and concentrated. The crude was purified by silica gel column (DCM: MeOH = 50:1 to 10:1) to give the desired compound P24 (605 mg, 84% yield) as a white solid. 'H-NMR (400 MHz, DMSO-r76), 8: 7.58 - 7.27 (m, 10H), 7.21 (s, 1H), 5.23 (s, 2H), 5.08 (d, J= 3.2 Hz, 2H), 4.34 (s, 2H), 3.86 - 3.66 (m, 3H), 3.41 (dd, J = 24.2, 10.2 Hz, 1H), 3.17 - 3.09 (m, 1H), 1.91 - 1.90 (m, 1H), 1.17 - 1.13 (m, 1H), 0.90 - 0.82 (m, 1H).

[0778] Preparation 25. Benzyl l-(2-allyl-5-(benzyloxy)-4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-fluorophenyl)-3-azabicyclo[3.1,0]hexane-3 -carboxylate (P25). A solution ofP24 (250 mg, 0.397 mmol), 2-allyl-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (133 mg, 0.794 mmol), cataCXium A Pd G3 (28 mg, 0.040 mmol) and K3PO4 (212 mg, 0.993 mmol) in dioxane / H2O (3 mL / 0.6 mL) was degassed with N2 and stirred at 90°C overnight. The reaction mixture was poured into water (50 mL), acidified with IM HC1 (aq.) to pH = 5 and extracted with EA (30 mL) 3 times. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The crude was purified165.ASBMondego.26.0001by preparative TLC (DCM: MeOH = 10:1) to give the desired compound P25 (160 mg, 68% yield) as a white solid. 'H-NMR (400 MHz, DMSO-d6), 8: 7.51 (d, J= 7.2 Hz, 2H), 7.44 - 7.25 (m, 8H), 6.97 (s, 1H), 6.01 - 5.82 (m, 1H), 5.15 (s, 2H), 5.12 - 4.97 (m, 3H), 4.91 (d, J= 17.0 Hz, 1H), 3.95 (s, 2H), 3.84 - 3.55 (m, 3H), 3.44 (br. s, 2H), 3.30 - 3.23 (m, 1H), 1.88 - 1.80 (m, 1H), 1.07 - 0.95 (m, 1H), 0.78 (t, J= 4.6 Hz, 1H).Synthesis of benzyl 4-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2- fluoro-6-(trifluoromethyl)phenyl)-3,6-dihydropyridine-l(2H)-carboxylate (P38)

[0779] Preparation 26. l-(Benzyloxy)-3-fluoro-2-nitrobenzene (P26).To a solution of l,3-difluoro-2-nitrobenzene (50 g, 314 mmol) and BnOH (40.8 g, 377 mmol) in DMF (500 mL) was added K2CO3 (86.9 g, 628 mmol) and then the reaction mixture was stirred at 80°C for 16 h. The reaction mixture was quenched with water (1000166.ASBMondego.26.0001mL), extracted with EA (1000 mL><3). Organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in PE = 0 to 20%) to afford the desired product P26 (78 g, 90.4% yield) as a white solid. ’H-NMR (400 MHz, CDC13), 8: 7.39 - 7.26 (m, 6H), 6.87 - 6.82 (m, 2H), 5.20 (s, 2H).

[0780] Preparation 27. l-(Benzyloxy)-4-bromo-3-fluoro-2-nitrobenzene (P27).To a solution of P26 (78 g, 284 mmol), TMSC1 (37.0 g, 341 mmol) and AcOH (17.1 g, 284 mmol) in ACN (1000 mL) was added NBS (75.8 g, 426 mmol) and then the reaction mixture was stirred at 30°C for 16 h. The reaction mixture was quenched with water (1000 mL), extracted with EA (1000 mL x 3). The combined organic layers were washed with brine, dried over Na2SC>4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in PE = 0 to 20%) to afford the desired product P27 (90 g, 87.5% yield) as a white solid. 'H-NMR (400 MHz, DMSO-d6), 8: 7.95 (t, J= 92 Hz, 1H), 7.45 - 7.30 (m, 6H), 5.34 (s, 2H).

[0781] Preparation 28. 6-(Benzyloxy)-3-bromo-2-fluoroaniline (P28).To a solution of P27 (90 g, 248 mmol) in EtOH (1000 mL) was added Fe (55.5 g, 993 mmol) and NH4CI (106 g, 1990 mmol). Then the reaction mixture was stirred at 70°C for 2 h. The reaction mixture was filtered, and the filtrate was quenched with water (1000 mL), extracted with EA (1000 mL x 3). The combined organic layers were washed with brine, dried over Na2SC>4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in PE = 0 to 20%) to afford the desired product P28 (60 g, 73.4% yield) as a white solid. 'H-NMR (400 MHz, CDCI3), 8: 7.40 - 7.34 (m, 5H), 6.82 - 6.78 (m, 1H), 6.56 - 6.53 (m, 1H), 5.06 (s, 2H), 3.80 (br. s, 2H).

[0782] Preparation 29. 6-(Benzyloxy)-3-bromo-2-fluoro-4-iodoaniline (P29).To a solution of P28 (14 g, 42.6 mmol), Ag2SC>4 (15.9 g, 51.0 mmol) in EtOH (1000 mL) was added I2 (13.0 g, 51.0 mmol) and then the reaction mixture was stirred at 25°C for 16 h. The reaction mixture was quenched with NaSOs (aq., 100 mL) and water (300 mL), extracted with EA (400 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum; the crude was purified by silica gel column chromatography (EA in PE = 0 to 40%) to afford the desired product P29 (11167.ASBMondego.26.0001g, 90% 55.1% yield) as a yellow solid. 'H-NMR (400 MHz, CDC13), 8: 7.41 - 7.37 (m, 5H), 7.13 (d, J= 2.0 Hz, 1H), 5.03 (s, 2H), 3.73 (br. s, 2H).

[0783] Preparation 30. A-(6-(Benzyloxy)-3-bromo-2-fluoro-4-iodophenyl)acetamide (P30).To a solution of P29 (11 g, 23.5 mmol) and pyridine (5.57 g, 70.4 mmol) in DCM (200 mb) was added AcCl (2.76 g, 35.2 mmol) and then the reaction mixture was stirred at 25°C for 4 h. The reaction mixture was fdtered and the filter cake was evaporated in vacuum to afford the desired product P30 (10.5 g, 86.8% yield) as a white solid. 'H-NMR (400 MHz, DMSO-CZ6), 6: 9.50 (s, 1H), 7.55 (s, 1H), 7.45 - 7.33 (m, 5H), 5.20 (s, 2H), 2.03 (s, 3H).

[0784] Preparation 31. Ar-(6-(Benzyloxy)-3-bromo-2-fluoro-4- (tri fluor om ethy l)pheny 1 )acetami de (P31 ).A suspension of P30 (8.7 g, 18.7 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (35.9 g, 187 mmol) and Cui (1.07 g, 5.61 mmol) in NMP (100 mL) was degassed with N2 and stirred at 85°C for 16 h. The reaction mixture was poured into NH4CI (15%, aq., 500 mL) and extracted with EA (300 mL x 3). The combined organic layers were washed with NaHCCh (10%, aq., 200 mL), brine, dried over Na? SO4 and concentrated. The crude was triturated with ACN and filtered. The cake was evaporated to give the desired compound P31 (4.4 g, 58% yield) as a white solid. ’H-NMR (400 MHz, DMSO-6), 8: 9.77 (s, 1H), 7.48 - 7.34 (m, 6H), 5.32 (s, 2H), 2.07 (s, 3H).

[0785] Preparation 32. 6-(Benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)aniline (P32).To a solution of P31 (2.9 g, 7.1 mmol) in MeOH / THF (25 mL / 25 mL) was added K2CO3 (2.9 g, 21.3 mmol) and stirred at 70°C overnight. The reaction mixture was concentrated, and the residue was dissolved in water (100 mL) and extracted with EA (50 mL x 3). The combined organic layers were washed with brine, dried over Na SO4 and concentrated to give the desire compound P32 (2.6 g, 100% yield) as a brown solid. 'H-NMR (400 MHz, DMSO-d6), 8: 7.56 - 7.47 (m, 2H), 7.44 - 7.36 (m, 2H), 7.35 - 7.32 (m, 1H), 7.15 (d, J = 1.2 Hz, 1H), 5.81 (s, 2H), 5.24 (s, 2H).

[0786] Preparation 33. tert- Butyl (A-(6-(benzyloxy)-3-bromo-2-fluoro-4- (trifluoromethyl)phenyl)sulfamoyl) carbamate (P33).168.ASBMondego.26.0001CSI (0.93 mL, 10.7 mmol) was added dropwise to a solution of tert-BuOH (1.02 mL, 10.7 mmol) in DCM (15 mL) and stirred at 25°C for 30 min. Then this solution was added to a solution of P32 (2.6 g, 7.1 mmol) and TEA (1.98 mL, 14.2 mmol) in DCM (15 mL) at rt and stirred overnight. The reaction mixture was diluted with DCM (50 mL), washed with NH4CI (aq.), brine, dried over Na2SC>4 and concentrated. And the residue was purified by silica gel column (PE: EA = 5:1 to 2:1) to give the desired compound P33 (2.44 g, 63% yield) as a white solid. 'H-NMR (400 MHz, DMSO-tZ6), 8: 11.18 (s, 1H), 9.98 (s, 1H), 7.52 (d, J= 7.2 Hz, 2H), 7.47 - 7.28 (m, 4H), 5.33 (s, 2H), 1.37 (s, 9H).

[0787] Preparation 34. [6-(Benzyloxy)-3-bromo-2-fluoro-4- (trifluoromethyl)phenyl]azanesulfonamide (P34).To a solution of P33 (2.44 g, 4.49 mmol) in DCM (15 mL) was added TFA (3.4 mL) and stirred at 20°C for 4 h. The reaction mixture was poured into NaHCCh (aq., 50 mL) and extracted with DCM (30 mL) 3 times. The combined organic layers were washed with brine, dried over Na2SC>4, filtered and concentrated. The residue was purified by silica gel column (PE: EA = 5:1 to 1:1) to give the desired compound P34 (1.6 g, 90% yield) as a white solid. 'H-NMR (400 MHz, DMSO-6), 8: 8.90 (s, 1H), 7.55 (d, J= 7.0 Hz, 2H), 7.42 - 7.31 (m, 4H), 6.99 (s, 2H), 5.32 (s, 2H).

[0788] Preparation 35. tert-Butyl A-(6-(benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)-A-sulfamoyl glycinate (P35).To a suspension of P34 (1.6 g, 3.61 mmol) and K2CO3 (2.0 g, 14.4 mmol) in ACN (18 mL) was added tert-butyl 2-bromoacetate (704 mg, 3.61 mmol) dropwise. The resulting mixture was stirred at 20°C for 4 h. The reaction mixture was filtered and concentrated to give a residue which was purified by silica gel column (PE: EA = 5:1 to 2:1) to give the desired compound P35 (1.7 g, 85% yield) as a white solid. ’H-NMR (400 MHz, DMSO-d6), 8: 7.53 - 7.51 (m, 2H), 7.45 - 7.35 (m, 4H), 7.29 (s, 2H), 5.31 (s, 2H), 4.30 (d, J= 17.3 Hz, 1H), 4.18 (d, J= 17.3 Hz, 1H), 1.30 (s, 9H).

[0789] Preparation 36. tV-(6-(Benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)-A-sulfamoylglycine (P36).To a solution of P35 (1.9 g, 3.41 mmol) in DCM (13 mL) was added TFA (2.6 mL, 34.1 mmol) at rt and stirred for 4 h. The reaction mixture was concentrated to give the desired169.ASBMondego.26.0001compound P36 (1.7 g, 100% yield) as a white solid. 'H-NMR (400 MHz, DMSO-t / e), 8: 7.59 - 7.34 (m, 6H), 7.24 (s, 2H), 5.31 (s, 2H), 4.36 (d, J = 18.0 Hz, 1H), 4.24 (d, J= 18.0 Hz, 1H).

[0790] Preparation 37. 5-(6-(Benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P37).To a solution of P36 (850 mg, 1.70 mmol) and TEA (0.71 mL, 5.1 mmol) inDCM (15 mL) was added T4P (50% in EA, 2.45 g, 3.40 mmol) at rt and stirred overnight. The mixture was diluted with DCM (30 mL), washed with water, brine, dried over Na2SO4 and concentrated. The crude was purified by silica gel column (DCM: MeOH = 100:1 to 10:1) to give the desired compound P37 (750 mg, 90% yield) as a white solid. 'H-NMR (400 MHz, DMSO-t / e), 8: 7.51 (s, 1H), 7.47 (d, J = 6.9 Hz, 2H), 7.41 - 7.34 (m, 3H), 5.34 (s, 2H), 4.40 (s, 2H).

[0791] Preparation 38. Benzyl 4-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-6-(trifluoromethyl)phenyl)-3,6-dihydropyridine-l(2H)-carboxylate (P38).A solution of P37 (300 mg, 0.621 mmol), benzyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(2H)-carboxylate (320 mg, 0.932 mmol), cataCXium A Pd G3 (44 mg, 0.062 mmol) and K3PO4 (329 mg, 1.55 mmol) in dioxane / H2O (6 mL / 1.2 mL) was degassed with N2 and stirred at 90°C overnight. The reaction mixture was poured into water (50 mL), acidified with 1 M HC1 (aq.) to pH = 5 and extracted with EA (30 mL) 3 times. The combined organic layers were washed with brine, dried over Na2SC>4, filtered and concentrated. The crude was purified by silica gel column (DCM: MeOH = 100:1 to 10:1) to give the desired compound P38 (360 mg, 84% yield) as white solids. LCMS (ESI): RT = 1.451 min, mass calc, for C29H25F4N3O6S 619.1 m / z found 618.1 [M-H]’.Synthesis of tert-butyl 2-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)- 2-fluoro-6-(trifluoromethyl)phenyl)-7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate (P43)170.ASBMondego.26.0001

[0792] Preparation 39. 6-(Benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)aniline (P39).A solution of A-(6-(benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)acetamide P31 (3.60 g, 8.00 mmol), and K2CO3 (3.73 g, 27.0 mmol) in MeOH (30 mL) and ACN (30 mL) was stirred at 60°C for 14 h. Then the mixture was diluted with water (50 mL) and extracted with EA (50 mL) twice. The combined organic layers were dried over Na2SO4(s) and filtered to give the desired product P39 (3.0 g, 92% yield) as a brown oil. ’H-NMR (400 MHz, CDCI3), 5: 7.43 - 7.38 (m, 5H), 7.00 (s, 1H), 5.10 (s, 2H), 4.20 (s, 2H).

[0793] Preparation 40. / ert-Butyl (A-(6-(benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)sulfamoyl) carbamate (P40).CSI (2.09 g, 14.8 mmol) was added into solution of / c7 / -BuOH (1.10 g, 14.8 mmol) and DCM (30 mL). After stirred at 0°C for 1 h, the solution was added into a mixture of P39 (3.0 g, 7.42 mmol) and TEA (2.25 g, 22.3 mmol) in DCM (30 mL). After stirred at 20°C for 2 h, the mixture was concentrated and purified by silica gel column chromatography (PE: EA = 10: 1 to 2: 1) to give the title compound P40 (2.0 g, 45 % yield) as a white solid. ’H-NMR. (400 MHz, CDCI3), 5: 7.43 - 7.34 (m, 5H), 7.15 (s, 1H), 7.04 (s, 1H), 5.18 (s, 2H), 1.47 (s, 9H).

[0794] Preparation 41. Ze / 7-Butyl A-(6-(benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)-7V-sulfamoylglycinate (P41).To a solution of P40 (2.0 g, 3.32 mmol) in DCM (15 mL) was added TFA (15 mL) at 0°C. After stirred at 0°C for 2 h, the mixture was concentrated and diluted into ACN (20 mL), added K2CO3 (490 mg, 3.55 mmol) and Ze / 7-butyl 2-bromoacetate (519 mg, 2.68 mmol).171.ASBMondego.26.0001After stirred at 20°C for 14 h, the mixture was concentrated and purified by silica gel column chromatography (PE: EA = 8: 1) to give the title compound P41 (1.0 g, 49 % yield) as a yellow oil. 'H-NMR (400 MHz, CDC13), 8: 7.49 - 7.41 (m, 5H), 7.20 (s, 1H), 5.18 (s, 2H), 5.06 (s, 2H), 4.28 - 4.26 (m, 2H), 1.44 (s, 9H).

[0795] Preparation 42. 5-(6-(Benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)phenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P42).To a solution of P41 (1.0 g, 1.62 mmol) inDCM (20 mL) was added TFA (10 mL) at 20°C. After stirred at 20°C for 2 h, the mixture was concentrated and diluted into DCM (30 mL), added TEA (700 mg, 6.9 mmol) and 50% T4P in EA (2.98 mg, 4.13 mmol). After stirred at 20°C for 2 h, the mixture was quenched with water (30 mL) and extracted with DCM (30 mL) twice. The combined organic layers were dried over Na2SC>4(s) and filtered to give the desired product P42 (620 mg, 56% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 8: 11.26 (s, 1H), 7.48 - 7.46 (m, 2H), 7.38 - 7.30 (m, 3H), 7.15 (s, 1H), 5.21 (s, 2H), 4.35 (s, 2H).

[0796] Preparation 43. / ert-Butyl 2-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadi azolidin-2 -yl)-2-fluoro-6-(trifluoromethyl)phenyl)-7-azabicyclo[2.2. l]hept-2-ene-7-carb oxy late (P43).A solution of P42 (620 mg, 0.73 mmol), (7-( / cv7-butoxycarbonyl)-7-azabicyclo[2.2.1 ]hept-2-en-2-yl)boronic acid (233 mg, 0.730 mmol), Pd(dppf)Ch (53 mg, 0.073 mmol) and K3PO4 (460 mg, 22.18 mmol) in dioxane (10 mL) and H2O (2 mL) was stirred at 90°C for 14 h. Then the mixture was concentrated and purified by silica gel column chromatography (DCM: MeOH = 10:1) and purified by C18 column (ACN:water, 0.1 % ammonium bicarbonate 5% to 95%) to give the title compound P43 (110 mg, 25% yield) as a yellow oil. LCMS (ESI): RT = 1.441 min, mass calc, for C27H27F4N3O6S 597.16, m / z found 620.1 [M+Na]+.Synthesis of 5-(8-fluoro-6-hydroxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidin]-7- yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P54)172.ASBMondego.26.0001

[0797] Preparation 44. (E)-4-(3-Fluoro-5-methoxyphenyl)but-3-enoic acid (P44).To a solution of 3-fluoro-5-methoxybenzaldehyde (90.0 g, 584 mmol) and (2-carboxyethyl)triphenylphosphonium bromide (265 g, 643 mmol) in DCM (1 L) was slowly added terABuOK (13 g, 1.46 mol) at -5°C. The reaction mixture was stirred at -5°C for 5 h. The reaction mixture was quenched with water (2 L) and extracted with DCM (500 mL). The water layer was adjusted to pH 4-5 with 50 % FA and extracted with MTBE (500 mL) twice. The organic layer was washed with brine, dried over Na2SC>4(s), filtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (DCM) to give the title product P44 (100 g, 73% yield) as a yellow oil.1H-NMR(400 MHz, CD3OD), 5: 6.73 - 6.71 (m, 2H), 6.55 - 6.51 (m, 1 H), 6.45 - 6.41 (m, 1H), 6.36 - 6.30 (m, 1H), 3.77 (s, 3H), 3.22 (d, J= 6.0 Hz, 2H).

[0798] Preparation 45. 4-(3-Fluoro-5-methoxyphenyl)butanoic acid (P45).173.ASBMondego.26.0001The mixture of P44 (100 g, 474 mmol) and Pd / C (1.0 g) in MeOH (500 mL) and THF (500 mL) was stirred at 20°C for 16 h under H2 atm. (1 atm). The reaction mixture was filtered, and the filtrate was concentrated in vacuum to afford the title product P45 (100.0 g, 100% yield) as a yellow oil. ‘H-NMR (400 MHz, CDCh), 8: 10.29 (br. s, 1H), 6.51 - 6.44 (m, 3H), 3.77 (s, 3H), 2.63 - 2.62 (m, 2H), 2.38 (t, J= 7.2 Hz, 2H), 1.99 - 1.91(m, 2H).

[0799] Preparation 46. 8-Fluoro-6-methoxy-3,4-dihydronaphthalen-l(2H)-one (P46). A solution of P45 (90.0 g, 382 mmol) in DMF (500 mL) was stirred at 100°C for 5 h. The mixture was quenched with sat. Na^CCL (200 mL) and extracted with EA (500 mL) twice. The organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (PE: EA = 5:1) to give the title product P46 (27 g, 33% yield) as a yellow solid and 6-fluoro-8-methoxy-tetralin-l-one (20 g, 24% yield) as a brown oil. P46: 'H-NMR (400 MHz, CDCh), 5: 6.56 - 6.46 (m, 2H), 3.89 (s, 3H), 2.90 (t, J= 6.0 Hz, 2H), 2.59 - 2.58 (m, 2H), 2.08 - 1.96 (m, 2H). 6-fluoro-8-methoxy-tetralin-l-one: 'H-NMR (400 MHz, CDCh), 5: 6.56 - 6.46 (m, 2H), 3.89 (s, 3H), 2.90 (t, J= 6.0 Hz, 2H), 2.62 (t, J= 6.4 Hz, 2H), 2.08 - 2.02(m, 2H).

[0800] Preparation 47. Ethyl 8-fluoro-6-methoxy-l,2,3,4-tetrahydronaphthalene-2-carboxylate (P47).To a solution of P46 (25 g, 116 mmol) in THF (400 mL) was slowly added NaH (18.6 g, 60%) at 0°C. After the reaction mixture was stirred at 0°C for 0.5 h, ethyl IH-imidazole-1-carboxylate (32.5 g, 232 mmol) was added and stirring continued at 20°C for 14 h. Then the mixture was quenched with ice-water (500 mL) and extracted with EA (300 mL). The organic layer was washed with brine, dried over Na2SC>4(s), filtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (PE: EA = 10:1) to give a keto / enol mixture (25 g, 81% yield) as a brown oil. To a solution of this mixture (20.0 g, 67.7 mmol) in TFA (200 mL) was added triethylsilane (78 mL) at 0°C. After stirred at 70°C for 2 h, the reaction mixture was concentrated and purified by silica gel column chromatography (PE: EA = 10:1) to give the title compound P47 (14 g, 74% yield) as a yellow oil.1H-NMR (400 MHz, CDCh), 5: 6.47 - 6.43 (m, 2H), 4.19 (q, J= 7.2 Hz, 2H), 3.75 (s, 3H), 3.05 - 3.00 (m, 1H), 2.83 - 2.62 (m, 4H), 2.19 - 2.16 (m, 1H), 1.86 -1.76 (m, 1H), 1.28 (t, J= 7.2 Hz, 3H).174.ASBMondego.26.0001

[0801] Preparation 48. Ethyl 2-(2-((ter / -butoxycarbonyl)amino)ethyl)-8-fluoro-6-methoxy-l,2,3,4-tetrahydro-naphthalene-2-carboxylate (P48).To a solution of P47 (14.0 g, 49.8 mmol) in THF (100 mL) was slowly added LDA (49.8 mb, 2 M) at -70°C. The mixture was stirred at -65°C for 1 h then stirred at 0°C for 0.5 h. / e / 7- Butyl l,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (22.2 g, 100 mmol) in THF (100 mL) was slowly added into the solution. After stirred at -65 °C for 1 h, the reaction mixture was quenched with saturated NH4CI solution (200 mL) and extracted with EA (100 mL) twice. The organic layer was washed with brine, dried over Na2SC>4(s), fdtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (PE: EA = 5:1) to give the title product P48 (14.0 g, 70% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 8: 6.48 -6.75 (m, 1H), 6.6 - 6.58 (m, 1H), 6.51 - 6.50 (m, 1H), 4.06 (q, J = 7.2 Hz, 2H), 3.70 (s, 3H), 3.09 - 3.05 (m, 1H), 2.99 - 2.87 (m, 2H), 2.68 -2.65 (m, 2H), 2.43 - 2.39 (m, 1H), 2.03 - 1.95 (m, 1H), 1.77 - 1.65 (m, 3H), 1.36 (s, 9H), 1.14 (t, J = 7.2 Hz, 3H).

[0802] Preparation 49. 8-Fluoro-6-methoxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidin]-2'-one (P49).The mixture of P48 (14.0 g, 30.8 mmol) in DCM (240 mL) was added TFA (120 mL). After stirred at 0°C for 2 h, the solution was concentrated and diluted into MeOH (300 mL), sodium methanolate (30 mL, 30 wt%, in MeOH) was added and stirring continued at 0°C for 1 h. The reaction mixture was quenched with saturated water (500 mL) and extracted with EA (500 mL). The organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (DCM: EA = 1:1) to give the title product P49 (7.0 g, 82% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 8: 6.85 (br. s, 1H), 6.48 - 6.47 (m, 2H), 3.76 (s, 3H), 3.47 - 3.38 (m, 2H), 2.93 - 2.66 (m, 4H), 2.08 - 1.99 (m, 3H), 1.73 -1.67(m, 3H).

[0803] Preparation 50. Benzyl 8-fluoro-6-hydroxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidine]-L-carboxylate (P50).To a solution of P49 (6.0 g, 21.7 mmol) in THF (150 mL) was slowly added LiAlH4 (1.65 g, 43.4 mmol) at 0°C. After stirred at 70°C for 5 h, the reaction mixture was quenched with Na2SC>4.5H2O(S) and filtered. The filtrate was concentrated to give a residue, which was 175.ASBMondego.26.0001diluted into DCM (80 mL), BBn (30.6 mL, IM in DCM) was added. The mixture was stirred at 0°C for 2 h and then concentrated. The residue was diluted into DCM (50 mL), added TEA (4.9 g, 48.9 mmol) and Cbz-OSu (6.08 g, 24.4 mmol). After stirred at 20°C for 2 h, the mixture was concentrated and purified by silica gel column chromatography (PE: EA = 5: 1) to give the title product P50 (4.6 g, 48% yield) as a colorless oil.1I I-NMR (400 MHz, CDC13), 8: 7.40 - 7.31 (m, 5H), 6.42 - 6.39 (m, 2H), 5.14 (s, 2H), 3.58 - 3.54 (m, 2H), 3.28 - 3.23 (m, 2H), 2.73 - 2.45 (m, 4H), 1.80 - 1.70 (m, 4H).

[0804] Preparation 51. Benzyl 6-(benzyloxy)-8-fluoro-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidine]-T-carboxylate (P51).To a solution of P50 (4.0 g, 9.01 mmol) in ACN (40 mL) was added K2CO3 (3.73 g, 27.0 mmol) and BnBr (2.31 g, 13.5 mmol) at 0°C. After stirred 50°C for2h, the reaction mixture was filter and concentrated to give the title product P51 (4.0 g, 90% yield) as a colorless oil.1H-NMR(400MHz, CDCI3), 8: 7.43 - 7.31 (m, 10H), 6.54 - 6.51 (m, 2H), 5.14 (s, 2H), 5.00 (s, 2H), 3.57 (s, 2H), 3.32 - 3.26 (m, 2H), 2.80 - 2.48 (m, 4H), 1.80 - 1.73 (m, 4H).

[0805] Preparation 52. Benzyl 6-(benzyloxy)-8-fluoro-7-iodo-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidine]-l'-carboxylate (P52).To a solution of 2,2,6,6-tetramethylpiperidine (1.7 g, 12.1 mmol) in THF (20 mL) was slowly added / / -BuLi (4.8 mL, 12.0 mmol, 2.5 M) at -78°C. The mixture was stirred at -78°C for 0.5 h. Then, P51 (2.0 g, 4.04 mmol) and Ai, Ai, Ar2, A2-tetramethylethane-l,2-diamine (700 mg, 6.06 mmol) in THF (20 mL) was slowly added into the mixture. The reaction mixture was stirred at -78°C for 1.5 h. Then, 12(1.5 g, 24.2 mmol) in THF (10 mL) was slowly added into. The reaction was stirred at -70°C for 0.5 h. The mixture was quenched with saturated NH4CI solution (60 mL) and extracted with EA (50 mL). The organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated in vacuum to leave a residue, which was diluted into DCM (30 mL), added Cbz-OSu (1.0 g, 4.04 mmol) and TEA (2.5g, 24.2 mmol). After stirred at 20°C for 2 h, the mixture was concentrated and purified by silica gel column chromatography (PE: EA = 10:1) to give the title product P52 (470 mg, 16% yield) as a yellow oil.1H-NMR (400 MHz, CDCI3), 8: 7.50 - 7.32 (m, 10H), 6.53 (s,lH), 5.14 - 5.11(m, 4H), 3.63 - 3.50 (m, 2H), 3.31 - 3.19 (m, 2H), 2.80 - 2.59 (m, 4H), 1.79 - 1.60 (m, 4H).176.ASBMondego.26.0001

[0806] Preparation 53. Benzyl 6-(benzyloxy)-7-((2-(ter / -butoxy)-2-oxoethyl)amino)-8-fluoro-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidine]-l'-carboxylate (P53).A mixture of P52 (470 mg, 0.68 mmol), / crz-butyl glycinate (172 mg, 1.3 mmol), CS2CO3 (641 g, 1.97 mmol), Brettphos (35 mg, 0.066 mmol) and Brettphos Pd G3 (60 mg, 0.066 mmol) in 1,4-di oxane (10 mb) was stirred at 100°C for 14 h. The reaction mixture was concentrated and purified by silica gel column chromatography (PE: EA = 2: 1) to give the title product P54 (200 mg, 42% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 5: 7.42 - 7.31 (m, 10H), 6.41 (s,lH), 5.14 - 5.04 (m, 4H), 3.95 (s, 2H), 3.57 - 3.52 (m, 2H), 3.32 -3.23 (m, 2H), 2.71 - 2.52 (m, 4H), 1.78 - 1.65 (m, 4H), 1.43 (s, 9H).

[0807] Preparation 54. Benzyl 6-(benzyloxy)-7-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-8-fluoro-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidine]-l'-carboxylate (P54).To a solution of sulfurisocyanatidic chloride (78 mg, 0.557 mmol) in DCM (5 mL) was slowly added / c / Z-BuOH (41 mg, 0.557 mmol) in DCM (5 mL) at 0°C. And the mixture was stirred at 0°C for 0.5 h. After, P53 (200 mg, 0.279 mmol) and TEA (169 mg, 1.67 mmol) in DCM (5 mL) was slowly added into the solution. After stirred at 0°C for 0.5 h, the reaction mixture was quenched with water (20 mL) and extracted with DCM (20 mL). The organic layer was concentrated and diluted into DCM (10 mL) and TFA (5 mL). After stirred at 0°C for 2 h, the organic layer was concentrated and diluted into DCM (5 mL), TEA (110 mg, 1.09 mmol) and T4P (394 mg, 50% in EA). After stirred at 0°C for 1 h, the mixture was concentrated and purified by silica gel column chromatography (PE: EA = 10:1) to give the title product P54 (120 mg, 67% yield) as a white solid. 'H-NMR (400 MHz, CDCh), 8: 7.50 - 7.36 (m, 2H), 7.37 - 7.30 (m, 8H), 6.73 (s,lH), 5.09 - 5.04 (m, 4H), 3.95 (s, 2H), 3.62 - 3.42 (m, 2H), 3.21 - 3.17 (m, 2H), 2.79 - 2.69 (m, 2H), 2.57 - 2.54 (m, 2H), 1.78 - 1.68 (m, 4H).Synthesis of benzyl 6'-(benzyloxy)-7'-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-8'- fluoro-3',4'-dihydro-TH-spiro[azetidine-3,2'-naphthalene]-l -carboxylate (P63)177.ASBMondego.26.0001

[0808] Preparation 55. Ethyl 2-((l,3-dioxoisoindolin-2-yl)methyl)-8-fluoro-6-methoxy-1,2,3,4-tetrahydronaphthalene -2 -carb oxy late (P55).To a solution of ethyl 8-fluoro-6-methoxy-l-oxo-l,2,3,4-tetrahydronaphthalene-2-carboxylate P47 (10 g, 33.8 mmol) inDMF (100 mL) was slowly added NaH (2.71 g, 60%) at 0°C. The reaction mixture was stirred at 40°C for 1.5 h. A-(Bromomethyl)phthalimide (10.5 g, 43.9 mmol) in DMF (20 mL) was added and stirring continued at 40°C for 2 h. Then the mixture was quenched with ice- water (300 mL) and extracted with EA (200 mL) twice. The organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated to get a residue, which was diluted into TFA (100 mL) and EtsSiH (40 mL), the reaction mixture was stirred at 80°C for 6 h. The reaction mixture was concentrated178.ASBMondego.26.0001and purified by silica gel column chromatography (PE: EA = 10:1) to give the title compound P55 (10 g, 65% yield) as a yellow solid. ’H-NVIR (400 MHz, CDCh), 8: 7.87 -7.85 (m, 2H), 7.74 - 7.72 (m, 2H), 6.44 - 6.40 (m, 2H), 4.12 - 4.06 (m, 2H), 3.76 (s, 2H), 3.73 (s, 3H), 3.21 - 3.27 (m, 1H), 2.89 - 2.74 (m, 2H), 2.61 - 2.57 (m, 1H), 2.33 - 2.29 (m, 1H), 1.84 - 1.77 (m, 1H), 1.17 (t, J = 7.2 Hz, 3H).

[0809] Preparation 56. te / -Butyl ((8-fluoro-2-(hydroxymethyl)-6-m ethoxy- 1,2, 3,4-tetrahydronaphthalen-2-yl)methyl)carbamate (P56).To a solution of P55 (10.0 g, 21.8 mmol) in z-PrOH (100 mL) / DCM (30 mL) / H20 (20 mb) was slowly added NaBH4 (5.0 g, 131 mmol) at 0°C. After the mixture was stirred at 30°C for 16 h, AcOH (20 mL) was slowly added into the solution and stirring continued at 90°C for 4 h. Then the reaction mixture was concentrated and diluted into THF (100 mL) and sat. NaHCCh (100 mL), BOC2O (7.1 g, 32.7 mmol) was added and the mixture was stirred at 20°C for 3 h. Then the reaction was diluted with H2O (200 mL) and extracted with EA (100 mL) twice. The organic layer was washed with brine, dried over Na2SC>4(s), filtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (PE: EA = 15: 1) to give a residue, which was crystallized from (DCM / PE, 30 mL: 30 mL) to get the title compound P56 (4.0 g, 43% yield) as a white solid.1H-NMR (400 MHz, CDCh), 6: 6.46 - 6.44 (m, 2H), 4.91 (s, 1H), 3.75 (s, 3H), 3.37 - 3.29 (m, 2H), 3.20 - 3.18 (m, 1H), 3.01 - 2.97 (m, 1H), 2.81 - 2.65 (m, 2H), 2.46 - 2.35 (m, 2H), 1.74 -1.55 (m, 2H), 1.46 (s, 9H).

[0810] Preparation 57. (2-((( / cr / -Butoxycarbonyl)amino)methyl)-8-fluoro-6-methoxy-l,2,3,4-tetrahydronaphthalen-2-yl)methyl methanesulfonate (P57).To a solution of P56 (3.3 g, 7.79 mmol) in DCM (50 mL) was added TEA (2.3 g, 23.4 mmol) and MS2O (2.0 g, 11.7 mmol). After stirred at 20°C for 14 h, the solution was concentrated in vacuum to leave a residue, which was purified by silica gel column chromatography (PE: EA = 15:1) to give the title compound P57 (3.8 g, 86% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 6: 6.47 - 6.45 (m, 2H), 4.89 (s, 1H), 4.10 - 4.00 (m, 2H), 3.75 (s, 3H), 3.35 - 3.11 (m, 2H), 3.04 (s, 3H), 2.89 - 2.74 (m, 2H), 2.58 - 2.47 (m, 2H), 1.74 - 1.65 (m, 2H), 1.44 (s, 9H).179.ASBMondego.26.0001

[0811] Preparation 58. / c / v-Butyl 8'-fluoro-6'-methoxy-3',4'-dihydro-l'H-spiro[azetidine-3, 2'-naphthalene]-l -carboxylate (P58).To a solution of P57 (3.8 g, 7.21 mmol) in DMF (60 mL) was slowly added NaH (537 mg, 60%) at 0°C. The reaction mixture was stirred at 50°C for 2 h, the mixture was quenched with ice-water (150 mL) and extracted with EA (50 mL) twice. The organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated purified by silica gel column chromatography (PE: EA = 10:1) to give the title compound P58 (1.5 g, 58% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 6: 6.47 - 6.42 (m, 2H), 3.75 (s, 3H), 3.74 - 3.65 (m, 4H), 2.84 (s, 3H), 2.81 (t, J = 6.8 Hz, 2H), 1.93 (t, J= 6.8 Hz, 2H), 1.44 (s, 9H).

[0812] Preparation 59. Zc / 7-Butyl 8'-fluoro-7'-iodo-6'-methoxy-3',4'-dihydro-rH-spiro[azetidine-3,2'-naphthalene]-l-carboxylate (P59).To a solution of 2, 2, 6, 6-tetram ethylpiperidine (711 mg, 5.05 mmol) in THF (10 mL) was slowly added / i-BuLi (2.0 mL, 5.0 mmol, 2.5 M) at -65°C. The mixture was stirred at -65°C for 0.5 h. Then, P58 (1.2 g, 3.36 mmol) in THF (10 mL) was slowly added into the mixture. The reaction mixture was stirred at -65°C for 1 h. After, I2 (1.27 g, 5.05 mmol) in THF (10 mL) was slowly added into. The reaction was stirred at -65°C for 2 h. The mixture was quenched with sat. NH4CI solution (30 mL) and extracted with EA (30 mL). The organic layer was washed with brine, dried over Na2SC>4(s), filtered and purified by silica gel column chromatography (PE: EA = 10:1) to give the title compound P59 (1.5 g, 80% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 6: 6.38 (s, 1H), 3.85 (s, 3H), 3.76 - 3.66 (m, 4H), 2.89 (s, 2H), 2.83 (t, J= 7.2Hz, 2H), 1.96 (t, J= 6.4Hz, 2H), 1.45 (s, 9H).

[0813] Preparation 60. Benzyl 8'-fluoro-6'-hydroxy-7'-iodo-3',4'-dihydro-l'H-spiro[azetidine-3,2'-naphthalene]-l-carboxylate (P60).To a solution of P59 (1.5 g, 2.68 mmol) in DCM (3 mL) was added 1 M BBr, in DCM (15 mL). After stirred at 0°C for 2 h, the mixture was concentrated and dissolved in DCM (20 mL). Then sat. NaHCCh (20 mL and CbzCl (680 mg, 4.03 mmol) were added. After stirred at 20°C for 4 h, the mixture was diluted with H O (30 mL) and extracted with EA (30 mL). The organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated and purified by silica gel column chromatography (PE: EA = 2: 1) to give the title compound P60 (1.5 g, 96% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 8: 7.36 - 7.29 (m,180.ASBMondego.26.00015H). 6.56 (s, 1H), 5.11 (s, 2H), 3.82 - 3.73 (m, 4H), 2.88 (s, 2H), 2.75 (t, J = 6.4Hz, 2H), 1.93 (t, J = 6.4Hz, 2H).

[0814] Preparation 61. Benzyl 6'-(benzyloxy)-8'-fluoro-7'-iodo-3',4'-dihydro-l'H-spiro[azetidine-3,2'-naphthalene]-l -carboxylate (P61).To a solution of P60 (1.5 g, 2.57 mmol) in ACN (20 mL) was added K2CO3 (710 mg, 5.14 mmol) and BnBr (655 mg, 3.86 mmol) at 0°C. The reaction mixture was stirred 55°C for 4 h. The reaction mixture was filtered and concentrated and purified by silica gel column chromatography (PE: EA = 10:1) to give the title compound P61 (1.1 g, 69% yield) as a yellow oil. 'H-NMR (400 MHz, CDCI3), 8: 7.49 - 7.47 (m, 2H), 7.41 - 7.29 (m, 8H), 6.41 (s, 1H), 5.10 (br. s, 4H), 3.81 - 3.74 (m, 4H), 2.89 (s, 2H), 2.78 (t,.7= 6.0 Hz, 2H), 1.94 (t,. / - 6,4Hz, 2H).

[0815] Preparation 62. Benzyl 6'-(benzyloxy)-7'-((2-( / e / 7-butoxy)-2-oxoethyl)amino)-8'-fluoro-3',4'-dihydro-l'H-spiro[azetidine-3,2'-naphthalene]-l-carboxylate (P62).The mixture of P61 (1.1 g, 1.78 mmol), tert-butyl glycinate (350 mg, 2.66 mmol), CS2CO3 (1.2 g, 3.56 mmol), Brettphos (95 mg, 0.178 mmol) and Brettphos Pd G3 (161 mg, 0.178 mmol) in 1,4-dioxane (20 mL) was stirred at 100°C for 14 h. The reaction mixture was concentrated and purified by silica gel column chromatography (PE: EA 15:1) to give the title compound P62 (750 mg, 67% yield) as a yellow oil. 'H-NMR (400 MHz, CDCI3), 8: 7.42 - 7.32 (m, 10H), 6.39 (s, 1H), 5.10 (s, 2H), 5.04 (s, 2H), 3.94 (s, 2H), 3.82 - 3.75 (m, 4H), 2.85 - 2.78 (m, 4H), 1.93 - 1.88 (m, 2H), 1.43 (s, 9H).

[0816] Preparation 63. Benzyl 6'-(benzyloxy)-7'-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-8'-fluoro-3',4'-dihydro-TH-spiro[azetidine-3,2'-naphthalene]-l-carboxylate (P63).To a solution of sulfurisocyanatidic chloride (265 mg, 1.88 mmol) in DCM (3 mL) was slowly added tert-BuOH (139 mg, 1.88 mmol) in DCM (3 mL) at 0°C. And the mixture was stirred at 0°C for 0.5 h. After, P62 (750 mg, 0.938 mmol) and TEA (380 mg, 3.76 mmol) in DCM (3 mL) was slowly added into the solution. After stirred at 0°C for 0.5 h, the reaction mixture was quenched with water (20 mL) and extracted with DCM (20 mL). The organic layer was concentrated and diluted into DCM (20 mL) and TFA (5 mL). After stirred at 20°C for 1 h, the organic layer was concentrated and diluted into DCM (10 mL), TEA (290 mg, 2.86 mmol) and T4P (650 mg, 50% in EA). After stirred at 0°C for 1 h, the181.ASBMondego.26.0001mixture was concentrated and purified by C18 column (ACN:water, 0.1% NH4HCO3 = 5% to 95%) to give the title compound P63 (300 mg, 67% yield ) as a white solid. 'H-NMR (400 MHz, CDCI3), 5: 7.32 - 7.20 (m, 10H), 6.42 (s, 1H), 5.06 (s, 2H), 4.98 (s, 2H), 4.26 (s, 2H), 3.70 - 3.62 (m, 4H), 2.71 - 2.67 (m, 4H), 1.81 (s, 2H).Synthesis of 5-(2,4-difluoro-3-(2-(isopentylamino)cyclopropyl)-6-methoxyphenyl)-l,2,5- thiadiazolidin-3-one 1,1 -di oxide (P78)

[0817] Preparation 64. 2, 6-Difluoro-4-methoxy-3 -nitrobenzaldehyde (P64).182.ASBMondego.26.0001H2SO4 (cone., 3.5 mL) was added dropwise to HNO3 (69%, 5.4 mL) at 0-5°C and stirred for 5 min. Then this mixture was added to a solution of 2,6-difluoro-4-methoxybenzaldehyde(10.0 g, 58.1 mmol) inH2SO4 (cone., 40 mL) atO-5°C. The resulting mixture was stirred at 0-5°C for 2 h. The mixture was poured into crushed ice (500 mL) slowly and the precipitate was collected by fdtration. The cake was dried to give the desired compound P64 (12 g, 95% yield) as a white solid. ’H-NMR (400 MHz, CDCI3), 8: 10.20 (s, 1H), 6.70 (dd, J= 11.6, 1.6 Hz, 1H), 4.03 (s, 3H).

[0818] Preparation 65. 3-Amino-2,6-difluoro-4-methoxybenzaldehyde (P65).To a suspension of P64 (12 g, 55 mmol) and Fe (15.4 g, 275 mmol) in EtOH (120 mL) and water (72 mL) was added HO Ac (3.3 g, 55 mmol) at rt. The resulting mixture was stirred at 80°C for 1 h. The reaction mixture was cooled, diluted with EA (500 mL) and fdtered through Celite. The cake was washed with EA. The fdtrate was washed with Na2CO3 (10%, aq., 500 mL), brine, dried over Na2SO4, fdtered and concentrated to give the deisred compound P65 (9.8 g, 95% yield) as a brown solid. LCMS (ESI): RT = 0.944 min, mass calc, for C8H7F2NO2 187.0 m / z found 188.0 [M+H]1.

[0819] Preparation 66. / c / 7-Butyl (tert-butoxycarbonyl)(2,4-difluoro-3-formyl-6-methoxyphenyl)carbamate (P66).To a solution of P65 (8.8 g, 47 mmol), TEA (26.2 mL, 188 mmol) and DMAP (574 mg, 4.7 mmol) in dioxane (88 mL) was added BOC2O (41.0 g, 188 mmol) and the resulting mixture was stirred at 80°C for 4 h. The reaction mixture was cooled, diluted with EA (500 mL), washed with NH4CI (aq., 200 mL), brine, dried over Na SO4, fdtered and concentrated. The crude was purified by silica gel column (PE: EA = 5: 1 to 1: 1) to give the desired compound P66 (6.1 g, 34% yield) as a brown solid. 'll-WIR (400 MHz, CDCI3), 8: 10.21 (s, 1H), 6.54 (d, J= 12.0 Hz, 1H), 3.93 (s, 3H), 1.43 (s, 18H).

[0820] Preparation 67. Ethyl (£’)-3-(3-(bis(ter / -butoxycarbonyl)amino)-2,6-difluoro-4-methoxyphenyl)acrylate (P67).A solution of P66 (6.1 g, 15.7 mmol) and ethyl triphenylphosphoranylideneacetate (6.0 g, 17.3 mmol) in dry DCM (60 mL) was stirred at rt overnight. The reaction mixture was concentrated, and the residue was purified by silica gel column (PE: EA = 10: 1) to give the desired compound P67 (5.7 g, 79% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-183.ASBMondego.26.0001de), 8: 7.54 (d, = 16.4 Hz, 1H), 7.15 (d,. / = 13.0 Hz, 1H), 6.51 (d,. / = 16.4 Hz, 1H), 4.21 (q, J= 7.1 Hz, 2H), 3.91 (s, 3H), 1.37 (s, 18H), 1.26 (t, J = 7.1 Hz, 3H).

[0821] Preparation 68. Ethyl 2-(3-(bis(te / 7-butoxycarbonyl)amino)-2,6-difluoro-4-methoxyphenyl)cyclopropane-l-carboxylate (P68).To a suspension of NaH (60%, 480 mg, 12.0 mmol) in DMSO (80 mL) was added trimethyl sulfoxonium iodide (2.6 g, 12 mmol) in portions and stirred at 25°C for 30 min. Then P67 (4.7 g, 8.6 mmol) was added in portions and stirred at 25°C for 3 h. The reaction mixture was poured into NH4CI (aq., 400 mL) and extracted with EA (100 mL) 3 times. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated, and the residue was purified by silica gel column (PE: EA = 10:1 to 5:1) to give the desired compound P68 (4.0 g, 68% yield) as a white solid. 'H-NMR. (400 MHz, CDCI3), 6: 6.42 (d, J= 12.0 Hz, 1H), 4.19 (q, J= 7.1 Hz, 2H), 3.79 (s, 3H), 2.45 - 2.32 (m, 1H), 2.06 - 2.02 (m, 1H), 1.60 - 1.51 (m, 2H), 1.42 (m, 18H), 1.29 (d, J= 7.1 Hz, 3H).

[0822] Preparation 69. 2-(3-(( / erZ-Butoxycarbonyl)amino)-2,6-difluoro-4-methoxyphenyl)cyclopropane-l -carboxylic acid (P69).To a solution of P68 (3.5 g, 7.43 mmol) in THF / MeOH / H₂O (14 mL / 14 mL / 7 mL) was added LiOH H2O (1.25 g, 29.7 mmol). The reaction mixture was stirred at rt overnight. The reaction mixture was poured into water (150 mL) and acidified with IM HC1 to pH = 4 and extracted with EA (50 mL) 3 times. The combined organic layers were washed with brine, dried overNa2SC>4, filtered and concentrated to give the desired compound P69 (2.3 g, 90% yield) as a white solid. 'H-NMR (400 MHz, CDCh), 8: 6.42 (d, J= 11.9 Hz, 1H), 5.87 (s, 1H), 3.81 (s, 3H), 2.51 - 2.41 (m, 1H), 2.11 - 2.02 (m, 1H), 1.64 - 1.52 (m, 2H), 1.49 (s, 9H).

[0823] Preparation 70. / c / 7-Butyl (3-(2-(((benzyloxy)carbonyl)amino)cyclopropyl)-2,4-difluoro-6-methoxyphenyl) carbamate (P70).To a solution ofP69 (2.3 g, 6.7 mmol), BnOH (3.6 g, 33.5 mmol) and TEA (1.87 mL, 13.4 mmol) in dry toluene (50 mL) was added DPP A (2.8 g, 10.1 mmol). The resulting mixture was degassed with N2 and stirred at 90°C for 16 h. The reaction mixture was concentrated, and the residue was purified by silica gel column (PE: EA 10:1 to 5:1) to give the desired compound P70 (2.3 g, 61% yield) as a white solid. LCMS (ESI): RT = 1.397 min, mass184.ASBMondego.26.0001calc, for C23H26F2N2O5448.2 m / z found 471.1 [M+Na]+. 'H-NMR (400 MHz, CDCI3), 8: 7.36 - 7.33 (m, 5H), 6.40 (d, J= 11.6 Hz, 1H), 5.73 (s, 1H), 5.12 (s, 3H), 3.80 (s, 3H), 3.13 - 2.96 (m, 1H), 1.98 - 1.85 (m, 1H), 1.49 (s, 9H), 1.44 - 1.32 (m, 2H).

[0824] Preparation 71. Benzyl (2-(3-amino-2,6-difluoro-4-methoxyphenyl)cyclopropyl)carbamate (P71).To a solution of P70 (1.3 g, 2.9 mmol) in DCM (10 mL) was added TFA (5.0 mL) at 25°C and stirred for 30 min. Then the mixture was gradually poured into NaHCCh (aq., 50 mL) and extracted with DCM (30 mL) 3 times. The combined organic layers were dried over Na2SO4, fdtered and concentrated to give the desired compound P71 (1.0 g, 60% yield) as a brown oil which was used for next directly. LCMS (ESI): RT = 1.279 min, mass calc, for C18H18F2N2O3348.1 m / z found 349.1 [M+H]+.

[0825] Preparation 72. Benzyl (2-(3-((N-(to7-butoxycarbonyl)sulfamoyl)amino)-2,6-difluoro-4-methoxyphenyl) cyclopropyl)carbamate (P72).To a solution of tert-BuOH (319 mg, 4.31 mmol) and TEA (0.8 mL) in DCM (10 mL) was added CSI (610 mg, 4.31 mmol) dropwise at 0°C and under N2 atm. and stirred at 25°C for 30 min. Then this solution was added to solution of P71 (1.0 g, 2.87 mmol) and TEA (0.8 mL) in DCM (15 mL) at 0°C. The resulting mixture was stirred at 0°C for 1 h and warmed to 25°C overnight. The reaction mixture was poured into NH4CI (aq., 50 mL) and extracted with DCM (25 mL) 3 times. The combined organic layers were washed with brine, dried over Na2SC>4, filtered and concentrated. The crude was purified by silica gel column (PE: EA = 5:1 to 1:1) to give the desired compound P72 (901 mg, 60% yield) as a white solid. ’H-NMR (400 MHz, DMSO-6), 8: 10.80 (s, 1H), 9.26 (s, 1H), 7.68 (s, 1H), 7.39 -7.36 (m, 6H), 6.84 (d, J= 12.6 Hz, 1H), 5.75 (s, 1H), 5.03 (s, 2H), 3.75 (s, 3H), 3.03 - 3.01 (m, 1H), 1.91 - 1.81 (m, 1H), 1.44 (s, 9H), 1.22 - 1.05 (m, 2H).

[0826] Preparation 73. Benzyl (2-(2,6-difluoro-4-methoxy-3- (sulfamoylamino)phenyl)cyclopropyl)carbamate (P73).To a solution of P72 (900 mg, 1.45 mmol) in DCM (2 mL) was slowly added TFA (0.2 mL) at 25°C. The reaction mixture was stirred at 25°C for 3 h. The reaction mixture was concentrated to give P73 (550 mg, 75% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-t / g), 8: 8.24 (s, 1H), 7.67 (s, 1H), 7.35 - 7.27 (m, 5H), 6.80 (d, J= 12.4 Hz, 1H),185.ASBMondego.26.00016.66 (s, 1H), 5.03 (s, 2H), 3.77 (s, 3H), 3.04 (br. s, 1H), 1.91 - 1.81 (m, 1H), 1.20 - 1.10 (m, 2H).

[0827] Preparation 74. Ze / 7-Butyl A-(3-(2-(((benzyloxy)carbonyl)amino)cyclopropyl)-2,4-difluoro-6-methoxyphenyl)-zV-sulfamoylglycinate (P74).To a solution of P73 (550 mg, 1.16 mmol) in ACN (10 mb) was added Na^CCh (560 mg, 4.06 mmol) and Zert-butyl 2-bromoacetate (251 mg, 1.29 mmol) at 25°C. The reaction mixture was stirred at rt for 16 h. The reaction mixture was extracted with EA (50 mL) and water (50 mL). The organic layer was washed with brine, dried over Na2SC>4(s), filtered and concentrated in vacuum to leave a residue which was purified by silica gel column chromatography (PE: EA = 4:1) to give P74 (500 mg, 91% yield) as a yellow solid.1H-NMR (400 MHz, DMSO-d6), 8: 7.68 (s, 1H), 7.35 - 7.27 (m, 5H), 6.88 (br. s, 2H), 6.82 (d, J = 12.8 Hz, 1H), 5.03 (s, 2H), 4.22 (d, J = 16.8 Hz, 1H), 3.96 (d, J = 16.8 Hz, 1H), 3.78 (s, 3H), 3.04 (br. s, 1H), 1.91 - 1.81 (m, 1H), 1.32 (s, 9H), 1.19 - 1.09 (m, 2H).

[0828] Preparation 75. A-(3-(2-(((Benzyloxy)carbonyl)amino)cyclopropyl)-2,4-difluoro-6-methoxyphenyl)-A-sulfamoylglycine (P75).To a solution of P74 (500 mg, 0.924 mmol) in DCM (5 mL) was slowly added TFA (0.5 mL) at 25°C. The mixture was stirred at 25°C for 4 h. The reaction mixture was concentrated to give P75 (400 g, 90% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-^), 8: 12.45 (br. s, 1H), 7.68 (s, 1H), 7.36 - 7.31 (m, 5H), 6.86 (s, 2H), 6.81 (d, J = 12.8 Hz, 1H), 5.03 (s, 2H), 4.28 (d, J = 18.0 Hz, 1H), 4.00 (d, J= 18.0 Hz, 1H), 3.76 (s, 3H), 3.08 - 3.02 (m, 1H), 1.88 - 1.81 (m, 1H), 1.26 - 1.10 (m, 2H).

[0829] Preparation 76. Benzyl (2-(3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2,6-difluoro-4-methoxyphenyl)cyclopropyl)carbamate (P76).The mixture of P75 (400 mg, 0.825 mmol) in DCM (20 mL) was added TEA (0.4 mL, 2.48 mmol) and T4P (1.2 g, 50% in EA, 0.65 mmol), then the reaction was stirred at 25°C for 16 h. The reaction mixture was poured into water (20 mL) and extracted with DCM (20 mL) twice, the combined organic layers were washed brine (50 mL), dried Na2SC>4(s), concentrated in vacuum to give a residue, which was purified by silica gel chromatography (DCM: MeOH= 20:1 to 10:1) to give the title compound P76 (250 mg, 63% yield) as a white solid. 'H-NMR (400 MHz, DMSO-z / e), 8: 10.23 (br. s, 1H), 7.68 (s, 1H), 7.35 - 7.25186.ASBMondego.26.0001(m, 5H), 6.80 (d,.7 = 12.8 Hz, 1H), 5.03 (s, 2H), 3.88 (s, 2H), 3.75 (s, 3H), 3.10 - 3.04 (m, 1H), 1.91 - 1.84 (m, 1H), 1.13 - 1.05 (m, 2H).

[0830] Preparation 77. 5-(3-(2-Aminocyclopropyl)-2,4-difluoro-6-methoxyphenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P77).To a solution of P76 (80 mg, 0.135 mmol) in MeOH (2 mL) was added Pd / C (10 mg) at 25°C. The reaction mixture was degassed with H2 and stirred at rt for 2 h. The reaction mixture was filtered. The filtrate was concentrated in vacuum to give the title compound P77 (50 mg) as a white solid. LCMS (ESI): RT = 0.396 min, mass calc, for C12H13F2N3O4S: 333.06 m / z found 334.0 [M+H]+.

[0831] Preparation 78. 5-(2,4-Difluoro-3-(2-(isopentylamino)cyclopropyl)-6-methoxyphenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P78).To a solution of P77 (50 mg, 0.096 mmol) in DCM (3 mL) was added AcOH (10 mg) and 3 -methylbutanal (10 mg, 0.096 mmol) at 0°C. The reaction mixture was stirred at rt for 2 h. The reaction mixture was added sodium hydroborate (10 mg, 0.24 mmol) then the mixture was stirred at 25°C for 2 h. Water (1 mL) was added and concentrated in vacuum to give a residue, which was purified by Cl 8 (ACN: 0.05% FA in water = 5% to 60%) to give P78 (34 mg, 62% yield) as a white solid. LCMS (ESI): RT = 1.108 min, mass calc, for C17H23F2N3O4S: 403.14 m / z found 404.0 [M+H]+.Synthesis of benzyl isopentyl(3-oxocyclobutyl)carbamate (P85)187.ASBMondego.26.0001

[0832] Preparation 79. te / 7-Butyl (3-hydroxycyclobutyl)carbamate (P79).To a solution of Zc / 7-butyl (3-oxocyclobutyl)carbamate (13.0 g, 70.3 mmol) in THF (130 mL) was slowly added sodium borohydride (2.7 g, 70.3 mmol) at 0°C and then the reaction mixture was stirred at 25°C for 1 h. The mixture was poured into ice water (100 mL), extracted with ethyl acetate (100 mLx3). Organic layer was washed with brine, dried over Na2SO4(s), filtered and concentrated to afford the desired product P79 (12.0 g, 92% yield) as a white solid. ‘H-NMR (400 MHz, CDC13), 6: 4.92 - 4.57 (m, 0.5H), 4.52 - 4.39 (m, 0.5H), 4.30 - 4.14 (m, 0.5H), 4.06 - 3.95 (m,lH), 3.71 - 3.54 (m, 0.5H), 2.81 - 2.69 (m, 1H), 2.34 -2.28 (m, 1H), 2.26 - 2.17 (m, 1H), 2.26 - 2.17 (m, 1H), 1.87 - 1.77 (m, 1H), 1.43 (s, 9H).

[0833] Preparation 80. rt-Butyl (3-(( / er / -butyldiphenylsilyl)oxy)cyclobutyl)carbamate (P80).To a solution of P79 (12.0 g, 57.8 mmol) in THF (120 mL) was added tert-butylchlorodiphenyl silane (23.8 g, 86.6 mmol) and imidazole (7.9 g, 115.5 mmol) at 25°C and then the reaction mixture was stirred at 25 °C for 16 h. The mixture was diluted with water (150 mL) and extracted with EA (150 mL) twice. Concentrating the organic phase give the residue, which was purified by silica gel column chromatography (PE: EA = 4:1) to afford the desired product P80 (24.0 g, 88% yield) as a yellow oil. 'H-NMR (400 MHz,188.ASBMondego.26.0001CDC13), 8: 7.64 -7.61 (m, 4H), 7.44 - 7.35(m, 6H), 4.63 - 4.56 (m, 0.5H), 4.46 - 4.39 (m, 0.5H), 3.97 - 3.90 (m, 0.5H), 3.59 - 3.42(m, 0.5H), 2.59 - 2.40 (m, 2H), 2.08 - 2.00 (m, 1H), 1.91 - 1.84 (m, 1H), 1.41 - 1.40 (m, 9H), 1.02 (s, 9H).

[0834] Preparation 81. 3-(( / erLbutyldiphenylsilyl)oxy)cyclobutan-l-amine hydrogen chloride (P81).To a solution of P80 (18.0 g, 38.1 mmol) in DCM (100 mL) was added 4M HC1 in 1,4-di oxane (50 mL, 200 mmol). After the solution was stirred at rt for 2 h, the mixture was concentrated to afford the desired product P81 (11.0 g, 80% yield) as a white solid.1H-NMR (400 MHz, CDCh), 8: 7.66 - 7.33 (m, 10H), 4.60 - 4.50 (m, 0.5H), 3.93 - 3.81 (m, 0.5H), 3.71 - 3.61 (m, 0.5H), 2.81 - 2.74 (m, 0.5H), 2.56 - 2.49 (m, 1H), 2.34 - 2.28 (m, 1H), 1.99 - 1.93 (m, 1H), 1.81 - 1.70 (m, 1H), 1.03 - 1.02 (m, 9H).

[0835] Preparation 82. 3-(( / e / 7-Butyldiphenylsilyl)oxy)--V-isopentylcyclobutan-l-amine (P82).To a solution of P81 (11.0 g, 27.4 mmol) in methanol (60 mL) and acetic acid (6 mL) was added 3 -methylbutanal (2.7 g, 27.4 mmol) at 25°C. After the mixture was stirred for 2 h, sodium cyanoborohydride (3.5 g, 54.8 mmol) was added at 0°C and stirring continued for 16 h at 25°C. The mixture was basified withNaHCCh aq. solution (60 mL) until pH=7 and extracted with DCM (60 mL) for three times. The combined organic layers were dried over Na2SO4(s) and filtered, the filtrate was concentrated to give a residue, which purified by silica gel column chromatography (PE: EA = 4:1 to 1:1) to afford the desired product P82 (3.5 g, 32% yield) as a yellow oil. LCMS (ESI): RT = 1.394 min, mass calc, for C25H37NOSi 395.3, m / z found 396.2 [M+H]L

[0836] Preparation 83. Benzyl (3-(( / c / 7-butyldiphenylsilyl)oxy)cyclobutyl)(isopentyl)carbamate (P83).To a solution of P82 (3.5 g, 8.1 mmol) in DCM (30 mL) was added benzyl chloroformate (1.5 g, 8.9 mmol) and TEA (2.5 g, 24.4 mmol) at 25°C. The reaction mixture was stirred at 25°C for 16 h. The mixture was diluted with water (20 mL) and extracted with EA (30 mL) twice. Concentrated the organic phase to give the residue, which was purified by silica gel column chromatography (PE: EA = 10:1 to 4:1) to afford the desired product P83 (3.7189.ASBMondego.26.0001g, 88% yield) as a yellow oil. LCMS (ESI): RT = 1.853 min, mass calc, for CasHnNChSi 529.3, m / z found 530.2 [M+H]+.

[0837] Preparation 84. Benzyl (3-hydroxycyclobutyl)(isopentyl)carbamate (P84).To a solution of P83 (3.7 g, 6.2 mmol) in THF (30 mL) was added IM TBAF in THE (30 mL, 30 mmol) at 25°C. The reaction mixture was stirred at 25°C for 16 h. The mixture was diluted with water (20 mL) and extracted with EA (30 mL) twice. Concentrated the organic phase to give the residue, which purified by silica gel column chromatography (PE: EA = 10:1 to 4:1) to afford P84 (1.9 g, 90% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 8: 7.38 - 7.29 (m, 5H), 5.12 (s, 2H), 4.61 - 4.57 (m, 0.5H), 4.46 - 4.36 (m, 0.5H), 4.02 -3.94 (m, 0.5H), 3.88 - 3.73 (m, 0.5H), 3.29 - 3.22 (m, 2H), 2.73 - 2.62 (m, 1H), 2.54 - 2.39 (m, 1H), 2.19 -2.07 (m, 1H), 2.00 - 1.89 (m, 1H), 1.78 - 1.71 (m, 1H), 1.54 - 1.40 (m, 1H), 1.40 - 1.34 (m, 2H), 0.90 - 0.88 (m, 6H).

[0838] Preparation 85. Benzyl isopentyl(3-oxocyclobutyl)carbamate (P85).To a solution of P84 (1.9 g, 5.9 mmol) in DCM (20 mL) was added Dess-martin reagent (3.0 g, 7.1 mmol) at 25°C. The reaction mixture was stirred at 25°C for 16 h. The mixture was diluted with water (20 mL) and extracted with EA (30 mL) twice. Concentrated the organic phase to give the residue, which was purified by silica gel column chromatography (PE: EA = 10: 1 to 3: 1) to afford the desired product P85 (1.8 g, 94% yield) as a yellow oil. 'H-NMR (400 MHz, CDCh), 8: 7.39 - 7.32 (m, 5H), 5.15 (s, 2H), 4.32 - 4.20 (m, 1H), 3.43 - 3.21 (m, 6H), 1.57 - 1.52 (m, 1H), 1.45 - 1.38 (m, 2H), 0.91 - 0.89 (m, 6H).Synthesis of benzyl (3-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)- 2,6-difluorophenyl)cyclobut-2-en-l-yl)(isopentyl)carbamate (P87)190.ASBMondego.26.0001

[0839] Preparation 86. Benzyl (3-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-5-((2-(trimethylsilyl)ethoxy)methyl)-l,2,5-thiadiazolidin-2-yl)-2,6-difluorophenyl)-3-hydroxycyclobutyl)(isopentyl)carbamate (P86).To a solution of 5-(6-(benzyloxy)-3-bromo-2,4-difluorophenyl)-2-((2-(trimethylsilyl)ethoxy)methyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (1.5 g, 2.4 mmol)in THF (10 mb) was added 1.3M isopropylmagnesium chloride lithium chloride complex (2.2 mL, 2.9 mmol) at -78°C under N2. After stirred at -78°C for 3 h, P85 (1.0 g, 3.1 mmol) was added at -78°C and stirring continued at 25°C for 16 h. The mixture was quenched with sat. ammonium chloride (15 mL) and extracted with DCM (15 mL) for three times. The combined organic layers were dried over Na2SO4(s) and filtered, the filtrate was concentrated to give a residue, which was purified by C18 column (ACN:0.02% ammonium bicarbonate aq. solution = 5% to 95%) to afford the desired product P86 (200 mg, 11% yield) as a yellow solid. LCMS (ESI): RT = 1.651 min, mass calc, for C38H49F2N3O8SSi 773.3m / z found 796.2 [M+Na]L

[0840] Preparation 87. Benzyl (3-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2,6-difluorophenyl)cyclobut-2-en-l-yl)(isopentyl)carbamate (P87).191.ASBMondego.26.0001To a solution of P86 (100 mg, 0.13 mmol) in DCM (4 mL) TFA (1 mL) was added. After stirred at 25 °C for 2 h, the mixture was basified with NaHCCh aq. solution (5 mL) until pH=7 and extracted with DCM (5 mL) for three times. The combined organic layers were dried over Na2SO4(s) and fdtered, the filtrate was concentrated to give a residue, which was purified by C18 column (ACN:0.02 % ammonium bicarbonate aq. solution = 5% to 95%) to afford the desired product P87 (60 mg, 74% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-6(+D2O)), 8: 7.50 - 7.32 (m, 10H), 6.96 (d, J= 12.4 Hz, 1H), 6.32 (s, 1H), 5.21 (s, 2H), 5.09 (s, 2H), 3.99 (s, 2H), 3.69 - 3.48 (m, 1H), 3.12 - 2.76 (m, 4H), 1.52 - 1.31 (m, 3H), 0.83 (s, 6H).Synthesis of 5 - [2-fluoro-4-( 1 H-imi dazol -2-y lamino)-6-meth oxy -phenyl ] - 1, 1 -dioxo- l,2,5-thiadiazolidin-3-one (P88)

[0841] Preparation 88. 5-[2-Fluoro-4-(lH-imidazol-2-ylamino)-6-methoxy-phenyl]-l,l-di oxo- 1, 2, 5 -thi adi azol i din-3 -one (P88).To a stirred solution of lH-imidazol-2-amine hydrochloride (222 mg, 1.85 mmol) in tertbutanol (6 mL) in a microwave vial, sodium terLbutoxide (ter / -BuONa, 178 mg, 1.85 mmol) was added. The mixture was stirred at rt for 30 min. Subsequently, 5-(4-bromo-2-fhioro-6-methoxy-phenyl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one (600 mg, 1.32 mmol) and potassium phosphate (K3PO4, 560 mg, 2.62 mmol) were added. Argon was bubbled through the reaction mixture for 5 min. Palladium(O) complex Pd2(dba)s (60 mg, 0.066 mmol) and tert-butyl BrettPhos (64 mg, 0.132 mmol) were then added. The vial was sealed and the reaction mixture was stirred at 120°C in a sand bath for 16 h. After cooling to rt, the reaction was diluted with water (6 mL) and acidified to approximately pH 5 using potassium hydrogen sulfate (KHSO4). The resulting solid was collected by filtration to afford -500 mg of crude product. 'HNMR (400 MHz, DMSO ), 8: 13.0 (br., 2H), 10.27 (s, 1H), 7.50-7.18 (m, 7H), 6.77-6.73 (m, 2H), 6.51 (s, 2H), 4.00 (s, 2H).192.ASBMondego.26.0001Synthesis of 5-[2-fluoro-6-methoxy-4-(4,5,6,7-tetrahydro-lH-benzimidazol-2- ylamino)phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (P91)

[0842] Preparation 89. 6,7,8,9-Tetrahydropyrimido[l,2-a]benzimidazole (P89).To a solution of 2-chlorocyclohexanone (350 mg, 2.64 mmol) in w-butanol (5 mL), 2-aminopyrimidine (250 mg, 2.64 mmol) was added. The reaction mixture was refluxed for 16 h. After cooling to rt, the mixture was diluted with a sat. aq. solution of NaHCCh and extracted with EA. The organic layer was separated, washed with water and brine, then dried over anh. Na2SC>4 and concentrated under reduced pressure. The crude residue was triturated with Et2O to afford P89 as a solid (350 mg, 61% yield). 'H NMR (400 MHz, DMSO-cA). 8: 8.64 (dd, J 1=6.1 Hz, J2=.l Hz, 1H), 8.40 (dd, J 7=4.3 Hz, J2=2.2 Hz, 1H), 6.99 (dd, Jl=6.1 Hz, J2=4.3 Hz, 1H), 2.78-2.71 (m, 4H), 1.91-1.83 (m, 4H).

[0843] Preparation 90. 4,5,6,7-Tetrahydro-lH-benzimidazol-2-amine (P90).To a solution of P89 (280 mg, 2.02 mmol) in ^-butanol (2 mb) in a microwave vial, hydrazine hydrate (200 mg, 60% solution) was added. The vial was sealed and the mixture was stirred in a sand bath at 130°C for 16 h. After completion, the reaction mixture was evaporated to dryness under reduced pressure. The resulting residue was triturated with diethyl ether to afford a solid, P90 (165 mg, 75% yield).NMR (400 MHz, DMSO-t / g), 8: 4.86 (br„ 2H), 2.28-2.26 (m, 4H), 1.65-1.63 (m, 4H).193.ASBMondego.26.0001

[0844] Preparation 91. 5-[2-Fluoro-6-methoxy-4-(4,5,6,7-tetrahydro-lH-benzimidazol-2-ylamino)phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (P91).A mixture of aryl bromide potassium salt (400 mg, 0.883 mmol), P90 (145 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in tert-butanol (5 mL) was degassed by bubbling argon through the solution for 5 min. To this mixture, Pd2(dba)s (20 mg, 0.027 mmol) and t-BuBrettPhos (26 mg, 0.054 mmol) were added. The vial was then sealed and heated in a sand bath at 120°C for 16 h with stirring. After cooling to rt, the reaction mixture was diluted with water (6 mL) and acidified to pH ~5 using KHSO4. The resulting solid was filtered, washed with water, and dried to afford P91 (240 mg, 58% yield). LSMS: RT = 4.36 min, [M+l]=472.0.Synthesis of 5-[2-fluoro-6-methoxy-4-(4,5,6,7-tetrahydro-lH-benzimidazol-2- ylamino)phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (P94)

[0845] Preparation 92. 2-Methylimidazo[l,2-a]pyrimidine (P92).To a solution of l-chloropropan-2-one (5.50 g, 59.7 mmol) in / / -butanol (50 mL), 2-aminopyrimidine (4.73 g, 50.0 mmol) was added. The reaction mixture was heated at 100°C for 16 h. After cooling to rt, the mixture was diluted with sat. aq. NaHCCh and extracted with EA. The organic layer was separated, washed with water and brine, then dried and evaporated to dryness under reduced pressure. The crude residue was purified by194.ASBMondego.26.0001flash chromatography (DCM-MeOH, 0 — > 5%) to afford 900 mg of a mixture of P92 and unreacted 2-aminopyrimidine.

[0846] Preparation 93. 4-Methyl-lH-imidazol-2-amine (P93).To a solution of crude P92 in EtOH (10 mL), hydrazine hydrate (200 mg, 60% solution) was added. The reaction mixture was refluxed for 8 h. After completion, the solvent was evaporated under reduced pressure. The resulting residue was purified by flash chromatography (DCM-MeOH, 10% 30%) to afford P93 (380 mg). 'H NMR (400 MHz, DMSO-< A), 8: 6.08 (s, 1H), 4.95 (br., 2H), 1.93 (s, 3H).

[0847] Preparation 94. 5-[2-Fluoro-6-methoxy-4-[(4-methyl-lH-imidazol-2-yl)amino]phenyl]- 1, 1 -di oxo- 1,2, 5-thiadiazolidin-3 -one (P94).A mixture of aryl bromide potassium salt (400 mg, 0.883 mmol), P93 (103 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in Zc / 7-butanol (5 mL) was degassed by bubbling argon through the solution for 5 min. Pd (dba)3 (20 mg, 0.027 mmol) and Z-BuBrettPhos (26 mg, 0.054 mmol) were then added, and the vial was sealed. The mixture was stirred at 120°C in a sand bath for 16 h. After cooling to rt, the reaction mixture was diluted with water (6 mL) and acidified to pH ~5 using KHSO4. The resulting solid was collected by filtration to afford crude P94 (240 mg).Synthesis of 5-[2-benzyloxy-4-[(4-cyclohexyl-lH-imidazol-2-yl)amino]-6-fluoro- phenyl]- 1, 1 -di oxo- 1,2,5 -thiadiazolidin-3 -one (P95)

[0848] Preparation 95. 5-[2-Benzyloxy-4-[(4-cyclohexyl-lH-imidazol-2-yl)amino]-6-fluoro-phenyl]- 1, 1 -dioxo- 1,2,5-thiadiazolidin-3 -one (P95).A mixture of aryl bromide potassium salt (400 mg, 0.883 mmol), 4-cyclohexyl-lH-imidazol-2-amine (175 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in ZerZ-butanol (5 mL) was degassed by bubbling argon through the solution for 5 min. Pd (dba) (20 mg, 0.027 mmol) and Z-BuBrettPhos (26 mg, 0.054 mmol) were then added, and the vial was 195.ASBMondego.26.0001sealed. The reaction mixture was stirred at 120°C in a sand bath for 16 h. After cooling to rt, it was diluted with water (6 mL) and acidified to approximately pH 5 using KHSO4. The resulting solid was collected by filtration to afford crude P95 (220 mg). LSMS: RT = 4.99 min, [M+l]=500.3.Synthesis of 5-[2-benzyloxy-6-fluoro-4-[(4-phenyl-lH-imidazol-2-yl)amino]phenyl]-l,l- dioxo-l,2,5-thiadiazolidin-3-one (P96)

[0849] Preparation 96. 5-[2-Benzyloxy-6-fluoro-4-[(4-phenyl-lH-imidazol-2-yl)amino]phenyl]- 1, 1 -dioxo- 1,2, 5-thiadi azolidin-3 -one (P96).A mixture of aryl bromide potassium salt (400 mg, 0.883 mmol), 4-phenyl-lH-imidazol-2-amine (169 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in Zc77-butanol (5 mL) was degassed by bubbling argon through the solution for 5 min. Pd2(dba)s (20 mg, 0.027 mmol) and ABuBrettPhos (26 mg, 0.054 mmol) were then added, and the vial was sealed. The reaction mixture was stirred at 120°C in a sand bath for 16 h. After cooling to rt, the mixture was diluted with water (6 mL) and acidified to approximately pH 5 using KHSO4. The resulting solid was collected by filtration to afford crude P96 (300 mg). LSMS: RT = 4.75 min, [M+l]=494.5.Synthesis of ethyl 2-[3-benzyloxy-5-fluoro-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2- yl)anilino]-lH-imidazole-4-carboxylate (P99)196.ASBMondego.26.0001

[0850] Preparation 97. Ethyl imidazo[l,2-a]pyrimidine-2-carboxylate (P97) and ethyl imidazo[l,2-a]pyrimidine-3-carboxylate (P97a).To a solution of ethyl 3-bromo-2-oxo-propanoate (7.50 g, 78.9 mmol) in EtOH (160 mL), 2-aminopyrimidine (15.4 g, 78.9 mmol) was added. The reaction mixture was heated under reflux for 16 h. After completion, the mixture was cooled to rt, diluted with a sat. aq. solution of NaHCOa, and extracted with EA. The organic layer was separated, washed successively with water and brine, then dried over anh. Na2SO4 and concentrated under reduced pressure. The crude product, containing a mixture of isomers, was purified by column chromatography on silica gel using a gradient of DCM / MeOH (0-2%) to afford two isomers: P97 (2.80 g, 17% yield) and P97a (1.40 g, 9% yield). For P97: 'H-NMR (400 MHz, CDC13), 5: 9.58-9.56 (m, 1H), 8.74-8.72 (m, 1H), 8.46 (s, 1H), 7.13 (dd, J1= A Hz,.72=4.3 Hz, 1H), 4.43 (q, 7.1 Hz, 2H), 1.43 (t, 7.1 Hz, 3H). For P97a: 'H-NMR (400 MHz, CDCI3), 8: 8.68-8.67 (m 1H), 8.50-8.53 (m, 1H), 8.16 (s, 1H), 6.99-6.96 (m, 1H), 4.47 (q, J=7.1 Hz, 2H), 1.44 (t, >7.1 Hz, 3H).

[0851] Preparation 98. Ethyl 2-amino-lH-imidazole-4-carboxylate (P98).To a solution of P97 (500 mg, 2.61 mmol) in EtOH (5 mL), hydrazine hydrate (218 mg, 60% w / w) was added. The reaction mixture was heated under reflux for 16 h. After completion, the solvent was removed under reduced pressure. The resulting residue was197.ASBMondego.26.0001triturated with Et O, affording P98 as a solid (300 mg, 75% yield). 'H-NMR (400 MHz, DMS04), 8: 7.26 (s, 1H), 4.89 (br., 2H), 4.27-4.24 (m, 2H), 1.34-1.32 (m, 3H). LSMS: RT = 3.20 min, [M+l]=156.4.

[0852] Preparation 99. Ethyl 2-[3-benzyloxy-5-fluoro-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)anilino]-lH-imidazole-4-carboxylate (P99).A mixture of aryl bromide potassium salt (400 mg, 0.883 mmol), P98 (165 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in to7-BuOH (5 mL) was degassed by bubbling argon through the solution for 5 min. Then, Pd (dba)3 (20 mg, 0.027 mmol) and / -BuBrettPhos (26 mg, 0.054 mmol) were added, and the vial was sealed. The reaction mixture was stirred at 120°C in a sand bath for 16 h. After cooling to rt, the mixture was diluted with water (6 mL) and acidified to approximately pH 5 using KHSO4. The resulting solid was collected by filtration to afford crude P99 (140 mg). LSMS: RT = 4.43 min, [M+l]=490.6.Synthesis of 2-[3-benzyloxy-5-fluoro-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)anilino]- N-isopentyl-lH-imidazole-4-carboxamide (P103)

[0853] Preparation 100. Imidazo[l,2-a]pyrimidine-2-carboxylic acid (P100).To a solution of P97 (1.25 g, 6.54 mmol) in EtOH (20 mL), a solution of NaOH (0.445 g, 11.1 mmol) in water (2 mL) was added. The reaction mixture was stirred at rt for 2 h. After completion, HC1 (1.1 mL, concentrated) was added dropwise until precipitation occurred. The resulting solid was collected by filtration, washed thoroughly with water, and dried in198.ASBMondego.26.0001air to afford P100 (830 mg, 78% yield). 'H-NMR (400 MHz, DMSO-tfc), 5: 13.32 (br., 1H), 9.54 (dd, J7=7.1 Hz, J2=\.l Hz, 1H), 8.76 (dd,, / / 4.3 Hz, J2=1.7 Hz, 1H), 8.39 (s, 1H), 7.34 (dd, Jl=6.1 Hz,.72=4,3 Hz, 1H).

[0854] Preparation 101. A-Isopentylimidazo[l,2-a]pyrimidine-2-carboxamide (P101).To a solution of P100 (400 mg, 2.45 mmol), / .w-butylamine (235 mg, 2.69 mmol), and TBTU (867 mg, 2.70 mmol) in DMF (2 mL), DIPEA (700 mg, 5.40 mmol) was added. The reaction mixture was stirred at rt for 16 h. After completion, the mixture was diluted with water and extracted with EA (2 * 10 mL). The combined organic layers were washed with brine, dried over anh. Na2SC>4, and concentrated under reduced pressure. The resulting residue was recrystallized from a mixture of Et O and hexane to afford P101 (320 mg, 56% yield).1H-NMR(400 MHz, DMSO-6), 8: 9.75 (dd, J 1=1.1 Hz, J2=\.l Hz, 1H), 8.68 (dd, Jl=4.2 Hz, J2=2A Hz, 1H), 8.54-8.51 (m, 1H), 8.44 (s, 1H), 7.24 (dd, J 1=6.8 Hz, J2=4.0 Hz, 1H), 3.34-3.29 (m, 2H), 1.69-1.59 (m, 1H), 1.45 (q, J=7.2 Hz, 2H), 0.91 (d, J=7.2 Hz, 6H).

[0855] Preparation 102. 2-Amino-7V-isopentyl-lH-imidazole-4-carboxamide (P102). To a solution of P101 (320 mg, 1.38 mmol) in EtOH (10 mL), hydrazine hydrate (0.5 mL, 60% w / w) was added. The reaction mixture was heated under reflux for 8 h. After completion, the solvent was removed under reduced pressure, and the crude residue was purified by flash chromatography on silica gel using a gradient of DCM / MeOH (10-30%) as eluent to afford P102 (190 mg, 70% yield). 'H-NMR (400 MHz, DMSO- 8: 7.37 (br., 1H), 7.00 (s, 1H), 5.32 (br., 2H), 3.20-3.15 (m, 2H), 1.61-1.51 (m, 1H), 1.34 (q, J=6.8 Hz, 2H), 0.88 (d, J=6.6 Hz, 6H).

[0856] Preparation 103. 2-[3-Benzyloxy-5-fluoro-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)anilino]-N-isopentyl-lH-imidazole-4-carboxamide (P103).A mixture of aryl bromide potassium salt (400 mg, 0.883 mmol), P102 (190 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in tert-BuOH (5 mL) was degassed by bubbling argon through the solution for 5 min. Pd (dba)3 (20 mg, 0.027 mmol) and / -BuBrettPhos (26 mg, 0.054 mmol) were then added, and the reaction vial was sealed. The mixture was stirred at 120°C in a sand bath for 16 h. After cooling to rt, the reaction mixture was diluted with water (6 mL) and acidified to approximately pH ~5 using KHSO4. The resulting solid199.ASBMondego.26.0001was collected by filtration to afford crude P103 (240 mg). LSMS: RT = 4.92 min, [M+l]=531.0.Synthesis of 5-(4-amino-2-(benzyloxy)-6-fluorophenyl)-l,2,5-thiadiazolidin-3-one 1,1- dioxide (P108)

[0857] Preparation 104. 2-(Benzyloxy)-4-bromo-6-fluoroaniline (P104).A solution of 6-(benzyloxy)-3-bromo-2-fluoro-4-(trifluoromethyl)aniline (P16, 25 g, 90 % purity, 69.4 mmol), Fe powder (19 g, 347 mmol) and NH4CI (18 g, 347 mmol) in MeOH (300 mL) and H2O (60 mL) was stirred at 70°C for 4 h. To the mixture was added water (1000 mL) and extracted with EA (500 mL) twice. The combined organic layers were dried over Na2SO4(s) and filtered and crystallized from hexane to give the desired product P104 (21 g, 90% purity, 88% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-tL), 8: 7.49 -7.33 (m, 5H), 6.97 (br. s, 2H), 5.16 (s, 2H), 4.84 (s, 2H).

[0858] Preparation 105. / e / 7-Butyl (N-(2-(benzyloxy)-4-bromo-6-fl uoropheny 1 )sul fam oy 1 )carb am ate (P 105).CSI (16.3 g, 116 mmol) was added into solution of / evT-BuOH (8.6 g, 116 mmol) and DCM (10 mL). After stirred at 0°C for 2 h, the solution was added into a mixture of P104 (19.0 g, 90% purity, 57.9 mmol) and TEA (29 g, 29 mmol) in DCM (200 mL). After stirred at200.ASBMondego.26.000120°C for 2 h, then water (500 mL) was added to the mixture and extracted with DCM (200 mL) twice. The combined organic layers were dried over Na2SC>4(s) and filtered and concentrated to give the desired product P105 (25 g, 90% purity, 84% yield) as a yellow oil. LCMS (ESI): RT = 1.507 min, mass calc, for ClxH2oBrFN205S 475.33, m / z found 492.0 [M+18]+.

[0859] Preparation 106. terz-Butyl A-(2-(benzyloxy)-4-bromo-6-fluorophenyl)-A-sulfamoylglycinate (P106).To a solution of P105 (25 g, 90% purity, 48.0 mmol) in DCM (300 mL) was added TFA (100 mL) at 20°C. After stirred at 20°C for 2 h, the mixture was concentrated and diluted into ACN (200 mL). K2CO3 (12 g, 84.0 mmol) and tert-butyl 2-bromoacetate (12.2 g, 63.0 mmol) were added. After stirred at 20°C for 14 h, water (500 mL) was added to the mixture and extracted with EA (500 mL) twice. The combined organic layers were dried over Na2SC>4(s) and filtered and crystallized from hexane to give the desired product P106 (22 g, 90% purity, 97% yield) as a white solid. LCMS (ESI): RT = 1.690 min, mass calc, for Ci9H22BrFN2O5S 489.36, m / z found 489.0 [M+H]L

[0860] Preparation 107. 5-(2-(Benzyloxy)-4-bromo-6-fluorophenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P107).To a solution of P106 (22 g, 90% purity, 40.6 mmol) in DCM (300 mL) was added TFA (100 mL) at 20°C. After stirred at 20°C for 1 h, the mixture was concentrated and diluted into DCM (20 mL). TEA (12 g, 116 mmol) and 50% T4P in EA (42 g, 58 mmol) were added. After stirred at 20°C for 4 h, the mixture was quenched with IN HC1 (300 mL) and extracted with DCM (150 mL) twice. The combined organic layers were dried over Na2SO4(s) and filtered. The mixture was concentrated and purified by silica gel column chromatography (DCM: MeOH=I0: 1) to give the desired product P107 (14 g, 67% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-d6), 5: 7.40 - 7.31 (m, 5H), 5.23 (s, 2H), 4.45 (s, 2H).

[0861] Preparation 108. 5-(4-Amino-2-(benzyloxy)-6-fluorophenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P108).A solution of P107 (4.4 g, 9.57 mmol), Cu powder (1.2 g, 19.1 mmol), ethanolamine (1.45 g, 23.9 mmol) and TMSN3 (2.2 g, 19.1 mmol) in DMA (80 mL) was stirred at 90°C for 14 h. Then the mixture was quenched with IN HC1 (500 mL) and extracted with EA (200 mL)201.ASBMondego.26.0001twice. The combined organic layers were dried over Na2SC>4(s) and filtered, and the mixture was concentrated and purified by silica gel column chromatography (DCM: MeOH=10:l) to give the desired product P108 (2.0 g, 54% yield) as a yellow solid. ’H-NMR (400 MHz, DMSO-t / s), 5: 7.44 - 7.31 (m, 5H), 6.16 (s, 1H), 6.05 - 6.01 (m, 1H), 5.05 (s, 2H), 4.33 (s, 2H).Synthesis of 5-(2-(benzyloxy)-4-((4,5-dihydro-lH-imidazol-2-yl)amino)-6-P110

[0862] Preparation 109. Dimethyl (3-(benzyloxy)-4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-5-fluorophenyl) carbonimidodithioate (P109).To a solution of P108 (500 mg, 1.28 mmol), Mel (540 mg, 3.84 mmol), in DMSO (2.5 mL) and carbon disulfide (2.5 mL) was added 20N sodium hydroxide aq. solution (0.13 mL, 2.56 mmol) at 0°C. After stirred at 0°C for 2 h, the reaction mixture was poured into water (15 mL) and extracted with EA (10 mL*3). The combined organic layers were concentrated to give the compound P109 (300 mg, 36% yield) as a yellow oil. LCMS (ESI): RT = 1.621 min; (ESI) mass calc, m / z for C18H18FN3O4S3 [M+H]+456.0, found 456.0.

[0863] Preparation 110. 5-(2-(Benzyloxy)-4-((4,5-dihydro-lH-imidazol-2-yl)amino)-6-fluorophenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (P110).To a solution of P109 (300 mg, 0.46 mmol) in DMF (1.5 mL) was added ethylenediamine (1.5 mL) at 25°C under N2 atm. After stirred at 100°C for 6 h, the reaction mixture was concentrated and was purified by combi-Flash (ACN: NH4OH 0.1% aq. solution, 0% to202.ASBMondego.26.000190%) to give Pl 10 (200 mg, 83% yield) as a yellow solid. LCMS (ESI): RT = 1.989 min; (ESI) mass calc, m / z for CISHISFNSOTS [M+H]+420.1, found 420.1.Synthesis of 5-[2-benzyloxy-6-fluoro-4-[(4-isobutyl-l / / -imidazol-2- yl)amino]phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (Pl 14)

[0864] Preparation 111. l-Bromo-4-methyl-pentan-2-one (Pill).To a solution of methyl isobutyl ketone (10.0 g, 100.0 mmol) in MeOH (50 ml) at -20°C a solution of Br2 in MeOH (15 ml) was added. The mixture was stirred for 3 h at rt, then a solution NaHCOs was carefully added. The mixture was extracted with Et O (3x30 ml), organic layers were washed with brine, evaporated to dryness to give Pill (15.6 g).

[0865] Preparation 112. 2-Isobutylimidazo[l,2-a]pyrimidine (P112).Pill was dissolved in EtOH (100 ml) and 2-aminipyrimidine (8.50 g, 90.0 mmol) was added. The mixture was refluxed for 24 h, then evaporated to dryness and diluted with an aq. Nal [CO3 solution. A solid was fdtered, washed with water to give Pl 12 (7.30 g, crude). ' H NMR (400 MHz, DMSO-tZg), 5: 8.87 (dd, JI = 6.6 Hz, J2 = 2.1 Hz, 1H), 8.43 (dd, JI = 4.2 Hz, J2 = 2.1 Hz, 1H), 6.97 (dd, JI = 6.8 Hz, J2 = 4.2 Hz, 1H), 2.10-1.99 (m, 1H), 1.43-1.24 (m, 2H), 0.91 (d, J= 6.8 Hz, 6H). LSMS: RT 3.32 min, [M+l] = 175.9.

[0866] Preparation 113. 4-Isobutyl-l / / -imidazol-2-amine (P113).To a solution of P112 (7.30 g, 41.7 mmol) in EtOH (70 ml) hydrazine hydrate (4.17g, 60%) was added and the mixture was refluxed for 8 h. The mixture was evaporated to dryness.203.ASBMondego.26.0001A residue was purified with column chromatography (DCM-MeOH 10 to 30%) to give P113 (1.2 g). ’HNMR (400 MHz, DMSO-c / 6), 5: 6.13 (s, 1H), 5.03 (br., 2H), 2.16 (d, J = 7.0 Hz, 2H), 1.82-1.72 (m, 1H), 0.84 (d, J= 6.6 Hz, 6H). LSMS: 3.57 min, [M+l] = 140.1.

[0867] Preparation 114. 4-Isobutyl-l / / -imidazol-2-amine (P114).A mixture of aryl bromide K salt (400 mg, 0.883 mmol), P113 (147 mg, 1.06 mmol), and K3PO4 (280 mg, 1.32 mmol) in LBuOH (5 mL) was sparged with Ar for 5 min. Pd2(dba)a (20 mg, 0.027 mmol) and / -BuBrettPhos (26 mg, 0.054 mmol) were added, and the vial was then capped. The mixture was stirred at 120°C in a sand bath for 16 h, then cooled to rt and diluted with water (6 mL). The solution was acidified with KHSO4 to pH~5, and the resulting solid was filtered off to afford crude P114 (120 mg). LSMS: RT 4.86 min, [M+l] = 474.4.Examples of the Final Compound

[0868] In the Table 3 presented certain non-limiting examples of the compound of Formula (A).

[0869] Table 3 Selected examples of the compound of Formula (I) and LCMS (ESI) data204.ASBMondego.26.0001205.ASBMondego.26.0001206.ASBMondego.26.0001207.ASBMondego.26.0001208.ASBMondego.26.0001209.ASBMondego.26.0001210.ASBMondego.26.0001211.ASBMondego.26.0001212.ASBMondego.26.0001213.ASBMondego.26.0001214.ASBMondego.26.0001215.ASBMondego.26.0001216.ASBMondego.26.0001217.ASBMondego.26.0001218.ASBMondego.26.0001219.ASBMondego.26.0001220.ASBMondego.26.0001221.ASBMondego.26.0001222.ASBMondego.26.0001223.ASBMondego.26.0001224.ASBMondego.26.0001225.ASBMondego.26.0001226.ASBMondego.26.0001227.ASBMondego.26.0001228.ASBMondego.26.0001229.ASBMondego.26.0001230.ASBMondego.26.0001231.ASBMondego.26.0001232.ASBMondego.26.0001233.ASBMondego.26.0001234.ASBMondego.26.0001235.ASBMondego.26.0001236.ASBMondego.26.0001237.ASBMondego.26.0001238.ASBMondego.26.0001239.ASBMondego.26.0001240.ASBMondego.26.0001241.ASBMondego.26.0001242.ASBMondego.26.0001243.ASBMondego.26.0001244.ASBMondego.26.0001245.ASBMondego.26.0001246.ASBMondego.26.0001247.ASBMondego.26.0001248.ASBMondego.26.0001*-[M-H]' massSynthesis of the Representative Examples of the compound

[0870] Example 1. 5-(3-(7-Azabicyclo[2.2.1]heptan-2-yl)-2-fluoro-6-hydroxy-4-methylphenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide hydrochloride (Compound 23).A mixture of Zc / 7-butyl 2-(3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-4-hydroxy-6-methylphenyl)-7-azabicyclo[2.2.1]heptane-7-carboxylate P12 (37 mg, 73.92 pmol) and 4.0 M HC1 in 1,4-dioxane (1 mb) was stirred at 20°C for 0.5 h. The reaction mixture was added to hexane (2 mL) to precipitate the solid, and the solid was washed 2 times with hexane, then the solid was vacuum lyophilization to give the compound 23 (8.3 mg, 29% yield) as a white solid. ’H-NMR (400 MHz, DMSO-6), 8: 9.36 (s, 1H), 8.79 -249.ASBMondego.26.00018.62 (m, 2H), 6.59 (s, 1H), 4.27 (d,.7 = 16.4 Hz, 2H), 3.93 (s, 2H), 3.62 - 3.53 (m, 1H), 3.33 - 3.27 (m, 1H), 2.24 (s, 3H), 2.22 - 2.04 (m, 2H), 1.90 - 1.63 (m, 4H).19F-NMR (376 MHz, DMSO-6), 5: -117.19 (s, IF).

[0871] Example 2. 5-(4-(3-Azabicyclo[3.1.0]hexan-l-yl)-2-fluoro-6-hydroxy-3-propylphenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 38).A suspension of benzyl l-(2-allyl-5-(benzyloxy)-4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate P25 (100 mg, 0.17 mmol) andPd / C (10%, 15 mg) inMeOH (2 mb) was degassed withH2 and stirred at rt for 40 min. The reaction mixture was filtered, and the filtrate was concentrated to give a residue which was purified by prep. HPLC (Column: WELCH Xtimate Cl 8 21.2*250 mm 10 pm; Condition: 10 - 35% ACN in water (0.1% FA) for 10 min, Flow rate: 30 mL / min, Detector: 214 nm) to give the desired compound 38 (3.93 mg, 7% yield) as a white solid. 'H-NMR (400 MHz, DMSO-r / 6), 5: 9.19 - 8.85 (m, 3H), 8.14 (s, 0.1H), 6.72 (d,.7= 1.0 Hz, 1H), 3.94 (s, 2H), 3.57 (dd, J= 11.3, 3.6 Hz, 1H), 3.49 (d, J= 11.4 Hz, 1H), 3.39 (d, J= 11.5 Hz, 1H), 3.15 (d, J= 11.4 Hz, 1H), 2.60 - 2.53 (m, 2H), 1.99 - 1.95 (m, 1H), 1.59 - 1.38 (m, 2H), 1.14 (t, J= 5.1 Hz, 1H), 1.06 -0.90 (m, 4H).19F-NMR (376 MHz, DMSO-6), 8: -120.71 (s, IF).

[0872] Example 3. 5-(3-Allyl-4-(3-azabicyclo[3.1.0]hexan-l-yl)-2-fluoro-6-hydroxyphenyl)-!,2,5-thiadiazolidin-3-one 1, 1 -dioxide hydrogen bromide salt (Compound 35).250.ASBMondego.26.0001To a solution of benzyl l-(2-allyl-5-(benzyloxy)-4-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-3-fluorophenyl)-3-azabicyclo[3.1,0]hexane-3-carboxylate P25 (55 mg, 0.093 mmol) in DCM (2 mL) was added BBn (1.0 M in DCM, 0.93 mb, 0.93 mmol) dropwise under ice bath and N2 atm. The resulting mixture was stirred at 0°C for 2 h. The reaction mixture was concentrated at 25°C and the residue was dissolved in DCM. Then MeOH (2 mL) was added at 0°C and stirred for 10 min and concentrated at 25°C. The crude was purified by prep. HPLC (Column: Xbridge 5u C18 150*19 mm; Condition: 12-22% ACN in water (0.1% TFA) for 9 min, Flow rate: 20 mL / min, Detector: 214 nm) to give the desired compound 35 (5.95 mg, 14% yield) as a white solid. 'H-NMR (400 MHz, CD3OD), 8: 6.82 (d, J= 1.6 Hz, 1H), 6.04 - 5.97 (m, 1H), 5.05 (dd, J= 10.2, 1.6 Hz, 1H), 4.91 - 4.86 (m, 1H), 4.26 (s, 2H), 3.73 (dd, J= 11.7, 3.8 Hz, 1H), 3.61 (d, J= 11.6 Hz, 1H), 3.53 (d, J = 11.7 Hz, 1H), 3.49 - 3.47 (m, 2H), 3.29 (s, 1H), 2.15 - 2.10 (m, 1H), 1.26 - 1.14 (m, 1H), 1.14 - 1.02 (m, 1H).

[0873] Example 4. 5-(2-Fluoro-6-hydroxy-3-(piperidin-4-yl)-4-(trifluoromethyl)phenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 60).251.ASBMondego.26.0001To a solution of benzyl 4-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-6-(trifluorornethyl)phenyl)-3,6-dihydropyridine-l(2H)-carboxylate P38 (150 mg, 0.242 mmol) in TFE (5 mL) was added Pd / C (10%, 100 mg) and Pd(OH)2 / C (20%, 100 mg). The resulting mixture was degassed with H2and stirred at 80°C for 48 h. The reaction mixture was filtered, and the filtrate was concentrated to give a residue which was purified by prep. HPLC (Column: WELCH Xtimate C1821.2*250 mm 10 pm; Condition: 9 - 25% ACN in water (0.1% NH4HCO3) for 10 min, Flow rate: 15 mL / min, Detector: 214 nm) to give the desired compound 60 (6.55 mg, 7% yield) as a white solid. 'H-NMR. (400 MHz, CD3OD), 8: 7.02 (s, 1H), 4.31 (s, 2H), 3.40 (d, J= 12.4 Hz, 2H), 3.15 - 3.07 (m, 1H), 2.97 (t, J= 12.7 Hz, 2H), 2.37 - 2.26 (m, 2H), 1.87 (d, J= 13.7 Hz, 2H).19F-NMR (376 MHz, DMSO-d6), 6: -60.48 (s, 3F), -114.66 (s, IF).

[0874] Example 5. 5-(2-Fluoro-6-hydroxy-3-(l,2,3,6-tetrahydropyridin-4-yl)-4-(trifluoromethyl)phenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 59).To a solution of benzyl 4-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-6-(trifluoromethyl)phenyl)-3,6-dihydropyridine-l(2H)-carboxylate P38 (70 mg, 0.113 mmol) in MeOH (2 mL) was added Pd / C (10%, 10 mg). The resulting mixture was degassed with H2and stirred at 25°C for 3 h. The reaction mixture was filtered, and the filtrate was concentrated to give a residue which was purified by prep. HPLC (Column: Welch 21.2*250 mm C18 10 pm; Condition: 5 - 25% ACN in water (0.1% NH3 H2O) for 9 min, Flow rate: 25 mL / min, Detector: 214 nm) to give the desired compound 59 (6.99 mg, 16% yield) as a white solid. 'H-NMR. (400 MHz, DMSO-d6), 8: 6.82 (d, J= 1.6 Hz, 1H), 6.04 - 5.97 (m, 1H), 5.06 - 5.03 (m, 1H), 4.91 (s, 1H), 4.26 (s, 2H), 3.73 (dd, J= 11.7, 3.8 Hz, 1H), 3.61 (d, J= 11.6 Hz, 1H), 3.53 (d, J= 11.7 Hz, 1H), 3.49 - 3.47 (m, 2H), 3.29 (s, 1H), 2.13 - 2.10 (m, 1H), 1.26 - 1.14 (m, 1H), 1.14 - 1.02 (m, 1H).19F-NMR(376MHz, DMSO-t / g), 8: -77.05 (s, 3F), -120.93 (s, IF).252.ASBMondego.26.0001

[0875] Example 6. 5-(3-(7-azabicyclo[2.2.1]heptan-2-yl)-2-fluoro-6-hydroxy-4-(trifluoromethyl)phenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 88).A solution of tert-butyl 2-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2-fluoro-6-(trifluoromethyl)phenyl)-7-azabicyclo[2.2.1]hept-2-ene-7-carboxylate P43 (110 mg, 0.180 mmol) and 10% Pd / C (30 mg) in MeOH (5 mL) was stirred at 20°C for 2 h under hydrogen atm. (balloon pressure). Then the mixture was fdtered and diluted in DCM (4 mL) and TFA (2 mL) at 0°C. After stirred at 0°C for 2 h, the mixture was concentrated and purified by C18 column (ACN:water, 0.1% TFA, 5% to 95%) and preparative HPLC column (ACN:water, 0.1% TFA, 5% to 95%) to give the title compound 88 (3.0 mg, 3% yield) as a white solid. 'H-NMR (400 MHz, CD3OD), 5: 7.18 (s, 1H), 4.40 - 4.19 (m, 4H), 3.87 - 3.79 (m, 1 H), 2.50 - 2.43 (m, 1H), 2.27 - 2.11 (m, 1H), 2.08 - 2.00 (m, 3H), 1.90 - 1.79 (m, 1H).19F-NMR (376 MHz, CDCh), 8: - 60.20 (s, 3F), - 76.99 (s, 3F), - 111.81 (s, IF).

[0876] Example 7. 5-(8-Fluoro-6-hydroxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidin]-7-yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 28).A solution of benzyl 6-(benzyloxy)-7-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-8-fluoro-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidine]-l'-carboxylate P54 (120 mg, 0.188 mmol) and PdCl2(20 mg) / C (30 mg) in CF3CH2OH (8 mL), DCM (8 mL) and THF (4mL) was stirred at 20°C for 5 h under H2atm. (balloon pressure). Then the mixture was filtered and concentrated to get the title compound (50 mg, 67 % yield) as a yellow solid,253.ASBMondego.26.0001crude 28 (25 mg) was further purified by C18 column (ACN:water (0.1% FA = 5% to 95%) to give the title compound 28 (1.6 mg, 2% yield) as a white solid. 'H-NMR. (400 MHz, CD3OD), 8: 8.48 (s, 1H), 6.56 (s, 1H), 4.25 (s, 2H), 3.47 - 3.43 (m, 2H), 3.13 (s, 2H), 2.85 - 2.82 (m, 2H), 2.70 (s, 2H), 1.98 - 1.93 (m, 2H), 1.85 (t, J = 7.2 Hz, 2H).19F-NMR (376 MHz, CD3OD), 8: -124.10 (s, IF).

[0877] Example 8. 5-(l'-Ethyl-8-fluoro-6-hydroxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidin]-7-yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 72).A mixture of 5-(8-fluoro-6-hydroxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidin]-7-yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide 28 (25 mg, 0.062 mmol), CH3CHO (8 mg, 0.186 mmol) in DCM / MeOH (2 mL / 2 mb) was stirred at rt for 0.5 h. Then, NaBH3CN (11 mg, 0.18 mmol) was added into the solution. After stirred at 20°C for 0.5 h, the mixture was concentrated and purified by silica gel column chromatography (DCM: MeOH = 8:1) to give a residue which was purified by C18 column (ACN:water 0.1% FA = 0% to 60%) to give the title compound 72 (1.6 mg, 6.6% yield) as a white solid. ’H-NMR (400 MHz, CD3OD), 8: 6.56 (s, 1H), 4.25 (s, 2H), 3.83 - 3.71 (m, 1H), 3.58 - 3.45 (m, 1H), 3.28 - 3.22 (m, 2H), 2.91 - 2.66 (m, 5H), 2.13 - 1.85 (m, 4H), 1.37 - 1.27 (m, 3H).19F-NMR (376 MHz, DMSO-6?6), 8: -124.64 (s, IF).

[0878] Example 9. 5-(8'-Fluoro-6'-hydroxy-3',4'-dihydro-rH-spiro[azetidine-3,2'-naphthalen]-7'-yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 5).254.ASBMondego.26.0001A solution of benzyl 6'-(benzyloxy)-7'-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-8'-fluoro-3',4'-dihydro-rH-spiro[azetidine-3,2'-naphthalene]-l-carboxylate P63 (40 mg, 0.064 mmol) and Pd / C (20 mg, 10%) in MeOH (8 mL) and EA (5 mL) was stirred at 20°C for 1 h under H2 atm. Then the catalyst was fdtered and the filtrate was concentrated and purified by C18 column (ACN:water (0.1% FA = 5% to 95%) to give the title compound 5 (2.8 mg, 13% yield) as a white solid. 'H-NMR. (400 MHz, DMSO-t / e), 6: 8.91 (br. s, 2.4H), 6.43 (s, 1H), 3.93 (s, 2H), 3.79 - 3.69 (m, 4H), 2.87 (s, 2H), 2.68 - 2.66 (m, 2H), 1.91 (t, J = 6.0 Hz, 2H).19F-NMR (376 MHz, CD3OD), 8: -122.42 (s, IF).

[0879] Example 10. 5-(l'-Ethyl-8-fluoro-6-hydroxy-3,4-dihydro-lH-spiro[naphthalene-2,3'-pyrrolidin]-7-yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 41).AcOH (20 mg) was added into a solution of 5-(8'-fluoro-6'-hydroxy-3',4'-dihydro-rH-spiro[azetidine-3,2'-naphthalen]-7'-yl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide 5 (20 mg, 0.088 mmol), CH3CHO (38 mg, 0.877 mmol) in DCM / MeOH (1 mL / 1 mL). After stirred at 30°C for 2 h. NaBH(OAc)3 (55 mg, 0.263 mmol) was added into the solution. The reaction mixture was stirred at 20°C for 3 h. The mixture was concentrated and purified by C18 column (ACN:water 0.1% FA = 0% to 60%) to give the title compound 41 (3.1 mg, 14% yield) as a white solid. 'H-NMR (400 MHz, DMSO-d6), 8: 9.84 (br. s, 1H), 9.14 (s, 1H), 6.44 (s, 1H), 3.93 (s, 2H), 3.83 (br. s, 2H), 3.18 - 3.14 (m, 2H), 2.88 (s, 2H), 2.70 (br. s, 2H), 1.93 (t, J= 6.0 Hz, 2H), 1.05 (t, J= 7.2 Hz, 3H).19F-NMR (376 MHz, DMSO-d6), 8: -122.37 (s, IF).

[0880] Example 11. 5-(5'-Fluoro-7'-hydroxy-l-isopropyl-spiro[azetidine-3,3'-tetralin]-6'-yl)-l,l-dioxo-l,2,5-thiadiazolidin-3-one (Compound 73).255.ASBMondego.26.0001AcOH (20 mg) was added into a solution of 5-(8'-fluoro-6'-hydroxy-3',4'-dihydro-l'H-spiro[azetidine-3,2'-naphthalen]-7'-yl)-l,2,5-thiadiazolidin-3-one 1, 1-dioxide 5 (35 mg, 0.102 mmol), acetone (59 mg, 1.02 mmol) in DCM / MeOH (2 mL / 2 mL). After stirred at 30°C for 2 h. Then, NaBH(OAc)3 (65 mg, 0.307 mmol) was added into the solution. The reaction mixture was stirred at 20°C for 2 h. The mixture was concentrated and purified by C18 column (ACN:water 0.1% FA = 0% to 60%) to give the title compound 73 (10.0 mg, 25% yield) as a white solid. 'H-NMR (400 MHz, DMSO-tfc), 8: 9.72 (br. s, 1H), 9.15 (s, 1H), 6.44 (s, 1H), 3.99 - 3.83 (m, 4H), 3.49 - 3.41 (m, 1H), 2.92 - 2.67 (m, 4H), 1.94 (br. s, 2H), 1.11 (d, J = 6.4 Hz, 6H).19F-NMR (376 MHz, DMSO-6), 6: -122.21- -122.42(m, IF).

[0881] Example 12. 5-(2,4-Difluoro-6-hydroxy-3-(2- (isopentylamino)cyclopropyl)phenyl)-l,2,5-thiadiazolidin-3-one 1, 1-dioxide (Compound 61)To a solution of 5-(2,4-difluoro-3-(2-(isopentylamino)cyclopropyl)-6-methoxyphenyl)-l,2,5-thiadiazolidin-3-one 1, 1-dioxide P78 (34 mg, 0.072 mmol) in DCM (2 mL) was added BBn (1,0M in DCM, 0.93 mL, 0.93 mmol) dropwise under ice bath and N2 atm. The256.ASBMondego.26.0001resulting mixture was stirred at 0°C for 2 h. The reaction mixture was concentrated at 25°C and the residue was dissolved in DCM. Then MeOH (2 mh) was added at 0°C and stirred for 10 min and concentrated at 25°C. The crude was purified by preparative HPLC (Column: Xbridge prep cl8 lOum OBD 19*150mm / WELCH Xtimate C18 21.2*250mm 10 pm Condition: A water (0.1% FA), B (ACN) 10-20% B in 8 min, hold at 100% B at for 2 min, back to 5% B with 0.5 min, stop at 13 min. Flow rate: 30 ml / min Detector: 214 / 254 nm) to give the desired compound 61 (2.3 mg, 8% yield) as a white solid. 'H-NMR (400 MHz, CD3OD), 5: 6.50 (d, J = 12.0 Hz, 1H), 4.22 (s, 2H), 3.31 - 3.26 (m, 2H), 3.13 (br. s, 1H), 2.23 (s, 1H), 1.77 - 1.68 (m, 1H), 1.63 - 1.58 (m, 2H), 1.52 - 1.41 (m, 2H), 0.99 (d, J = 6.4 Hz, 6H).19F-NMR (376 MHz, CD3OD), 5: -113.1 - -113.9 (m, IF), -118.9 - -119.3 (m, IF).

[0882] Example 13. 5-(2,4-Difluoro-6-hydroxy-3-(3- (isopentylamino)cyclobutyl)phenyl)-l,2,5-thiadiazolidin-3-one 1,1 -dioxide hydrogen chloride (Compound 100).To a solution of benzyl (3-(4-(benzyloxy)-3-(l,l-dioxido-4-oxo-l,2,5-thiadiazolidin-2-yl)-2,6-difluorophenyl)cyclobut-2-en-l-yl)(isopentyl)carbamateP87 (60 mg, 0.1 mmol) inEA (4 mL) was added 10% palladium on activated carbon (10 mg) at rt. After stirred at hydrogen of balloon at rt for 16 h, the reaction mixture was filtered and concentrated to give the crude reside, which was purified by C18 column (ACN:0.02% HC1 aq. solution = 5% to 95%) to afford the desired product 100 (10 mg, 25% yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-c / 6), 8: 10.34 (s, 1H), 9.29 (s, 1H), 9.04 (s, 1H), 6.59 (t, J =8.8 Hz, 1H), 4.05 (s, 2H), 3.80 - 3.62 (m, 2H), 3.30 - 3.10 (m, 1H), 2.77 - 2.67 (m, 2H), 2.64 -2.58 (m, 2H), 2.45 - 2.34 (m, 1H), 1.63 - 1.42 (m, 3H), 0.90 - 0.87 (m, 6H).257.ASBMondego.26.0001

[0883] Example 14. Analytical data of certain compounds of the present disclosure.

[0884] Example 15. 5-[2-Fluoro-6-hydroxy-4-(lH-imidazol-2-ylamino)phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (Compound 144).To a solution of P88 (500 mg, crude) in dimethylacetamide (DMA, 5 mL), palladium on carbon (Pd / C, 10 wt%, 100 mg) was added. The mixture was stirred in an autoclave under hydrogen atm. (20 bar) at rt for 16 h. After completion, the reaction mixture was filtered through a Celite® pad, and the catalyst was washed with DMA. The combined filtrate was 258.ASBMondego.26.0001concentrated to dryness under reduced pressure. The residue was treated with ACN, and the resulting solid was collected by filtration to afford 250 mg of crude product 144 (approximate purity: 80%). Purification by HPLC afforded 95 mg of product 144 with a purity of 95%. ’H NMR (400 MHz, DMS0 ), 6: 12.98 (br., 2H), 10.08 (s, 1H), 9.73 (s, 1H), 7.16 (s, 2H), 6.55 (dd, Jl= 11.5 Hz, J2= 2.6 Hz, 1H), 6.61-6.50 (m, 1H), 3.95 (s, 2H).

[0885] Example 16. 5-[2-Fluoro-6-hydroxy-4-(4,5,6,7-tetrahydro-lH-benzimidazol-2-ylamino)phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (Compound 153).P91 153To a solution of P91 (240 mg, 0.505 mmol) in a 1: 1 mixture of trifluoroethanol (TFE) and THF (5 mL), Pd / C (10 wt%, 25 mg) was added. The mixture was stirred under a hydrogen atm. (1 bar) at rt for 16 h. After completion, the reaction mixture was filtered to remove the catalyst, and the filtrate was concentrated to dryness under reduced pressure. The resulting residue was triturated with Et2O to afford compound 153 as a solid (50 mg, 26% yield). 'H NMR (400 MHz, DM SO- ), 6: 12.56 (s, 2H), 9.91 (s, 1H), 9.58 (s, 1H), 6.55 (dd,, / = 11.7, 2.5 Hz, 1H), 6.50 (t, J= 1.8 Hz, 1H), 3.92 (s, 2H), 2.44 (s, 4H), 1.74 (s, 4H).

[0886] Example 17. 5-[2-Fluoro-6-hydroxy-4-[(4-methyl-lH-imidazol-2-yl)amino]phenyl]- 1, 1 -di oxo- 1,2, 5-thiadiazolidin-3 -one (Compound 145).259.ASBMondego.26.0001To a solution of crude P94 (240 mg) in HFIP (5 mL), Pd / C (10%, 25 mg) was added. The mixture was stirred under a hydrogen atm. (1 bar) at rt for 16 h. After completion, the catalyst was removed by filtration, and the filtrate was concentrated to dryness under reduced pressure. The crude residue was purified by preparative HPLC to afford compound 145 (7 mg, 3.7% yield).

[0887] Example 18. 5-[4-[(4-Cyclohexyl-lH-imidazol-2-yl)amino]-2-fluoro-6-hydroxy-phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (Compound 158).To a solution of crude P95 (220 mg) in HFIP (5 mL), Pd / C (10%, 25 mg) was added. The mixture was stirred under a hydrogen atm. (1 bar) at rt for 16 h. Upon completion, the catalyst was removed by filtration, and the filtrate was concentrated to dryness under reduced pressure. The crude residue was purified by preparative HPLC to afford compound 158 (7 mg).

[0888] Example 19. 5-[2-Fluoro-6-hydroxy-4-[(4-phenyl-lH-imidazol-2-yl)amino]phenyl]-l,l-dioxo-l,2,5-thiadiazolidin-3-one (Compound 157).To a solution of crude P96 (300 mg) in HFIP (5 mL), Pd / C (10%, 25 mg) was added. The mixture was stirred under a hydrogen atm. (1 bar) at rt for 16 h. After completion, the catalyst was removed by filtration, and the filtrate was concentrated to dryness under260.ASBMondego.26.0001reduced pressure. The crude residue was purified by preparative HPLC to yield compound 157 (10 mg).

[0889] Example 20. Ethyl 2-[3-fluoro-5-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)anilino]-lH-imidazole-4-carboxylate (Compound 156).To a solution of crude P99 (140 mg) in HFIP (5 mL), 10% Pd / C (25 mg) was added. The mixture was stirred under a hydrogen atm. (1 bar) at rt for 16 h. Upon completion, the reaction mixture was filtered to remove the catalyst, and the filtrate was concentrated to dryness under reduced pressure. The residue was purified by preparative HPLC to afford compound 156 as a pure product (5 mg).

[0890] Example 21. 2-[3-Fluoro-5-hydroxy-4-(l,l,4-trioxo-l,2,5-thiadiazolidin-2-yl)anilino]-N-isopentyl-lH-imidazole-4-carboxamide (Compound 160).160 To a solution of crude P103 (240 mg) in HFIP (5 mL), 10% Pd / C (25 mg) was added. The mixture was stirred under a hydrogen atm. (1 bar) at rt for 16 h. After completion, the catalyst was removed by filtration, and the filtrate was concentrated to dryness under reduced pressure. The resulting residue was purified by preparative HPLC to afford compound 160 as a pure product (4.5 mg).261.ASBMondego.26.0001

[0891] Example 22. 5-(4-((4,5-Dihydro-lH-imidazol-2-yl)amino)-2-fluoro-6-hydroxyphenyl)-l,2,5-thiadiazolidin-3-one 1,1-dioxide (Compound 178).To a solution of P110 (200 mg, 0.38 mmol) and activated carbon (50 mg) in methanol (3 mb) was added PdCh (50 mg) at 25°C under H2 atm. After stirred at 25°C for 2 h, the reaction mixture was filtered and purified by HPLC (ACN: FA, 0.1% aq. Solution, 0% to 25%) to give compound 178 (10.5 mg, 96.51% purity, 7% yield) as an off-white solid.1H-NMR (400 MHz, DMSO-6), 6: 8.28 (s,0.7 H), 6.52 - 6.48 (m, 1H), 3.92 (s, 2H), 3.56 (s, 4H).

[0892] Example 23. 5-[2-Fluoro-6-hydroxy-4-[(4-isobutyl-l / f-imidazol-2-yl)amino]phenyl]- 1, 1 -di oxo- 1,2, 5-thiadiazolidin-3 -one (Compound 191).To a solution of P114 (120 mg) in DMA (5 mb), Pd / C (10%, 50 mg) was added, and the mixture was stirred under H2 (1 bar) at rt for 16 h. The catalyst was then filtered off, and the filtrate was evaporated to dryness. The residue was purified by HPLC to afford compound 191 (33 mg). 'H-NMR (400 MHz, DMSO-6), 8: 12.87 (s, 2H), 10.02 (s, 1H), 9.73 (s, 1H), 6.93 (s, 1H), 6.58 - 6.42 (m, 2H), 3.94 (s, 2H), 2.37 (d, J= 7.0 Hz, 2H), 1.88 (dt, J= 13.5, 6.8 Hz, 1H), 0.90 (d, J= 6.6 Hz, 6H).

[0893] Example 24. 'H-NMR spectra of certain examples.262.ASBMondego.26.0001263.ASBMondego.26.0001264.ASBMondego.26.0001265.ASBMondego.26.0001Biological Assays

[0894] Example A. Primary assay used to determine potency of PTPN2 enzymatic activity inhibition.Compound activity was determined using GST-tagged PTPN2 protein (Cat# 31592, ActiveMotif) (SEQ ID NO: 1) in an in vitro enzymatic reaction. The enzymatic reaction was carried out in assay buffer (50 mM HEPES Na salt pH 7.2-7.4, 2 mM EDTA, 100 mM NaCl, 52 ng / pL BSA, and 6 mM DTT). The compounds were dispensed on a 384 well Diamond Well Plate (Axigen, Cat#P-384-120SQ-C-S) using the Biomek FX liquid handling system at lOOx solutions of compounds in DMSO. 2x PTPN2 (final concentration 0.004ng / pL) was prepared in lx Assay buffer and 25 pL of mixture per well was added into Reaction plate (Optiplate, black, Perkin Elmer, Cat#6007270). Add 25 pL of lx buffer to Ctrl' (Substrate w / o PTPN2) wells followed by centrifugation at 100 g for 1 min. Next step the Compounds were added to Reaction plate using Biomek station via following steps: 3 pl of lOOx compounds (in DMSO) were mixed with 27 pL of Assay Buffer, then 5 pL of this mixture was added to Reaction plate with 25 pL of PTPN2 Mix. Plates were centrifuged for 1 min at 100 g and incubated for another 10 min at rt. Finally, 20 pL of 2.5x Substrate (DiFMUP, Invitrogen™ Cat # D6567) mix was added into appropriate wells of Reaction plate to the final concentration of 2 pM, plate was centrifuged at 100 g for 1 min followed by incubation at rt for 60 min, and the Fluorescence Intensity was measured using a Microplate Reader (ClarioStar Plus, excitation 360 nm, emission 450 nm). The % inhibition was then used to calculate the Ki values.

[0895] The Ki values are shown in Table A, wherein “A” corresponds to Ki < 10.0 nM, “B” corresponds to 10.0 nM < Ki < 100.0 nM, and “C” corresponds to 100.0 nM < Ki.

[0896] Table A: PTPN2 enzymatic activity Inhibition266.ASBMondego.26.0001*Kt: inhibition constant - the concentration required to occupy 50% of the receptor; wherein “A” corresponds to K, < 10.0 nM, “B’’ corresponds to 10.0 nM < Ki < 100.0 nM, “C” corresponds to 100.0 nM < K

[0897] Example B. Tumor cells B16F10 cellular growth IFN^-induced inhibition assay.267.ASBMondego.26.0001B16F10 mouse melanoma cells (ATCC Cat# CRL- 6475) were seeded at a density of 500 cells per well in a 384-well clear bottom plate (Coming Cat #3712, Coming, N. Y.) in 40 pL total volume of DMEM + 10% FBS (PanEco Cat# C420, Russia and Sigma Cat # F4135, St. Louis, MO). Cells were allowed to adhere overnight at 37°C, 5% CO2. On the following day, 250x solutions of compounds in DMSO (Sigma Cat # D2650) were prepared into Cmpnds plate (Diamond Well Plate, Axigen, Cat#P-384-120SQ-C-S) (final concentration of lx) and DMSO only controls were included. Dilution Plate (Diamond Well Plate (Axigen, Cat#P-384-120SQ-C-S) was prepared by adding 49 pL of culture medium per well: half of the plate with culture medium only, half with culture medium + IFNy (5 ng / ml). A 1 pL aliquot of 250x compounds (Cmpnds plate) was added to 49 pL of culture medium (Dilution plate), then a 10 pL aliquot of the mixture was transferred to Reaction plate with 40 pL of cells followed by centrifugation at 240 g for 1 min. After 3 days of incubation, 10 pL of CellTiter-Glo (Promega) was added to the cells, plates were centrifuged at 240 g for 1 min, and luminescence signal was measured. For each compound, the percent growth inhibition at every compound dose level was calculated relative to the “DMSO / with IFNy” control and used to determine the IC50.

[0898] The IC50 values are shown in Table B, wherein “A” corresponds to IC50 < 5.0 pM, “B” corresponds to 5.0 pM < IC50 < 50.0 pM, “C” corresponds to 50.0 pM < IC50.

[0899] Table B. Growth Inhibition of Bl 6F 10268.ASBMondego.26.0001269.ASBMondego.26.0001Equivalents

[0900] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.270.ASB

Claims

Mondego.26.0001CLAIMSWhat is claimed is:

1. A compound of Formula (A):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R1is -OH;R2is selected from H, Ci-Ce alkyl, and R5; orR1and R2together with the atom to which they are attached and any intervening atoms, form 5-6 membered heteroaryl, wherein heteroaryl is optionally substituted with one or more substituents independently selected from halogen, -OH, Ci-Ce alkyl, -NH2, - CN;R3is selected from H, -OH, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl and R5, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -OH, -CN, halogen, =0, -NR31R32, -C(O)NR31R32, and 3-10 membered heterocyclyl, or two substituents together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl;R4is selected from H, -OH, halogen, Ci-Ce alkyl, C2-C6 alkenyl, C3-C10 cycloalkyl,3-10 membered heterocyclyl, 5-10 membered heteroaryl, R5, aryl,271.ASBMondego.26.0001wherein the alkyl, cycloalkyl, heterocyclyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, -CN, Ci-C6alkyl, Ci-Ce alkoxy; orR3and R4together with the atoms to which they are attached and any intervening atoms, form a 6 membered cycloalkyl, a 6 membered aryl, a 6 membered heterocyclyl, optionally substituted with one or more R6;each R6is independently selected from Ci-Ce alkyl, -OH, -NHCH2R24,272.ASBMondego.26.0001two geminal or vicinal R6form C3-C10 cycloalkyl, 3-10 membered heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0; or two geminal R6form =0;each E is independently selected from CR52and N;Q is selected from O, S(O)k, C(R21)2, NR22;Q* is selected from O, S(O)k, CH2, NR28;each V is independently selected from CR26and N;W is 5-6 membered cycloalkyl, heterocyclyl or heteroaryl, wherein cycloalkyl, heterocyclyl or heteroaryl optionally substituted with one or more R23;Z is selected from O and NH;each R* is H, or two R* form a bond;each R** is H, or two R** form a bond;Rais selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;Rbis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rcis H, or Raand Rcform a double bond;Rdis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Reis H, or Reand Rgform a double bond;R1is selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rgis H;Rhis selected from Ci-Ce alkyl, 3-8 membered cycloalkyl;R7is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl;each R22is independently selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl;R23is selected from Ci-Ce alkyl, Ci-Ce alkoxy;273.ASBMondego.26.0001R24is selected from Ci-Ce alkyl and C2-C6 alkenyl, wherein alkyl or alkenyl is optionally substituted with one or more substituents independently selected from halogen, OH, CN;R25is selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy;each R26is independently selected from H, Ci-Ce alkyl, C3-C7 cycloalkyl, C4-C7 cycloalkenyl, -NHCi-Ce alkyl, and Ci-Ce alkoxy;R27is selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy;R28is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy;R31is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;R33is selected from H, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl;each R41is independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, C3-Cs cycloalkyl, 3-7 membered heterocyclyl, aryl, 5-6 membered heteroaryl;R43is H; orR31and R43together with the atoms to which they are attached and any intervening atoms, form 5-6 membered heteroaryl, or 5-7 membered heterocycloalkenyl, wherein heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;R51is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl, wherein alkyl or cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, =0, Ci-Ce alkyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, aryl;each R52is independently selected from H, Ci-Ce alkyl;or two R52together with the atoms to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl;274.ASBMondego.26.0001R61is selected from H, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, -C(O)N(R28)2, -C(O)OR28, wherein alkyl, cycloalkyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2;R62is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;or R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl, 5-10 membered heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, Ci-Ce alkyl-C(O)-, -C(O)N(R28)2;b is an integer selected from 0, 1, 2 and 3;k is an integer selected from 0, 1, and 2;p is an integer selected from 1, 2 and 3;q is an integer selected from 0, 1 and 2;t is an integer selected from 0 and 1;r is an integer selected from 0 and 1.

2. The compound of claim 1, wherein the compound has the Formula (I):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:Q is selected from O, S(O)k, C(R21)2, NR22;R4is selected from H, -OH, halogen, Ci-Ce alkyl, C2-Ce alkenyl, C3-C10 cycloalkyl, 4-10 membered heterocyclyl;each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl; or275.ASBMondego.26.0001two R21together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl optionally substituted with one or more R22; ortwo R21attached to two vicinal atoms form a double bond; ortwo R21attached to geminal atom form =0;each R22is independently selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl;R31is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;k is an integer selected from 0, 1, and 2;m is an integer selected from 0, 1, 2, and 3;n is an integer selected from 1, 2, and 3.

3. The compound of claim 1, wherein the compound has the Formula (11):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:Q is selected from O, S, S(O)k, C(R21)2, NR22;R3is selected from H, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0;276.ASBMondego.26.0001each R21is independently selected from H, OH, halogen, Ci-Ce alkyl, -NR31R32, -C(O)NR31R32, or 3-10 membered heterocyclyl; ortwo R21together with the atoms to which they are attached and any intervening atoms, form 3-8 membered cycloalkyl or 3-10 membered heterocyclyl; ortwo R21attached to two vicinal atoms form a double bond; ortwo R21attached to geminal atom form =0;R22is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, -C(O)OCH2Aryl;R31is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;k is an integer selected from 0, 1, and 2;m is an integer selected from 0, 1, 2, and 3;n is an integer selected from 1, 2, and 3.

4. The compound of claim 1, wherein the compound is of Formula (III):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R3is selected from H, halogen, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, wherein alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, =0;Z is selected from O and NH;277.ASBMondego.26.0001W is 5-6 membered cycloalkyl, heterocyclyl or heteroaryl, wherein cycloalkyl, heterocyclyl or heteroaryl optionally substituted with one or more R23;R23is selected from Ci-Ce alkyl, Ci-Ce alkoxy,t is an integer selected from 0 and 1;r is an integer selected from 0 and 1.

5. The compound of claim 1, wherein the compound is of Formula (IV):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R7is selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;Rais selected from H, Ci-Ce alkyl, 3-8 membered cycloalkyl;Rbis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rcis H; orRaand Rcform a double bond;Rdis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Reis H;Rfis selected from H, OH, halogen, Ci-Ce alkyl, Ci-Ce alkoxy, 3-8 membered cycloalkyl;Rgis H; orReand Rgform a double bond.

6. The compound of claim 1, wherein the compound is of Formula (V):278.ASBMondego.26.0001or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R11is selected from Ci-Ce alkyl, 3-8 membered cycloalkyl;p is an integer selected from 1, 2 and 3.

7. The compound of claim 1, wherein the compound is of Formula (VI):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:Rhis selected from Ci-Ce alkyl, 3-8 membered cycloalkyl;R24is selected from Ci-Ce alkyl and C2-C6 alkenyl, wherein alkyl or alkenyl is optionally substituted with one or more substituents independently selected from halogen, OH, CN.

8. The compound of claim 1, wherein the compound is of Formula (VII):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:279.ASBMondego.26.0001R10isH;R11is H; orR10and R11together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0;R12isH;R13is H; orR12and R13together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl, wherein cycloalkyl or heterocyclyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, C3-C7 cycloalkyl, OH, halogen, CN, and =0;provided that when R10and R11each is H, then R12and R13together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl and when R12and R13each is H, then R10and R11together with the atom to which they are attached and any intervening atoms, form 4-8 membered cycloalkyl or heterocyclyl.

9. The compound of claim 1, wherein the compound is of Formula (VIII):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;280.ASBMondego.26.0001each from R25, R26and R27is independently selected from H, Ci-Cg alkyl, and Ci-Ce alkoxy.

10. The compound of claim 1, wherein the compound is of Formula (IX):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;each from R25, R26and R27is independently selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy.

11. The compound of claim 1, wherein the compound is of Formula (X):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:each V is independently selected from CR26and N;each R* is H; ortwo R* form a bond;each R** is H; ortwo R** form a bond;281.ASBMondego.26.0001each from R25, R27, R42, and R44is independently selected from H, Ci-Ce alkyl, and Ci-Ce alkoxy;each R26is independently selected from H, Ci-Ce alkyl, C3-C7 cycloalkyl, C4-C7 cycloalkenyl, -NHCi-Cg alkyl, and Ci-Ce alkoxy;R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl.

12. The compound of claim 1, wherein the compound is of Formula (XI):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy.

13. The compound of claim 1, wherein the compound is of Formula (XII):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:Q* is selected from O, S(O)k, CH2, NR28;k is an integer selected from 0, 1, and 2;each R28is independently selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl; each R29is independently selected from H, OH, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and Ci-Ce alkoxy.282.ASBMondego.26.000114. The compound of claim 1, wherein the compound is of Formula (XIII):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:R28is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R31is selected from Ci-Ce alkyl, C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atom to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl.

15. The compound of claim 1, wherein the compound is of Formula (XIV):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:Q is selected from O, S(O)k, CH2, NH;R30is selected from H, halogen, Ci-Ce alkyl, wherein alkyl is optionally substituted with one or more substituents independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen;283.ASBMondego.26.0001each R41is independently selected from Ci-Ce alkyl, -NH2, -OH, -CN, halogen, C3-Cs cycloalkyl, 3-7 membered heterocyclyl, aryl, 5-6 membered heteroaryl;b is an integer selected from 0, 1, 2 and 3;k is an integer selected from 0, 1, and 2;q is an integer selected from 0, 1 and 2.

16. The compound of claim 1, wherein the compound is of Formula (XV):or a pharmaceutically acceptable salt, prodrug, stereoisomer, solvate, or tautomer thereof, wherein:each E is independently selected from CR52and N;R28is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R51is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl, wherein alkyl or cycloalkyl is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, =0, Ci-Ce alkyl, Ci-Ce alkoxy, C3-C8 cycloalkyl, aryl;each R52is independently selected from H, Ci-Ce alkyl;or two R52together with the atoms to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl.

17. The compound of claim 1, wherein the compound is of Formula (XVI):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,284.ASBMondego.26.0001wherein:each R* is H, or two R* form a bond;each R28is independently selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;R61is selected from H, Ci-Ce alkyl, C3-C10 cycloalkyl, aryl, -C(O)N(R28)2, -C(O)OR28, wherein alkyl, cycloalkyl, or aryl is optionally substituted with one or more substituents independently selected from halogen, -OH, CN, -NO2;R62is selected from H, Ci-Ce alkyl, C3-C8 cycloalkyl;or R61and R62together with the atom to which they are attached and any intervening atoms, form 5-10 membered cycloalkyl, 5-10 membered heterocyclyl, aryl or heteroaryl, wherein cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, Ci-Ce alkyl-C(O)-, -C(O)N(R28)2.

18. The compound of claim 1, wherein compound is of Formula (XVII):or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof,wherein:R33is selected from H, halogen, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl19. The compound of claim 1, wherein compound is of Formula (B):285.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, prodrug, isotopic derivative, or tautomer thereof, wherein:R28is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R31is selected from H, Ci-Ce alkyl, and C3-C8 cycloalkyl;R32is selected from H, Ci-Ce alkyl; orR31and R32together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl;R43is H; orR32and R43together with the atoms to which they are attached and any intervening atoms, form 5-10 membered heterocyclyl or heteroaryl, wherein heterocyclyl or heteroaryl is optionally substituted with one or more substituents independently selected from halogen, OH, -CN, Ci-Ce alkyl, C3-C8 cycloalkyl, and aryl;R45is selected from halogen, -CN, -OH, and Ci-Ce alkyl;z is an integer selected from 0 and 1.

20. A compound selected from:286.ASBMondego.26.0001287.ASBMondego.26.0001288.ASBMondego.26.0001289.ASBMondego.26.0001290.ASBMondego.26.0001291.ASBMondego.26.0001292.ASBMondego.26.0001293.ASBMondego.26.0001294.ASBMondego.26.0001295.ASBMondego.26.0001296.ASBMondego.26.0001297.ASBMondego.26.0001298.ASBMondego.26.0001299.ASBMondego.26.0001300.ASBMondego.26.0001301.ASBMondego.26.0001302.ASBMondego.26.0001303.ASBMondego.26.0001304.ASBMondego.26.0001305.ASBMondego.26.0001306.ASBMondego.26.0001307.ASBMondego.26.0001308.ASBMondego.26.0001309.ASBMondego.26.0001310.ASBMondego.26.0001311.ASBMondego.26.0001312.ASBMondego.26.0001313.ASBMondego.26.0001314.ASBMondego.26.0001315.ASBMondego.26.0001316.ASBMondego.26.0001317.ASBMondego.26.0001318.ASBMondego.26.0001319.ASBMondego.26.0001320.ASBMondego.26.0001321.ASBMondego.26.0001322.ASBMondego.26.0001323.ASBMondego.26.0001324.ASBMondego.26.0001325.ASBMondego.26.0001326.ASBMondego.26.0001327.ASBMondego.26.0001328.ASBMondego.26.0001329.ASBMondego.26.0001or a pharmaceutically acceptable salt, stereoisomer, solvate, or tautomer thereof.

21. A pharmaceutical composition comprising a compound of Formula (A) or a pharmaceutically acceptable salt, stereoisomer, solvate, or tautomer thereof, and a pharmaceutically acceptable carrier.

22. The pharmaceutical composition of claim 21, further comprising one or more additional pharmaceutically active agents.

23. A method of inhibiting of PTPN1 and / or PTPN2, comprising of administering to a subject a compound of Formula (A) or a pharmaceutical composition thereof.

24. A method of treating a disease or disorder associated with PTPN1 and / or PTPN2, comprising of administering to a subject a compound of Formula (A) or a pharmaceutical composition thereof.

25. A method of treating disease or disorder selected from cancer, rheumatic disease, inflammatory disease, immune disease, metabolic disease or disorder, infectious disease, neurodegenerative disease, genetic disorder, cardiological disease comprising of administering to a subject in need of a treatment a compound of Formula (A) or a pharmaceutical composition thereof.

26. The method of claim 25, wherein rheumatic disease is selected from oligoarticular juvenile idiopathic arthritis; rheumatoid factor-negative polyarticular juvenile idiopathic arthritis.330.ASBMondego.26.000127. The method of claim 25, wherein inflammatory disease is selected from inflammatory bowel disease, inflammatory bowel disease 20 (IBD20), inflammatory bowel disease 1 (IBD1), Crohn's disease.

28. The method of claim 25, wherein immune disease is selected from immunodeficiency 31c (IMD31C), celiac disease 1 (CELIAC 1).

29. The method of claim 25, wherein cancer is selected from T-cell acute lymphoblastic leukemia, ovarian cancer (OC), primary mediastinal B-cell lymphoma, bladder cancer, bone cancer, brain cancer, breast cancer, cardiac cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, fibrosarcoma, gastric cancer, gastrointestinal cancer, head, spine and neck cancer, Kaposi's sarcoma, kidney cancer, leukemia, liver cancer, lymphoma, melanoma, multiple myeloma, pancreatic cancer, penile cancer, testicular germ cell cancer, thymoma carcinoma, thymic carcinoma, lung cancer, ovarian cancer, prostate cancer, marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), pancreatic adenocarcinoma, and chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL).

30. The method of claim 25, wherein metabolic disease or disorder is selected from obesity - body mass index quantitative trait locus 11 (BMIQ11); diabetes mellitus; type 2 diabetes mellitus (T2D); leptin deficiency or dysfunction; ovemutrition.

31. The method of claim 25, wherein infectious disease is selected from bubonic plague.

32. The method of claim 25, wherein genetic disorder is selected from Noonan syndrome, Noonan syndrome with multiple lentigines, RASopathy.

33. The method of claim 25, wherein cardiological disease is selected from Essential Hypertension.

34. The method of any one of claims 23-33, wherein the subject is a mammal.

35. The method of claim 34, wherein the subject is a human.331.ASB